Pharsight

1. Abilify Mycite Kit patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9258035	OTSUKA	Multi-mode communication ingestible event markers and systems, and methods of using the same	Mar, 2029 (4 years from now)
US9060708	OTSUKA	Multi-mode communication ingestible event markers and systems, and methods of using the same	Mar, 2029 (4 years from now)
US8674825	OTSUKA	Pharma-informatics system	Apr, 2029 (4 years from now)
US8956288	OTSUKA	In-body power source having high surface area electrode	Jul, 2029 (4 years from now)
US10441194	OTSUKA	Ingestible event marker systems	Jul, 2029 (4 years from now)
US8945005	OTSUKA	Controlled activation ingestible identifier	Aug, 2029 (4 years from now)
US9433371	OTSUKA	In-body device with virtual dipole signal amplification	Sep, 2029 (4 years from now)
US8718193	OTSUKA	Active signal processing personal health signal receivers	Dec, 2029 (5 years from now)
US9149577	OTSUKA	Body-associated receiver and method	Dec, 2029 (5 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
M(M-150)	Dec 05, 2017
New Indication(I-746)	Jul 27, 2020

Drugs and Companies using ARIPIPRAZOLE ingredient

Market Authorisation Date: 13 November, 2017

Treatment: Method of using a receiver to receive a signal from a tablet embedded with a sensor that communicates information through the body of a patient; Method of using a tablet embedded with a sensor that co...

Dosage: TABLET

Strength	Dosage	Availability
2MG	TABLET	Prescription
30MG	TABLET	Prescription
10MG	TABLET	Prescription
5MG	TABLET	Prescription
20MG	TABLET	Prescription
15MG	TABLET	Prescription

ABILIFY MYCITE KIT family patents

2. Acanya patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8895070	BAUSCH	Topical pharmaceutical formulations containing a low concentration of benzoyl peroxide in suspension in water and a water-miscible organic solvent	Jun, 2029 (4 years from now)
US10624918	BAUSCH	Topical pharmaceutical formulations containing a low concentration of benzoyl peroxide in suspension in water and a water-miscible organic solvent	Jun, 2029 (4 years from now)
US8663699	BAUSCH	Topical pharmaceutical formulations containing a low concentration of benzoyl peroxide in suspension in water and a water-miscible organic solvent	Jun, 2029 (4 years from now)
US9078870	BAUSCH	Topical pharmaceutical formulations containing a low concentration of benzoyl peroxide in suspension in water and a water-miscible organic solvent	Jun, 2029 (4 years from now)
US10220049	BAUSCH	Topical pharmaceutical formulations containing a low concentration of benzoyl peroxide in suspension in water and a water-miscible organic solvent	Jun, 2029 (4 years from now)
US8288434	BAUSCH	Topical pharmaceutical formulations containing a low concentration of benzoyl peroxide in suspension in water and a water-miscible organic solvent	Aug, 2029 (4 years from now)

Drugs and Companies using BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE ingredient

Market Authorisation Date: 23 October, 2008

Treatment: Treatment of acne; Topical treatment of acne vulgaris in patients 12 years or older

Dosage: GEL

Strength	Dosage	Availability
2.5%;EQ 1.2% BASE	GEL	Prescription

ACANYA family patents

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

3. Actoplus Met patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9320714	TAKEDA PHARMS USA	Tablet	Feb, 2029 (4 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
M(M-116)	May 17, 2015

Drugs and Companies using METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE ingredient

Market Authorisation Date: 29 August, 2005

Treatment: NA

Dosage: TABLET

Strength	Dosage	Availability
500MG;EQ 15MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	TABLET	Discontinued
850MG;EQ 15MG BASE	TABLET	Prescription

ACTOPLUS MET family patents

4. Acuvail patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7842714	ABBVIE	Ketorolac tromethamine compositions for treating ocular pain	Aug, 2029 (4 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Product(NP)	Jul 22, 2012

Drugs and Companies using KETOROLAC TROMETHAMINE ingredient

Market Authorisation Date: 22 July, 2009

Treatment: NA

Dosage: SOLUTION/DROPS

Strength	Dosage	Availability
0.45%	SOLUTION/DROPS	Prescription

ACUVAIL family patents

5. Adlyxin patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9855388	SANOFI-AVENTIS US	Dosing and drive mechanism for drug delivery device	Apr, 2029 (4 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE)	Jul 27, 2021

Drugs and Companies using LIXISENATIDE ingredient

NCE-1 date: 27 July, 2020

Market Authorisation Date: 27 July, 2016

Treatment: Improvement in glycemic control in type 2 diabetes mellitus patients by use of a pen injector

Dosage: SOLUTION

Strength	Dosage	Availability
0.3MG/3ML (0.1MG/ML)	SOLUTION	Prescription
0.15MG/3ML (0.05MG/ML)	SOLUTION	Prescription

ADLYXIN family patents

6. Afrezza patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9446133	MANNKIND	Dry powder inhaler and system for drug delivery	Jun, 2029 (4 years from now)
US9192675	MANNKIND	Dry powder inhaler and system for drug delivery	Jun, 2029 (4 years from now)
US9662461	MANNKIND	Dry powder drug delivery system and methods	Jun, 2029 (4 years from now)
US10342938	MANNKIND	Dry powder drug delivery system	Jun, 2029 (4 years from now)
US8912193	MANNKIND	Dry powder inhaler and system for drug delivery	Jun, 2029 (4 years from now)
US9393372	MANNKIND	Dry powder drug delivery system	Jul, 2029 (4 years from now)
US10046031	MANNKIND	Use of ultrarapid acting insulin	Aug, 2029 (4 years from now)
US9943571	MANNKIND	Use of ultrarapid acting insulin	Aug, 2029 (4 years from now)
US8119593	MANNKIND	Method of treating diabetes type 2 by metformin and an ultrarapid acting insulin	Aug, 2029 (4 years from now)
US8258095	MANNKIND	Method of controlling glycemia by ultrarapid acting insulin without adjusting an insulin dose for meal content	Aug, 2029 (4 years from now)
US8623817	MANNKIND	Method of treating diabetes type 2 by administering ultrarapid acting insulin	Sep, 2029 (4 years from now)
US9339615	MANNKIND	Dry powder inhaler and system for drug delivery	Oct, 2029 (4 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Product(NP)	Jun 27, 2017

Drugs and Companies using INSULIN RECOMBINANT HUMAN ingredient

Market Authorisation Date: 27 June, 2014

Treatment: Use of an inhaler to administer dry powder medicament; Treatment of patient having diabetes mellitus via oral inhalation of fdkp microparticles comprising insulin; Method of delivering to a patient wi...

Dosage: POWDER

Strength	Dosage	Availability
8 UNITS/INH	POWDER	Prescription
4 UNITS/INH	POWDER	Prescription
12 UNITS/INH	POWDER	Prescription

AFREZZA family patents

7. Agamree patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10857161	CATALYST PHARMS	Non-hormonal steroid modulators of NF-kB for treatment of disease	May, 2029 (4 years from now)
US8334279	CATALYST PHARMS	Non-hormonal steroid modulators of NF-κB for treatment of disease	May, 2029 (4 years from now)
US11833159	CATALYST PHARMS	Non-hormonal steroid modulators of NF-kB for treatment of disease	May, 2029 (4 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE)	Oct 26, 2028
Orphan Drug Exclusivity(ODE-450)	Oct 26, 2030

Drugs and Companies using VAMOROLONE ingredient

NCE-1 date: 27 October, 2027

Market Authorisation Date: 26 October, 2023

Treatment: Treatment of duchenne muscular dystrophy

Dosage: SUSPENSION

Strength	Dosage	Availability
40MG/ML	SUSPENSION	Prescription

AGAMREE family patents

8. Akeega patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8436185	JANSSEN BIOTECH	Pharmaceutically acceptable salts of 2-{4-[(3S)-piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide	Apr, 2029 (4 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Product(NP)	Aug 11, 2026

Drugs and Companies using ABIRATERONE ACETATE; NIRAPARIB TOSYLATE ingredient

Market Authorisation Date: 11 August, 2023

Treatment: NA

Dosage: TABLET

Strength	Dosage	Availability
500MG;EQ 100MG BASE	TABLET	Prescription
500MG;EQ 50MG BASE	TABLET	Prescription

AKEEGA family patents

9. Aliqopa patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
USRE46856	BAYER HEALTHCARE	Substituted 2,3-dihydroimidazo[1,2-c]quinazoline derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis	Oct, 2029 (4 years from now)
US8466283	BAYER HEALTHCARE	Substituted 2,3-dihydroimidazo[1,2-c]quinazoline derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis	Oct, 2029 (4 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE)	Sep 14, 2022
Orphan Drug Exclusivity(ODE)	Sep 14, 2024
Orphan Drug Exclusivity(ODE-155)	Sep 14, 2024

Drugs and Companies using COPANLISIB DIHYDROCHLORIDE ingredient

NCE-1 date: 14 September, 2021

Market Authorisation Date: 14 September, 2017

Treatment: Treatment of adult patients with relapsed follicular lymphoma who have received at least two prior systemic therapies

Dosage: POWDER

Strength	Dosage	Availability
60MG/VIAL	POWDER	Discontinued

ALIQOPA family patents

10. Alunbrig patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9273077	TAKEDA PHARMS USA	Phosphorus derivatives as kinase inhibitors	May, 2029 (4 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE)	Apr 28, 2022
New Indication(I-847)	May 22, 2023
Orphan Drug Exclusivity(ODE)	Apr 28, 2024
Orphan Drug Exclusivity(ODE-142)	Apr 28, 2024
Orphan Drug Exclusivity(ODE-300)	May 22, 2027

Drugs and Companies using BRIGATINIB ingredient

NCE-1 date: 28 April, 2021

Market Authorisation Date: 28 April, 2017

Treatment: Treatment of anaplastic lymphoma kinase (alk)-positive metastatic non-small cell lung cancer (nsclc)

Dosage: TABLET

Strength	Dosage	Availability
90MG	TABLET	Prescription
30MG	TABLET	Prescription
180MG	TABLET	Prescription

ALUNBRIG family patents

11. Amvuttra patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8106022	ALNYLAM PHARMS INC	Carbohydrate conjugates as delivery agents for oligonucleotides	Dec, 2029 (5 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE)	Jun 13, 2027
Orphan Drug Exclusivity(ODE-212)	Jun 13, 2029

Drugs and Companies using VUTRISIRAN SODIUM ingredient

NCE-1 date: 13 June, 2026

Market Authorisation Date: 13 June, 2022

Treatment: Amvuttra is indicated for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults

Dosage: SOLUTION

Strength	Dosage	Availability
EQ 25MG BASE/0.5ML (EQ 25MG BASE/0.5ML)	SOLUTION	Prescription

AMVUTTRA family patents

12. Angiomax patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7582727 (Pediatric)	SANDOZ	Pharmaceutical formulations of bivalirudin and processes of making the same	Jan, 2029 (4 years from now)
US7598343 (Pediatric)	SANDOZ	Pharmaceutical formulations of bivalirudin and processes of making the same	Jan, 2029 (4 years from now)

Drugs and Companies using BIVALIRUDIN ingredient

Market Authorisation Date: 15 December, 2000

Treatment: NA

Dosage: INJECTABLE

Strength	Dosage	Availability
250MG/VIAL	INJECTABLE	Prescription

ANGIOMAX family patents

13. Anoro Ellipta patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8201556	GLAXOSMITHKLINE	Medicament dispenser	Feb, 2029 (4 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Product(NP)	Dec 18, 2016
New Chemical Entity Exclusivity(NCE)	Dec 18, 2018
M(M-245)	Jun 09, 2022

Drugs and Companies using UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE ingredient

NCE-1 date: 18 December, 2017

Market Authorisation Date: 18 December, 2013

Treatment: NA

Dosage: POWDER

Strength	Dosage	Availability
EQ 0.0625MG BASE/INH;EQ 0.025MG BASE/INH	POWDER	Prescription

ANORO ELLIPTA family patents

14. Arnuity Ellipta patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8201556	GLAXOSMITHKLINE	Medicament dispenser	Feb, 2029 (4 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Product(NP)	Aug 20, 2017
New Patient Population(NPP)	May 17, 2021
New Strength(NS)	May 17, 2021
M(M-290)	Mar 01, 2026

Drugs and Companies using FLUTICASONE FUROATE ingredient

Market Authorisation Date: 17 May, 2018

Treatment: NA

Dosage: POWDER

Strength	Dosage	Availability
0.1MG/INH	POWDER	Prescription
0.05MG/INH	POWDER	Prescription
0.2MG/INH	POWDER	Prescription

ARNUITY ELLIPTA family patents

15. Atripla patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8598185	GILEAD SCIENCES	Unitary pharmaceutical dosage form	Apr, 2029 (4 years from now)

Drugs and Companies using EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE ingredient

Market Authorisation Date: 12 July, 2006

Treatment: NA

Dosage: TABLET

Strength	Dosage	Availability
600MG;200MG;300MG	TABLET	Discontinued

ATRIPLA family patents

16. Auvi-q patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8226610	KALEO INC	Medical injector with compliance tracking and monitoring	Apr, 2029 (4 years from now)
US8021344	KALEO INC	Medicament delivery device configured to produce an audible output	Nov, 2029 (4 years from now)

Drugs and Companies using EPINEPHRINE ingredient

Market Authorisation Date: 17 November, 2017

Treatment: NA

Dosage: SOLUTION

Strength	Dosage	Availability
EQ 0.3MG/DELIVERY	SOLUTION	Prescription
EQ 0.15MG/DELIVERY	SOLUTION	Prescription
EQ 0.1MG/DELIVERY	SOLUTION	Prescription

AUVI-Q family patents

17. Baxdela patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8871938	MELINTA	Process for making quinolone compounds	Sep, 2029 (4 years from now)
US8497378	MELINTA	Process for making quinolone compounds	Dec, 2029 (5 years from now)
USRE46617	MELINTA	Process for making quinolone compounds	Dec, 2029 (5 years from now)
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8410077	MELINTA	Sulfoalkyl ether cyclodextrin compositions	Mar, 2029 (4 years from now)
US7635773	MELINTA	Sulfoalkyl ether cyclodextrin compositions	Mar, 2029 (4 years from now)
US9750822	MELINTA	Sulfoalkyl ether cyclodextrin compositions	Mar, 2029 (4 years from now)
US9200088	MELINTA	Sulfoalkyl ether cyclodextrin compositions	Mar, 2029 (4 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE)	Jun 19, 2022
New Indication(I-815)	Oct 24, 2022
Generating Antibiotic Incentives Now(GAIN)	Jun 19, 2027

Drugs and Companies using DELAFLOXACIN MEGLUMINE ingredient

NCE-1 date: 19 June, 2026

Market Authorisation Date: 19 June, 2017

Treatment: NA

Dosage: POWDER; TABLET

Strength	Dosage	Availability
EQ 300MG BASE/VIAL	POWDER	Prescription
EQ 450MG BASE	TABLET	Prescription

BAXDELA family patents

18. Belsomra patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7951797	MERCK SHARP DOHME	Substituted diazepan orexin receptor antagonists	Nov, 2029 (5 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE)	Aug 13, 2019
M(M-253)	Jan 29, 2023

Drugs and Companies using SUVOREXANT ingredient

NCE-1 date: 13 August, 2018

Market Authorisation Date: 13 August, 2014

Treatment: Treatment of insomnia

Dosage: TABLET

Strength	Dosage	Availability
5MG	TABLET	Prescription
10MG	TABLET	Prescription
20MG	TABLET	Prescription
15MG	TABLET	Prescription

BELSOMRA family patents

19. Belviq patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8168624	EISAI INC	Crystalline forms of (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine hydrochloride	Apr, 2029 (4 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE)	Jun 27, 2017

Drugs and Companies using LORCASERIN HYDROCHLORIDE ingredient

NCE-1 date: 27 June, 2016

Market Authorisation Date: 27 June, 2012

Treatment: NA

Dosage: TABLET

BELVIQ family patents

20. Belviq Xr patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8168624	EISAI INC	Crystalline forms of (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine hydrochloride	Apr, 2029 (4 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE)	Jun 27, 2017

Drugs and Companies using LORCASERIN HYDROCHLORIDE ingredient

NCE-1 date: 27 June, 2016

Market Authorisation Date: 15 July, 2016

Treatment: NA

Dosage: TABLET, EXTENDED RELEASE

BELVIQ XR family patents

21. Besivance patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8937062	BAUSCH AND LOMB	Compositions and methods for treating, reducing, ameliorating, or preventing infections caused by antibacterial drug-resistant bacteria	Nov, 2029 (5 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE)	May 28, 2014

Drugs and Companies using BESIFLOXACIN HYDROCHLORIDE ingredient

NCE-1 date: 28 May, 2013

Market Authorisation Date: 28 May, 2009

Treatment: Method of treating ocular bacterial infections

Dosage: SUSPENSION/DROPS

BESIVANCE family patents

22. Braftovi patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8946250	ARRAY BIOPHARMA INC	3,4-diarylpyrazoles as protein kinase inhibitors	Jul, 2029 (4 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Indication(I-826)	Apr 08, 2023
New Chemical Entity Exclusivity(NCE)	Jun 27, 2023
Orphan Drug Exclusivity(ODE-194)	Jun 27, 2025
New Indication(I-928)	Oct 11, 2026
Orphan Drug Exclusivity(ODE-445)	Oct 11, 2030

Drugs and Companies using ENCORAFENIB ingredient

NCE-1 date: 27 June, 2022

Market Authorisation Date: 27 June, 2018

Treatment: NA

Dosage: CAPSULE

BRAFTOVI family patents

23. Brenzavvy patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7838499	THERACOSBIO	Benzylbenzene derivatives and methods of use	Jan, 2029 (4 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE)	Jan 20, 2028

Drugs and Companies using BEXAGLIFLOZIN ingredient

NCE-1 date: 20 January, 2027

Market Authorisation Date: 20 January, 2023

Treatment: An adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes

Dosage: TABLET

BRENZAVVY family patents

24. Breo Ellipta patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11116721	GLAXO GRP LTD	Pharmaceutical formulations comprising 4-{(1R)-2-[(6-{2-[(2,6-dichlorobenzyl)oxy]ethoxy}hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl) phenol	Feb, 2029 (4 years from now)
US11116721 (Pediatric)	GLAXO GRP LTD	Pharmaceutical formulations comprising 4-{(1R)-2-[(6-{2-[(2,6-dichlorobenzyl)oxy]ethoxy}hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl) phenol	Aug, 2029 (4 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Product(NP)	Apr 30, 2018
New Indication(I-708)	Apr 30, 2018
New Chemical Entity Exclusivity(NCE)	May 10, 2018
M(M-202)	May 15, 2020
New Patient Population(NPP)	May 13, 2026
New Strength(NS)	May 13, 2026
Pediatric Exclusivity(PED)	Nov 13, 2026

Drugs and Companies using FLUTICASONE FUROATE; VILANTEROL TRIFENATATE ingredient

NCE-1 date: 13 November, 2025

Market Authorisation Date: 12 May, 2023

Treatment: Maintenance treatment of asthma in patients aged 5 years and older. recommended dosages: breo 100/25 or 200/25 ages 18 years and older; Breo 100/25 ages 12-17 years, and breo 50/25, ages 5-11 years

Dosage: POWDER

BREO ELLIPTA family patents

25. Brisdelle patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8658663	SEBELA IRELAND LTD	Method of treating thermoregulatory disfunction with paroxetine	Apr, 2029 (4 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Product(NP)	Jun 28, 2016

Drugs and Companies using PAROXETINE MESYLATE ingredient

Market Authorisation Date: 28 June, 2013

Treatment: Treatment of moderate to severe vasomotor symptoms associated with menopause

Dosage: CAPSULE

BRISDELLE family patents

26. Bromsite patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8778999	SUN PHARM	Non-steroidal anti-inflammatory ophthalmic compositions	Aug, 2029 (4 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Product(NP)	Apr 08, 2019

Drugs and Companies using BROMFENAC SODIUM ingredient

Market Authorisation Date: 08 April, 2016

Treatment: Treatment of postoperative inflammation and prevention of ocular pain in patients undergoing cataract surgery

Dosage: SOLUTION/DROPS

BROMSITE family patents

27. Bydureon patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7919598	ASTRAZENECA AB	Crystal structures of SGLT2 inhibitors and processes for preparing same	Dec, 2029 (5 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Product(NP)	Jan 27, 2015
M(M-162)	Sep 24, 2018
M(M-212)	Oct 20, 2020
M(M-224)	Apr 02, 2021
M(M-240)	Feb 15, 2022
New Patient Population(NPP)	Jul 22, 2024
Pediatric Exclusivity(PED)	Jan 22, 2025

Drugs and Companies using EXENATIDE SYNTHETIC ingredient

Market Authorisation Date: 27 January, 2012

Treatment: NA

Dosage: FOR SUSPENSION, EXTENDED RELEASE

BYDUREON family patents

28. Bydureon Pen patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7919598	ASTRAZENECA AB	Crystal structures of SGLT2 inhibitors and processes for preparing same	Dec, 2029 (5 years from now)
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8827963	ASTRAZENECA AB	Administering device with holding mechanism	Feb, 2029 (4 years from now)
US8690837	ASTRAZENECA AB	Mixing device for a two-chamber ampoule	May, 2029 (4 years from now)
US8827963 (Pediatric)	ASTRAZENECA AB	Administering device with holding mechanism	Aug, 2029 (4 years from now)
US8690837 (Pediatric)	ASTRAZENECA AB	Mixing device for a two-chamber ampoule	Nov, 2029 (5 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
M(M-224)	Apr 02, 2021
M(M-240)	Feb 15, 2022
New Patient Population(NPP)	Jul 22, 2024
Pediatric Exclusivity(PED)	Jan 22, 2025

Drugs and Companies using EXENATIDE SYNTHETIC ingredient

Market Authorisation Date: 27 January, 2012

Treatment: NA

Dosage: FOR SUSPENSION, EXTENDED RELEASE

BYDUREON PEN family patents

29. Cabtreo patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9561208	BAUSCH	Topical pharmaceutical formulations containing a low concentration of benzoyl peroxide in suspension in water and a water-miscible organic solvent	Jun, 2029 (4 years from now)
US10220049	BAUSCH	Topical pharmaceutical formulations containing a low concentration of benzoyl peroxide in suspension in water and a water-miscible organic solvent	Jun, 2029 (4 years from now)
US10624918	BAUSCH	Topical pharmaceutical formulations containing a low concentration of benzoyl peroxide in suspension in water and a water-miscible organic solvent	Jun, 2029 (4 years from now)
US8288434	BAUSCH	Topical pharmaceutical formulations containing a low concentration of benzoyl peroxide in suspension in water and a water-miscible organic solvent	Aug, 2029 (4 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Product(NP)	Oct 20, 2026

Drugs and Companies using ADAPALENE; BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE ingredient

Market Authorisation Date: 20 October, 2023

Treatment: Topical treatment of acne vulgaris in adult and pediatric patients 12 years of age and older

Dosage: GEL

CABTREO family patents

30. Caldolor patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9649284	CUMBERLAND PHARMS	Treating critically ill patients with intravenous ibuprofen	Sep, 2029 (4 years from now)
US9295639	CUMBERLAND PHARMS	Treating critically ill patients with intravenous ibuprofen	Sep, 2029 (4 years from now)
US8871810	CUMBERLAND PHARMS	Treating critically ill patients with intravenous ibuprofen	Sep, 2029 (4 years from now)
US8735452	CUMBERLAND PHARMS	Treating patients with intravenous ibuprofen	Sep, 2029 (4 years from now)
US9138404	CUMBERLAND PHARMS	Treating critically ill patients with intravenous ibuprofen	Sep, 2029 (4 years from now)
US9114068	CUMBERLAND PHARMS	Treating patients with intravenous ibuprofen	Sep, 2029 (4 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Product(NP)	Jun 11, 2012
New Dosing Schedule(D-152)	Nov 20, 2018
M(M-128)	Nov 19, 2024
New Patient Population(NPP)	May 11, 2026

Drugs and Companies using IBUPROFEN ingredient

Market Authorisation Date: 11 June, 2009

Treatment: Management of mild to moderate pain, management of moderate to severe pain as an adjunct to opioid analgesics in a critically ill patient with intravenous ibuprofen in need thereof; Methods of treatin...

Dosage: SOLUTION

CALDOLOR family patents

31. Caplyta patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
USRE48825	INTRA-CELLULAR	4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl)-1-(4-fluorophenyl)-1-butanone toluenesulfonic acid salt crystal forms	Mar, 2029 (4 years from now)
US9586960	INTRA-CELLULAR	4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de] quinoxalin-8(7H)-yl)-1-(4-fluorophenyl)-1-butanone toluenesulfonic acid salt crystal forms	Mar, 2029 (4 years from now)
US8648077	INTRA-CELLULAR	4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl)-1-(4-fluorophenyl)-1-butanone toluenesulfonic acid addition salt and salt crystals	Dec, 2029 (5 years from now)
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9199995	INTRA-CELLULAR	4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl)-1-(4-fluorophenyl)-1-butanone toluenesulfonic acid addition salt and salt crystals	Mar, 2029 (4 years from now)
US9616061	INTRA-CELLULAR	Methods and compositions for sleep disorders and other disorders	May, 2029 (4 years from now)
US9168258	INTRA-CELLULAR	Methods and compositions for sleep disorders and other disorders	May, 2029 (4 years from now)
US10117867	INTRA-CELLULAR	Methods and compositions for sleep disorders and other disorders	May, 2029 (4 years from now)
US8598119	INTRA-CELLULAR	Methods and compositions for sleep disorders and other disorders	Dec, 2029 (5 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Indication(I-882)	Dec 17, 2024
New Chemical Entity Exclusivity(NCE)	Dec 20, 2024

Drugs and Companies using LUMATEPERONE TOSYLATE ingredient

NCE-1 date: 21 December, 2023

Market Authorisation Date: 22 April, 2022

Treatment: Modulation of 5-hydroxytryptamine 2 receptor activity in schizophrenia; Treatment of bipolar depression; Treatment of schizophrenia

Dosage: CAPSULE

CAPLYTA family patents

32. Carnexiv patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8410077	LUNDBECK PHARMS LLC	Sulfoalkyl ether cyclodextrin compositions	Mar, 2029 (4 years from now)
US7635773	LUNDBECK PHARMS LLC	Sulfoalkyl ether cyclodextrin compositions	Mar, 2029 (4 years from now)
US9750822	LUNDBECK PHARMS LLC	Sulfoalkyl ether cyclodextrin compositions	Mar, 2029 (4 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE)	Oct 07, 2023
Orphan Drug Exclusivity(ODE-124)	Oct 07, 2023

Drugs and Companies using CARBAMAZEPINE ingredient

Market Authorisation Date: 07 October, 2016

Treatment: NA

Dosage: SOLUTION

CARNEXIV family patents

33. Colcrys patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7601758	TAKEDA PHARMS USA	Methods for concomitant administration of colchicine and macrolide antibiotics in the treatment of gout flares	Feb, 2029 (4 years from now)
US7906519	TAKEDA PHARMS USA	Methods for concomitant administration of colchicine and a second active agent	Feb, 2029 (4 years from now)
US8440721	TAKEDA PHARMS USA	Methods for concomitant administration of colchicine and a second active agent	Feb, 2029 (4 years from now)
US7820681	TAKEDA PHARMS USA	Methods for concomitant administration of colchicine and a second active agent	Feb, 2029 (4 years from now)
US7915269	TAKEDA PHARMS USA	Methods for concomitant administration of colchicine and a second active agent	Feb, 2029 (4 years from now)
US8440722	TAKEDA PHARMS USA	Methods for concomitant administration of colchicine and a second active agent	Feb, 2029 (4 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Indication(I-603)	Jul 30, 2012
Orphan Drug Exclusivity(ODE)	Jul 29, 2016

Drugs and Companies using COLCHICINE ingredient

Market Authorisation Date: 29 July, 2009

Treatment: Method of treating gout flares; Method of administering colchicine to familial mediterranean fever patients; Method of using colchicine for the prophylaxis of gout flares

Dosage: TABLET

COLCRYS family patents

34. Consensi patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9662315	PURPLE BIOTECH	Ameliorating drug-induced elevations in blood pressure by adjunctive use of antihypertensive drugs	May, 2029 (4 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Combination(NC)	May 31, 2021

Drugs and Companies using AMLODIPINE BESYLATE; CELECOXIB ingredient

Market Authorisation Date: 31 May, 2018

Treatment: Treatment of adult patients for whom treatment with both amlodipine for hypertension and celecoxib for osteoarthritis are appropriate

Dosage: TABLET

CONSENSI family patents

35. Contrave patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8088786	NALPROPION	Layered pharmaceutical formulations	Feb, 2029 (4 years from now)
US11324741	NALPROPION	Methods for treating visceral fat conditions	May, 2029 (4 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Combination(NC)	Sep 10, 2017

Drugs and Companies using BUPROPION HYDROCHLORIDE; NALTREXONE HYDROCHLORIDE ingredient

Market Authorisation Date: 10 September, 2014

Treatment: For chronic weight management for treating overweight or obesity

Dosage: TABLET, EXTENDED RELEASE

CONTRAVE family patents

36. Copiktra patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9216982	SECURA	Certain chemical entities, compositions and methods	Jan, 2029 (4 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE)	Sep 24, 2023
Orphan Drug Exclusivity(ODE-208)	Sep 24, 2025
Orphan Drug Exclusivity(ODE-209)	Sep 24, 2025

Drugs and Companies using DUVELISIB ingredient

NCE-1 date: 24 September, 2022

Market Authorisation Date: 24 September, 2018

Treatment: For the treatment of patients with chronic lymphocytic leukemia (cll) and/or small lymphocytic leukemia (sll)

Dosage: CAPSULE

COPIKTRA family patents

37. Cotellic patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7803839	GENENTECH INC	Azetidines as MEK inhibitors for the treatment of proliferative diseases	Nov, 2029 (5 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE)	Nov 10, 2020
Orphan Drug Exclusivity(ODE)	Nov 10, 2022
Orphan Drug Exclusivity(ODE-101)	Nov 10, 2022
M(M-278)	Jul 28, 2025
New Indication(I-902)	Oct 28, 2025
Pediatric Exclusivity(PED)	Jan 28, 2026
Orphan Drug Exclusivity(ODE-416)	Oct 28, 2029

Drugs and Companies using COBIMETINIB FUMARATE ingredient

NCE-1 date: 28 January, 2025

Market Authorisation Date: 10 November, 2015

Treatment: NA

Dosage: TABLET

COTELLIC family patents

38. Daklinza patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8329159	BRISTOL-MYERS SQUIBB	Hepatitis C virus inhibitors	Jul, 2029 (4 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Dosing Schedule(D-161)	Feb 05, 2019
New Dosing Schedule(D-162)	Feb 05, 2019
New Indication(I-726)	Feb 05, 2019
New Indication(I-727)	Feb 05, 2019
New Chemical Entity Exclusivity(NCE)	Jul 24, 2020

Drugs and Companies using DACLATASVIR DIHYDROCHLORIDE ingredient

NCE-1 date: 25 July, 2019

Market Authorisation Date: 24 July, 2015

Treatment: NA

Dosage: TABLET

DAKLINZA family patents

39. Desyrel patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8133893	PRAGMA	Trazodone and trazodone hydrochloride in purified form	Mar, 2029 (4 years from now)

Drugs and Companies using TRAZODONE HYDROCHLORIDE ingredient

Market Authorisation Date: 01 January, 1982

Treatment: NA

Dosage: TABLET

DESYREL family patents

40. Dexilant Solutab patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9241910	TAKEDA PHARMS USA	Orally-disintegrating solid preparation	Mar, 2029 (4 years from now)

Drugs and Companies using DEXLANSOPRAZOLE ingredient

Market Authorisation Date: 26 January, 2016

Treatment: NA

Dosage: TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE

DEXILANT SOLUTAB family patents

41. Dojolvi patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8697748	ULTRAGENYX PHARM INC	Glycogen or polysaccharide storage disease treatment method	Apr, 2029 (4 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE)	Jun 30, 2025
Orphan Drug Exclusivity(ODE-311)	Jun 30, 2027

Drugs and Companies using TRIHEPTANOIN ingredient

NCE-1 date: 30 June, 2024

Market Authorisation Date: 30 June, 2020

Treatment: NA

Dosage: LIQUID

DOJOLVI family patents

42. Dovato patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9242986	VIIV HLTHCARE	Synthesis of carbamoylpyridone HIV integrase inhibitors and intermediates	Dec, 2029 (5 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Combination(NC)	Apr 08, 2022
New Indication(I-839)	Aug 06, 2023
New Patient Population(NPP)	Apr 05, 2027

Drugs and Companies using DOLUTEGRAVIR SODIUM; LAMIVUDINE ingredient

Market Authorisation Date: 08 April, 2019

Treatment: NA

Dosage: TABLET

DOVATO family patents

43. Duaklir Pressair patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10085974	COVIS	Dosage and formulation	Mar, 2029 (4 years from now)
US11000517	COVIS	Dosage and formulation	Mar, 2029 (4 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Combination(NC)	Mar 29, 2022

Drugs and Companies using ACLIDINIUM BROMIDE; FORMOTEROL FUMARATE ingredient

Market Authorisation Date: 29 March, 2019

Treatment: Maintenance treatment of chronic obstructive pulmonary disease (copd)

Dosage: POWDER, METERED

DUAKLIR PRESSAIR family patents

44. Durysta patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7799336	ABBVIE	Hypotensive lipid-containing biodegradable intraocular implants and related methods	Apr, 2029 (4 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Product(NP)	Mar 04, 2023

Drugs and Companies using BIMATOPROST ingredient

Market Authorisation Date: 04 March, 2020

Treatment: NA

Dosage: IMPLANT

DURYSTA family patents

45. Dutrebis patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7754731	MERCK SHARP DOHME	Potassium salt of an HIV integrase inhibitor	Mar, 2029 (4 years from now)
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7754731 (Pediatric)	MERCK SHARP DOHME	Potassium salt of an HIV integrase inhibitor	Sep, 2029 (4 years from now)

Drugs and Companies using LAMIVUDINE; RALTEGRAVIR POTASSIUM ingredient

Market Authorisation Date: 06 February, 2015

Treatment: Treatment of hiv-1 infection

Dosage: TABLET

DUTREBIS family patents

46. Duzallo patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8546437	IRONWOOD PHARMS INC	Compounds and compositions and methods of use	Apr, 2029 (4 years from now)
US8084483	IRONWOOD PHARMS INC	Compounds and compositions and methods of use	Aug, 2029 (4 years from now)
US8357713	IRONWOOD PHARMS INC	Compounds and compositions and methods of use	Dec, 2029 (5 years from now)

Drugs and Companies using ALLOPURINOL; LESINURAD ingredient

Market Authorisation Date: 18 August, 2017

Treatment: Treatment of hyperuricemia associated with gout in patients who have not achieved target serum uric acid levels with a medically appropriate daily dose of allopurinol alone

Dosage: TABLET

DUZALLO family patents

47. Dyanavel Xr patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8062667	TRIS PHARMA INC	Modified release formulations containing drug-ion exchange resin complexes	Mar, 2029 (4 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Product(NP)	Oct 19, 2018

Drugs and Companies using AMPHETAMINE; AMPHETAMINE ASPARTATE/DEXTROAMPHETAMINE SULFATE ingredient

Market Authorisation Date: 19 October, 2015

Treatment: NA

Dosage: SUSPENSION, EXTENDED RELEASE

DYANAVEL XR family patents

48. Ella patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8735380	LAB HRA PHARMA	Ulipristal acetate tablets	Feb, 2029 (4 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE)	Aug 13, 2015
M(M-271)	Jun 24, 2024

Drugs and Companies using ULIPRISTAL ACETATE ingredient

NCE-1 date: 13 August, 2014

Market Authorisation Date: 13 August, 2010

Treatment: NA

Dosage: TABLET

ELLA family patents

49. Embeda patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8623418	ALPHARMA PHARMS	Pharmaceutical composition	Nov, 2029 (4 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Combination(NC)	Aug 13, 2012

Drugs and Companies using MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE ingredient

Market Authorisation Date: 13 August, 2009

Treatment: Treatment of moderate to severe chronic pain by administering an intact composition as claimed

Dosage: CAPSULE, EXTENDED RELEASE

EMBEDA family patents

50. Entereg patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8645160	CUBIST PHARMS	Methods for delivering a drug to a hospital patient for short-term use while minimizing long-term use of the drug	Jun, 2029 (4 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE)	May 20, 2013
M(M-128)	Oct 18, 2016

Drugs and Companies using ALVIMOPAN ingredient

NCE-1 date: 20 May, 2012

Market Authorisation Date: 20 May, 2008

Treatment: Treating a subject undergoing abdominal surgery by administering alvimopan to accelerate the time to upper and lower gastrointestinal recovery following surgeries that include partial bowel resection ...

Dosage: CAPSULE

ENTEREG family patents

51. Eohilia patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9050368	TAKEDA PHARMS USA	Corticosteroid compositions	Aug, 2029 (4 years from now)
US8324192	TAKEDA PHARMS USA	Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract	Aug, 2029 (4 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Product(NP)	Feb 09, 2027
Orphan Drug Exclusivity(ODE-466)	Feb 09, 2031

Drugs and Companies using BUDESONIDE ingredient

Market Authorisation Date: 09 February, 2024

Treatment: Treatment of eosinophilic esophagitis

Dosage: SUSPENSION

EOHILIA family patents

52. Epclusa patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8633309	GILEAD SCIENCES INC	Nucleoside phosphoramidates	Mar, 2029 (4 years from now)
US7964580	GILEAD SCIENCES INC	NA	Mar, 2029 (4 years from now)
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8889159	GILEAD SCIENCES INC	Compositions and methods for treating hepatitis C virus	Mar, 2029 (4 years from now)
US8889159 (Pediatric)	GILEAD SCIENCES INC	Compositions and methods for treating hepatitis C virus	Sep, 2029 (4 years from now)
US7964580 (Pediatric)	GILEAD SCIENCES INC	NA	Sep, 2029 (4 years from now)
US8633309 (Pediatric)	GILEAD SCIENCES INC	Nucleoside phosphoramidates	Sep, 2029 (4 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE)	Jun 28, 2021
New Dosing Schedule(D-177)	Nov 15, 2022
New Patient Population(NPP)	Mar 19, 2023
New Strength(NS)	Mar 19, 2023
M(M-264)	Jul 14, 2023
M(M-277)	Apr 27, 2025
Orphan Drug Exclusivity(ODE-293)	Mar 19, 2027
Orphan Drug Exclusivity(ODE-376)	Jun 10, 2028
Pediatric Exclusivity(PED)	Dec 10, 2028

Drugs and Companies using SOFOSBUVIR; VELPATASVIR ingredient

Market Authorisation Date: 10 June, 2021

Treatment: For the treatment of hepatitis c

Dosage: PELLETS; TABLET

EPCLUSA family patents

53. Esbriet patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8609701	GENENTECH INC	Pirfenidone treatment for patients with atypical liver function	Apr, 2029 (4 years from now)
US7635707	GENENTECH INC	Pirfenidone treatment for patients with atypical liver function	Apr, 2029 (4 years from now)
US8592462	GENENTECH INC	Pirfenidone treatment for patients with atypical liver function	Apr, 2029 (4 years from now)
US7566729	GENENTECH INC	Modifying pirfenidone treatment for patients with atypical liver function	Apr, 2029 (4 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE)	Oct 15, 2019
Orphan Drug Exclusivity(ODE)	Oct 15, 2021
Orphan Drug Exclusivity(ODE-77)	Oct 15, 2021

Drugs and Companies using PIRFENIDONE ingredient

NCE-1 date: 15 October, 2018

Market Authorisation Date: 11 January, 2017

Treatment: Dosage modification following grade 2 abnormality in liver function biomarker alt or ast after pirfenidone administration, by administering sub-2400 mg/day dose, followed by full daily dose; Continued...

Dosage: CAPSULE; TABLET

ESBRIET family patents

54. Eucrisa patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8039451	ANACOR PHARMS INC	Boron-containing small molecules	Jun, 2029 (4 years from now)
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8039451 (Pediatric)	ANACOR PHARMS INC	Boron-containing small molecules	Dec, 2029 (5 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE)	Dec 14, 2021
New Patient Population(NPP)	Mar 23, 2023
Pediatric Exclusivity(PED)	Sep 23, 2023
New Dosing Schedule(D-191)	Apr 03, 2026

Drugs and Companies using CRISABOROLE ingredient

NCE-1 date: 23 September, 2022

Market Authorisation Date: 14 December, 2016

Treatment: NA

Dosage: OINTMENT

EUCRISA family patents

55. Evomela patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8410077	ACROTECH BIOPHARMA	Sulfoalkyl ether cyclodextrin compositions	Mar, 2029 (4 years from now)
US9200088	ACROTECH BIOPHARMA	Sulfoalkyl ether cyclodextrin compositions	Mar, 2029 (4 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE)	Mar 10, 2023
Orphan Drug Exclusivity(ODE-110)	Mar 10, 2023

Drugs and Companies using MELPHALAN HYDROCHLORIDE ingredient

Market Authorisation Date: 10 March, 2016

Treatment: NA

Dosage: POWDER

EVOMELA family patents

56. Evotaz patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8148374	BRISTOL	Modulators of pharmacokinetic properties of therapeutics	Sep, 2029 (4 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE)	Aug 27, 2017

Drugs and Companies using ATAZANAVIR SULFATE; COBICISTAT ingredient

NCE-1 date: 27 August, 2016

Market Authorisation Date: 29 January, 2015

Treatment: Treatment of hiv infection using a composition containing a pharmacokinetic enhancer that inhibits cytochrome p450 monooxygenase

Dosage: TABLET

EVOTAZ family patents

57. Evzio patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8226610	KALEO INC	Medical injector with compliance tracking and monitoring	Apr, 2029 (4 years from now)
US8223610	KALEO INC	Apparatus and method for initializing information recording medium, apparatus and method for recording information, and information recording medium	Apr, 2029 (4 years from now)
US8021344	KALEO INC	Medicament delivery device configured to produce an audible output	Nov, 2029 (4 years from now)

Drugs and Companies using NALOXONE HYDROCHLORIDE ingredient

Market Authorisation Date: 03 April, 2014

Treatment: NA

Dosage: SOLUTION

EVZIO family patents

58. Evzio (autoinjector) patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8226610	KALEO INC	Medical injector with compliance tracking and monitoring	Apr, 2029 (4 years from now)
US8021344	KALEO INC	Medicament delivery device configured to produce an audible output	Nov, 2029 (4 years from now)

Drugs and Companies using NALOXONE HYDROCHLORIDE ingredient

Market Authorisation Date: 19 October, 2016

Treatment: NA

Dosage: SOLUTION

EVZIO (AUTOINJECTOR) family patents

59. Exondys 51 patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
USRE47769	SAREPTA THERAPS INC	Antisense oligonucleotides for inducing exon skipping and methods of use thereof	Feb, 2029 (4 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE)	Sep 19, 2021
Orphan Drug Exclusivity(ODE)	Sep 19, 2023
Orphan Drug Exclusivity(ODE-122)	Sep 19, 2023

Drugs and Companies using ETEPLIRSEN ingredient

NCE-1 date: 19 September, 2020

Market Authorisation Date: 19 September, 2016

Treatment: NA

Dosage: SOLUTION

EXONDYS 51 family patents

60. Farxiga patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7919598	ASTRAZENECA AB	Crystal structures of SGLT2 inhibitors and processes for preparing same	Dec, 2029 (5 years from now)
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7851502 (Pediatric)	ASTRAZENECA AB	Pharmaceutical formulations containing an SGLT2 inhibitor	Feb, 2029 (4 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
M(M-157)	Mar 11, 2018
New Chemical Entity Exclusivity(NCE)	Jan 08, 2019
M(M-212)	Oct 20, 2020
M(M-238)	Feb 22, 2022
New Indication(I-841)	Oct 18, 2022
New Indication(I-834)	May 05, 2023
New Indication(I-857)	Apr 30, 2024
M(M-298)	May 08, 2026
New Patient Population(NPP)	Jun 12, 2027
Pediatric Exclusivity(PED)	Dec 12, 2027

Drugs and Companies using DAPAGLIFLOZIN ingredient

NCE-1 date: 12 December, 2026

Market Authorisation Date: 08 January, 2014

Treatment: NA

Dosage: TABLET

FARXIGA family patents

61. Ferriprox patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8703156	CHIESI	Liquid formulation for deferiprone with palatable taste	Oct, 2029 (4 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE)	Oct 14, 2016
Orphan Drug Exclusivity(ODE)	Oct 14, 2018
Orphan Drug Exclusivity(ODE-16)	Oct 14, 2018
New Indication(I-859)	Apr 30, 2024
Orphan Drug Exclusivity(ODE-417)	Apr 30, 2028
Orphan Drug Exclusivity(ODE-418)	Apr 30, 2028
Orphan Drug Exclusivity(ODE-419)	Apr 30, 2028
Orphan Drug Exclusivity(ODE-420)	Apr 30, 2028
Orphan Drug Exclusivity(ODE-421)	Apr 30, 2028

Drugs and Companies using DEFERIPRONE ingredient

NCE-1 date: 15 October, 2015

Market Authorisation Date: 20 April, 2018

Treatment: Method of treating transfusional iron overload

Dosage: SOLUTION

FERRIPROX family patents

62. Finacea patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9211259	LEO PHARMA AS	Antibiotic kit and composition and uses thereof	Feb, 2029 (4 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Product(NP)	Jul 29, 2018

Drugs and Companies using AZELAIC ACID ingredient

Market Authorisation Date: 29 July, 2015

Treatment: Topical treatment of inflammatory papules and pustules of mild to moderate rosacea

Dosage: AEROSOL, FOAM

FINACEA family patents

63. Firmagon patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10729739	FERRING	Methods of treating prostate cancer with GnRH antagonist	Feb, 2029 (4 years from now)
US9579359	FERRING	Method of treating prostate cancer with GnRH antagonist	Feb, 2029 (4 years from now)
US10973870	FERRING	Methods of treating prostate cancer with GnRH antagonist	Feb, 2029 (4 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE)	Dec 24, 2013

Drugs and Companies using DEGARELIX ACETATE ingredient

NCE-1 date: 24 December, 2012

Market Authorisation Date: 24 December, 2008

Treatment: Treatment of advanced prostate cancer with a reduced likelihood of causing a gonadotrophin releasing hormone agonist side-effect

Dosage: POWDER

FIRMAGON family patents

64. Fyarro patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8911786	AADI	Nanoparticle comprising rapamycin and albumin as anticancer agent	Feb, 2029 (4 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Product(NP)	Nov 22, 2024
Orphan Drug Exclusivity(ODE-386)	Nov 22, 2028

Drugs and Companies using SIROLIMUS ingredient

Market Authorisation Date: 22 November, 2021

Treatment: Treatment of adult patients with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor (pecoma)

Dosage: POWDER

FYARRO family patents

65. Galafold patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10813921	AMICUS THERAP US	Method to predict response to pharmacological chaperone treatment of diseases	Feb, 2029 (4 years from now)
US8592362	AMICUS THERAP US	Method to predict response to pharmacological chaperone treatment of diseases	Feb, 2029 (4 years from now)
US9095584	AMICUS THERAP US	Method to predict response to pharmacological chaperone treatment of diseases	Feb, 2029 (4 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE)	Aug 10, 2023
Orphan Drug Exclusivity(ODE-205)	Aug 10, 2025

Drugs and Companies using MIGALASTAT HYDROCHLORIDE ingredient

NCE-1 date: 10 August, 2022

Market Authorisation Date: 10 August, 2018

Treatment: The treatment of fabry patients

Dosage: CAPSULE

GALAFOLD family patents

66. Gelnique patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10449173	ABBVIE	Method for treating overactive bladders and a device for storage and administration of topical oxybutynin compositions	Nov, 2029 (4 years from now)
US9259388	ABBVIE	Method for treating overactive bladders and a device for storage and administration of topical oxybutynin compositions	Nov, 2029 (4 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Dosage Form(NDF)	Jan 27, 2012

Drugs and Companies using OXYBUTYNIN CHLORIDE ingredient

Market Authorisation Date: 27 January, 2009

Treatment: Treatment of patients with an overactive bladder with symptoms of urinary frequency, urgency, or urge incontinence with a single unit dose of 10% oxybutynin chloride gel; Treatment of overactive bladd...

Dosage: GEL

GELNIQUE family patents

67. Gemtesa patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8653260	UROVANT	Hydroxymethyl pyrrolidines as beta 3 adrenergic receptor agonists	Apr, 2029 (4 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE)	Dec 23, 2025

Drugs and Companies using VIBEGRON ingredient

NCE-1 date: 23 December, 2024

Market Authorisation Date: 23 December, 2020

Treatment: NA

Dosage: TABLET

GEMTESA family patents

68. Genosyl patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9701538	VERO BIOTECH INC	Conversion of nitrogen dioxide (NO2) to nitric oxide (NO)	Jan, 2029 (4 years from now)
US8944049	VERO BIOTECH INC	Systems and devices for generating nitric oxide	Aug, 2029 (4 years from now)
US9604028	VERO BIOTECH INC	Systems and devices for generating nitric oxide	Aug, 2029 (4 years from now)
US10926054	VERO BIOTECH INC	Systems and devices for generating nitric oxide	Aug, 2029 (4 years from now)
US11511252	VERO BIOTECH INC	Conversion of nitrogen dioxide (NO2) to nitric oxide (NO)	Sep, 2029 (4 years from now)

Drugs and Companies using NITRIC OXIDE ingredient

Market Authorisation Date: 20 December, 2019

Treatment: A method for delivering nitric oxide to a patient with pulmonary hypertension or hypoxia

Dosage: GAS

GENOSYL family patents

69. Genvoya patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8148374	GILEAD SCIENCES INC	Modulators of pharmacokinetic properties of therapeutics	Sep, 2029 (4 years from now)
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9891239	GILEAD SCIENCES INC	Modulators of pharmacokinetic properties of therapeutics	Sep, 2029 (4 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Patient Population(NPP)	Sep 25, 2020
New Chemical Entity Exclusivity(NCE)	Nov 05, 2020
New Dosing Schedule(D-173)	Dec 10, 2021

Drugs and Companies using COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE ingredient

NCE-1 date: 06 November, 2019

Market Authorisation Date: 05 November, 2015

Treatment: Treatment of hiv infection; Treatment of hiv infection using a composition containing a pharmacokinetic enhancer that inhibits cytochrome p450 monooxygenase

Dosage: TABLET

GENVOYA family patents

70. Giapreza patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10548943	LA JOLLA PHARMA	Method of treating low blood pressure	Dec, 2029 (5 years from now)
US10335451	LA JOLLA PHARMA	Method of treating low blood pressure	Dec, 2029 (5 years from now)
US9867863	LA JOLLA PHARMA	Method of treating low blood pressure	Dec, 2029 (5 years from now)
US10500247	LA JOLLA PHARMA	Method of treating low blood pressure	Dec, 2029 (5 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE)	Dec 21, 2022

Drugs and Companies using ANGIOTENSIN II ACETATE ingredient

NCE-1 date: 21 December, 2021

Market Authorisation Date: 23 December, 2021

Treatment: Increasing blood pressure with an initial rate of about 20 ng/kg/min angiotensin ii in a human subject having septic shock, and titrating the rate up.; Treating hypotension with about 20 ng/kg/min to ...

Dosage: SOLUTION

GIAPREZA family patents

71. Gilotrif patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8426586	BOEHRINGER INGELHEIM	Process for preparing amino crotonyl compounds	Oct, 2029 (4 years from now)
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8545884	BOEHRINGER INGELHEIM	Solid pharmaceutical formulations comprising BIBW 2992	Dec, 2029 (5 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE)	Jul 12, 2018
New Indication(I-730)	Apr 15, 2019
Orphan Drug Exclusivity(ODE-50)	Jul 12, 2020
New Indication(I-763)	Jan 12, 2021
Orphan Drug Exclusivity(ODE)	Apr 15, 2023
Orphan Drug Exclusivity(ODE-115)	Apr 15, 2023
Orphan Drug Exclusivity(ODE-230)	Jan 12, 2025
M(M-276)	Apr 07, 2025
Pediatric Exclusivity(PED)	Oct 07, 2025

Drugs and Companies using AFATINIB DIMALEATE ingredient

NCE-1 date: 07 October, 2024

Market Authorisation Date: 12 July, 2013

Treatment: NA

Dosage: TABLET

GILOTRIF family patents

72. Gimoti patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11020361	EVOKE PHARMA INC	Nasal formulations of metoclopramide	Dec, 2029 (5 years from now)
US11813231	EVOKE PHARMA INC	Nasal formulations of metoclopramide	Dec, 2029 (5 years from now)
US11628150	EVOKE PHARMA INC	Nasal formulations of metoclopramide	Dec, 2029 (5 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Product(NP)	Jun 19, 2023

Drugs and Companies using METOCLOPRAMIDE HYDROCHLORIDE ingredient

Market Authorisation Date: 19 June, 2020

Treatment: Nasal administration of metoclopramide for treatment of diabetic gastroparesis

Dosage: SPRAY, METERED

GIMOTI family patents

73. Givlaari patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8106022	ALNYLAM PHARMS INC	Carbohydrate conjugates as delivery agents for oligonucleotides	Dec, 2029 (5 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE)	Nov 20, 2024
Orphan Drug Exclusivity(ODE-273)	Nov 20, 2026

Drugs and Companies using GIVOSIRAN SODIUM ingredient

NCE-1 date: 21 November, 2023

Market Authorisation Date: 20 November, 2019

Treatment: Treatment of acute hepatic porphyria

Dosage: SOLUTION

GIVLAARI family patents

74. Glyxambi patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7579449 (Pediatric)	BOEHRINGER INGELHEIM	Glucopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture	Feb, 2029 (4 years from now)
US8551957	BOEHRINGER INGELHEIM	Pharmaceutical composition comprising a glucopyranosyl-substituted benzene derivate	Oct, 2029 (4 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Combination(NC)	Jan 30, 2018
New Chemical Entity Exclusivity(NCE)	Aug 01, 2019
New Indication(I-739)	Dec 02, 2019
M(M-258)	Jul 03, 2022
M(M-252)	Mar 30, 2023

Drugs and Companies using EMPAGLIFLOZIN; LINAGLIPTIN ingredient

NCE-1 date: 01 August, 2018

Market Authorisation Date: 30 January, 2015

Treatment: Method of treating type 2 diabetes mellitus by administering linagliptin in combination with empagliflozin

Dosage: TABLET

GLYXAMBI family patents

75. Harvoni patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7964580	GILEAD SCIENCES INC	NA	Mar, 2029 (4 years from now)
US8633309	GILEAD SCIENCES INC	Nucleoside phosphoramidates	Mar, 2029 (4 years from now)
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8889159	GILEAD SCIENCES INC	Compositions and methods for treating hepatitis C virus	Mar, 2029 (4 years from now)
US7964580 (Pediatric)	GILEAD SCIENCES INC	NA	Sep, 2029 (4 years from now)
US8889159 (Pediatric)	GILEAD SCIENCES INC	Compositions and methods for treating hepatitis C virus	Sep, 2029 (4 years from now)
US8633309 (Pediatric)	GILEAD SCIENCES INC	Nucleoside phosphoramidates	Sep, 2029 (4 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Dosing Schedule(D-153)	Nov 12, 2018
New Indication(I-718)	Nov 12, 2018
New Indication(I-719)	Nov 12, 2018
New Indication(I-720)	Nov 12, 2018
New Dosing Schedule(D-158)	Feb 12, 2019
New Dosing Schedule(D-159)	Feb 12, 2019
New Dosing Schedule(D-160)	Feb 12, 2019
New Chemical Entity Exclusivity(NCE)	Oct 10, 2019
New Patient Population(NPP)	Apr 07, 2020
New Dosing Schedule(D-177)	Nov 15, 2022
Orphan Drug Exclusivity(ODE)	Apr 07, 2024
ODE(ODE)	Aug 28, 2026
Orphan Drug Exclusivity(ODE-136)	Apr 07, 2024
Pediatric Exclusivity(PED)	Oct 07, 2024
Orphan Drug Exclusivity(ODE-262)	Aug 28, 2026
Orphan Drug Exclusivity(ODE-263)	Aug 28, 2026
Orphan Drug Exclusivity(ODE-264)	Aug 28, 2026

Drugs and Companies using LEDIPASVIR; SOFOSBUVIR ingredient

Market Authorisation Date: 28 August, 2019

Treatment: For the treatment of hepatitis c

Dosage: PELLETS; TABLET

HARVONI family patents

76. Horizant patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8795725	AZURITY	GABA analog prodrug sustained release oral dosage forms	Jun, 2029 (4 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Indication(I-652)	Jun 06, 2015
New Chemical Entity Exclusivity(NCE)	Apr 06, 2016
Orphan Drug Exclusivity(ODE)	Jun 06, 2019
Orphan Drug Exclusivity(ODE-25)	Jun 06, 2019

Drugs and Companies using GABAPENTIN ENACARBIL ingredient

NCE-1 date: 07 April, 2015

Market Authorisation Date: 13 December, 2011

Treatment: Management of postherpetic neuralgia (phn) in adults

Dosage: TABLET, EXTENDED RELEASE

HORIZANT family patents

77. Ibsrela patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US12016856	ARDELYX INC	Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders	Dec, 2029 (5 years from now)
US8969377	ARDELYX INC	Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders	Dec, 2029 (5 years from now)
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9408840	ARDELYX INC	Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorder	Dec, 2029 (5 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE)	Sep 12, 2024

Drugs and Companies using TENAPANOR HYDROCHLORIDE ingredient

NCE-1 date: 13 September, 2023

Market Authorisation Date: 12 September, 2019

Treatment: Method of treating irritable bowel syndrome with constipation by administering tenapanor

Dosage: TABLET

IBSRELA family patents

78. Inbrija patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
USRE43711	MERZ PHARMS	Pulmonary delivery for levodopa	Feb, 2029 (4 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Product(NP)	Dec 21, 2021

Drugs and Companies using LEVODOPA ingredient

Market Authorisation Date: 21 December, 2018

Treatment: Intermittent treatment of off episodes in patients with parkinson's disease treated with carbidopa/levodopa by inhalation of levodopa powder particles

Dosage: POWDER

INBRIJA family patents

79. Incruse Ellipta patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8201556	GLAXO GRP ENGLAND	Medicament dispenser	Feb, 2029 (4 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE)	Dec 18, 2018
M(M-172)	Feb 24, 2019
M(M-245)	Jun 09, 2022

Drugs and Companies using UMECLIDINIUM BROMIDE ingredient

NCE-1 date: 18 December, 2017

Market Authorisation Date: 30 April, 2014

Treatment: NA

Dosage: POWDER

INCRUSE ELLIPTA family patents

80. Inomax patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US11931377	MALLINCKRODT HOSP	Methods of administering inhaled nitric oxide gas	Jun, 2029 (4 years from now)
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8795741	MALLINCKRODT HOSP	Methods for treating patients who are candidates for inhaled nitric oxide treatment	Jun, 2029 (4 years from now)
US8846112	MALLINCKRODT HOSP	Methods of distributing a pharmaceutical product comprising nitric oxide gas for inhalation	Jun, 2029 (4 years from now)
US8282966	MALLINCKRODT HOSP	Methods of reducing the risk of occurrence of pulmonary edema in children in need of treatment with inhaled nitric oxide	Jun, 2029 (4 years from now)
US8293284	MALLINCKRODT HOSP	Methods of reducing the risk of occurrence of pulmonary edema in term or near-term neonates in need of treatment with inhaled nitric oxide	Jun, 2029 (4 years from now)
US8431163	MALLINCKRODT HOSP	Methods of reducing the risk of occurrence of pulmonary edema associated with inhalation of nitric oxide gas	Jun, 2029 (4 years from now)
US11931377 (Pediatric)	MALLINCKRODT HOSP	Methods of administering inhaled nitric oxide gas	Dec, 2029 (5 years from now)
US8293284 (Pediatric)	MALLINCKRODT HOSP	Methods of reducing the risk of occurrence of pulmonary edema in term or near-term neonates in need of treatment with inhaled nitric oxide	Dec, 2029 (5 years from now)
US8795741 (Pediatric)	MALLINCKRODT HOSP	Methods for treating patients who are candidates for inhaled nitric oxide treatment	Dec, 2029 (5 years from now)
US8846112 (Pediatric)	MALLINCKRODT HOSP	Methods of distributing a pharmaceutical product comprising nitric oxide gas for inhalation	Dec, 2029 (5 years from now)
US8431163 (Pediatric)	MALLINCKRODT HOSP	Methods of reducing the risk of occurrence of pulmonary edema associated with inhalation of nitric oxide gas	Dec, 2029 (5 years from now)
US8282966 (Pediatric)	MALLINCKRODT HOSP	Methods of reducing the risk of occurrence of pulmonary edema in children in need of treatment with inhaled nitric oxide	Dec, 2029 (5 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
M(M-132)	Dec 21, 2013
Pediatric Exclusivity(PED)	Jun 21, 2014
M(M-167)	Oct 09, 2018

Drugs and Companies using NITRIC OXIDE ingredient

Market Authorisation Date: 23 December, 1999

Treatment: A method of reducing the risk of pulmonary edema in patients in need of treatment with inhaled nitric oxide; A method for treating a pediatric patient who is experiencing idiopathic pulmonary arterial...

Dosage: GAS

INOMAX family patents

81. Intermezzo patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8242131	PURDUE PHARMA	Methods of treating middle-of-the-night insomnia	Aug, 2029 (4 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Product(NP)	Nov 23, 2014

Drugs and Companies using ZOLPIDEM TARTRATE ingredient

Market Authorisation Date: 23 November, 2011

Treatment: Method of treating middle-of-the-night insomnia

Dosage: TABLET

INTERMEZZO family patents

82. Invokamet patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7943582	JANSSEN PHARMS	Crystalline form of 1-(β-D-glucopyransoyl)-4-methyl-3-[5-(4-fluorophenyl)-2- thienylmethyl]benzene hemihydrate	Feb, 2029 (4 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Combination(NC)	Aug 08, 2017
New Chemical Entity Exclusivity(NCE)	Mar 29, 2018
New Indication(I-735)	May 20, 2019
M(M-197)	Feb 01, 2020
New Indication(I-788)	Oct 29, 2021

Drugs and Companies using CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE ingredient

NCE-1 date: 29 March, 2017

Market Authorisation Date: 08 August, 2014

Treatment: Reduction of risk of major adverse cardiovascular events in the treatment of type 2 diabetes mellitus patients

Dosage: TABLET

INVOKAMET family patents

83. Invokamet Xr patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7943582	JANSSEN PHARMS	Crystalline form of 1-(β-D-glucopyransoyl)-4-methyl-3-[5-(4-fluorophenyl)-2- thienylmethyl]benzene hemihydrate	Feb, 2029 (4 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Combination(NC)	Aug 08, 2017
New Chemical Entity Exclusivity(NCE)	Mar 29, 2018
New Indication(I-735)	May 20, 2019
New Indication(I-788)	Oct 29, 2021

Drugs and Companies using CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE ingredient

NCE-1 date: 29 March, 2017

Market Authorisation Date: 20 September, 2016

Treatment: Treatment of type 2 diabetes mellitus

Dosage: TABLET, EXTENDED RELEASE

INVOKAMET XR family patents

84. Invokana patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7943582	JANSSEN PHARMS	Crystalline form of 1-(β-D-glucopyransoyl)-4-methyl-3-[5-(4-fluorophenyl)-2- thienylmethyl]benzene hemihydrate	Feb, 2029 (4 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE)	Mar 29, 2018
New Indication(I-733)	May 20, 2019
M(M-197)	Feb 01, 2020
New Indication(I-788)	Oct 29, 2021
New Indication(I-809)	Sep 27, 2022

Drugs and Companies using CANAGLIFLOZIN ingredient

NCE-1 date: 29 March, 2017

Market Authorisation Date: 29 March, 2013

Treatment: Reduction of risk of major adverse cardiovascular events in the treatment of type 2 diabetes mellitus patients

Dosage: TABLET

INVOKANA family patents

85. Isentress patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7754731	MSD SUB MERCK	Potassium salt of an HIV integrase inhibitor	Mar, 2029 (4 years from now)
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7754731 (Pediatric)	MSD SUB MERCK	Potassium salt of an HIV integrase inhibitor	Sep, 2029 (4 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE)	Oct 12, 2012
New Dosage Form(NDF)	Dec 20, 2016
New Patient Population(NPP)	Nov 22, 2020
M(M-114)	Mar 28, 2015
New Dosing Schedule(D-167)	May 26, 2020
Pediatric Exclusivity(PED)	May 22, 2021

Drugs and Companies using RALTEGRAVIR POTASSIUM ingredient

NCE-1 date: 22 May, 2020

Market Authorisation Date: 12 October, 2007

Treatment: Treatment of hiv infection

Dosage: TABLET; TABLET, CHEWABLE; POWDER

ISENTRESS family patents

86. Isentress Hd patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7754731	MSD SUB MERCK	Potassium salt of an HIV integrase inhibitor	Mar, 2029 (4 years from now)
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7754731 (Pediatric)	MSD SUB MERCK	Potassium salt of an HIV integrase inhibitor	Sep, 2029 (4 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Strength(NS)	May 26, 2020
New Patient Population(NPP)	Nov 22, 2020
Pediatric Exclusivity(PED)	May 22, 2021

Drugs and Companies using RALTEGRAVIR POTASSIUM ingredient

NCE-1 date: 22 May, 2020

Market Authorisation Date: 12 October, 2007

Treatment: Treatment of hiv infection

Dosage: TABLET

ISENTRESS HD family patents

87. Isturisa patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8314097	RECORDATI RARE	Organic compounds	Mar, 2029 (4 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE)	Mar 06, 2025
Orphan Drug Exclusivity(ODE-286)	Mar 06, 2027

Drugs and Companies using OSILODROSTAT PHOSPHATE ingredient

NCE-1 date: 06 March, 2024

Market Authorisation Date: 06 March, 2020

Treatment: NA

Dosage: TABLET

ISTURISA family patents

88. Izba patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9144561	NOVARTIS	Pharmaceutical compositions having desirable bioavailability	Mar, 2029 (4 years from now)
US8754123	NOVARTIS	Pharmaceutical compositions having desirable bioavailability	May, 2029 (4 years from now)
US8722735	NOVARTIS	Pharmaceutical compositions having desirable bioavailability	Oct, 2029 (4 years from now)
US8178582	NOVARTIS	Pharmaceutical compositions having desirable bioavailability	Oct, 2029 (4 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Product(NP)	May 15, 2017

Drugs and Companies using TRAVOPROST ingredient

Market Authorisation Date: 15 May, 2014

Treatment: NA

Dosage: SOLUTION/DROPS

IZBA family patents

89. Janumet patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8414921 (Pediatric)	MSD SUB MERCK	Pharmaceutical compositions of combinations of dipeptidyl peptidase-4 inhibitors with metformin	Jan, 2029 (4 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE)	Oct 16, 2011
M(M-244)	Aug 12, 2022
M(M-187)	Dec 04, 2023
Pediatric Exclusivity(PED)	Jun 04, 2024

Drugs and Companies using METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE ingredient

NCE-1 date: 05 June, 2023

Market Authorisation Date: 30 March, 2007

Treatment: NA

Dosage: TABLET

JANUMET family patents

90. Jardiance patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7579449 (Pediatric)	BOEHRINGER INGELHEIM	Glucopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture	Feb, 2029 (4 years from now)
US8551957	BOEHRINGER INGELHEIM	Pharmaceutical composition comprising a glucopyranosyl-substituted benzene derivate	Oct, 2029 (4 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
M(M-159)	Jun 26, 2018
M(M-160)	Jun 26, 2018
M(M-161)	Jun 26, 2018
M(M-174)	Mar 18, 2019
New Chemical Entity Exclusivity(NCE)	Aug 01, 2019
New Indication(I-739)	Dec 02, 2019
New Indication(I-869)	Aug 18, 2024
M(M-82)	Feb 24, 2025
Pediatric Exclusivity(PED)	Dec 20, 2026
New Patient Population(NPP)	Jun 20, 2026
New Indication(I-922)	Sep 21, 2026

Drugs and Companies using EMPAGLIFLOZIN ingredient

NCE-1 date: 20 December, 2025

Market Authorisation Date: 01 August, 2014

Treatment: Method of treating type 2 diabetes mellitus by administering linagliptin in combination with empagliflozin

Dosage: TABLET

JARDIANCE family patents

91. Jatenzo patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8241664	TOLMAR	Pharmaceutical delivery systems for hydrophobic drugs and compositions comprising same	Mar, 2029 (4 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Product(NP)	Mar 27, 2022

Drugs and Companies using TESTOSTERONE UNDECANOATE ingredient

Market Authorisation Date: 27 March, 2019

Treatment: Method of treating testosterone deficiency

Dosage: CAPSULE

JATENZO family patents

92. Jentadueto patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10973827	BOEHRINGER INGELHEIM	DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation	Apr, 2029 (4 years from now)
US9415016	BOEHRINGER INGELHEIM	DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation	Apr, 2029 (4 years from now)
US10022379	BOEHRINGER INGELHEIM	DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation	Apr, 2029 (4 years from now)
US10022379 (Pediatric)	BOEHRINGER INGELHEIM	DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation	Oct, 2029 (4 years from now)
US10973827 (Pediatric)	BOEHRINGER INGELHEIM	DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation	Oct, 2029 (4 years from now)
US9415016 (Pediatric)	BOEHRINGER INGELHEIM	DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation	Oct, 2029 (4 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Combination(NC)	Jan 30, 2015
New Chemical Entity Exclusivity(NCE)	May 02, 2016
M(M-146)	Jul 30, 2017
M(M-258)	Jul 03, 2022
M(M-252)	Mar 30, 2023
M(M-295)	Jun 20, 2026
Pediatric Exclusivity(PED)	Dec 20, 2026

Drugs and Companies using LINAGLIPTIN; METFORMIN HYDROCHLORIDE ingredient

NCE-1 date: 20 December, 2025

Market Authorisation Date: 30 January, 2012

Treatment: Use of a pharmaceutical composition comprising linagliptin, metformin and a basic amino acid to treat type 2 diabetes mellitus

Dosage: TABLET

JENTADUETO family patents

93. Jentadueto Xr patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9415016	BOEHRINGER INGELHEIM	DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation	Apr, 2029 (4 years from now)
US10022379	BOEHRINGER INGELHEIM	DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation	Apr, 2029 (4 years from now)
US9415016 (Pediatric)	BOEHRINGER INGELHEIM	DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation	Oct, 2029 (4 years from now)
US10022379 (Pediatric)	BOEHRINGER INGELHEIM	DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation	Oct, 2029 (4 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
M(M-258)	Jul 03, 2022
M(M-252)	Mar 30, 2023
M(M-295)	Jun 20, 2026
Pediatric Exclusivity(PED)	Dec 20, 2026

Drugs and Companies using LINAGLIPTIN; METFORMIN HYDROCHLORIDE ingredient

Market Authorisation Date: 27 May, 2016

Treatment: Use of a pharmaceutical composition comprising linagliptin, metformin and a basic amino acid to treat type 2 diabetes mellitus

Dosage: TABLET, EXTENDED RELEASE

JENTADUETO XR family patents

94. Juluca patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9242986	VIIV HLTHCARE	Synthesis of carbamoylpyridone HIV integrase inhibitors and intermediates	Dec, 2029 (5 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE)	Aug 12, 2018
New Combination(NC)	Nov 21, 2020

Drugs and Companies using DOLUTEGRAVIR SODIUM; RILPIVIRINE HYDROCHLORIDE ingredient

NCE-1 date: 12 August, 2017

Market Authorisation Date: 21 November, 2017

Treatment: NA

Dosage: TABLET

JULUCA family patents

95. Kalydeco patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10646481	VERTEX PHARMS INC	Pharmaceutical composition and administrations thereof	Aug, 2029 (4 years from now)
US11564916	VERTEX PHARMS INC	Pharmaceutical composition and administrations thereof	Aug, 2029 (4 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE)	Jan 31, 2017
New Indication(I-740)	Feb 21, 2017
New Indication(I-705)	Dec 30, 2017
Orphan Drug Exclusivity(ODE)	Jan 31, 2019
Orphan Drug Exclusivity(ODE-20)	Jan 31, 2019
New Patient Population(NPP)	May 03, 2026
Orphan Drug Exclusivity(ODE-186)	Feb 21, 2021
Orphan Drug Exclusivity(ODE-187)	Dec 29, 2021
Orphan Drug Exclusivity(ODE-188)	Mar 17, 2022
Orphan Drug Exclusivity(ODE-190)	May 17, 2024
Orphan Drug Exclusivity(ODE-189)	Jul 31, 2024
Orphan Drug Exclusivity(ODE-199)	Aug 15, 2025
Orphan Drug Exclusivity(ODE-236)	Apr 29, 2026
Orphan Drug Exclusivity(ODE-338)	Dec 21, 2027
Orphan Drug Exclusivity(ODE-435)	May 03, 2030

Drugs and Companies using IVACAFTOR ingredient

NCE-1 date: 01 February, 2016

Market Authorisation Date: 03 May, 2023

Treatment: Treatment of cf in a patient age 4 months to <6 years who has one mutation in the cftr gene that is responsive to ivacaftor based on clinical and/or in vitro assay data using the composition recited i...

Dosage: GRANULE

KALYDECO family patents

96. Kalydeco patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11564916	VERTEX PHARMS	Pharmaceutical composition and administrations thereof	Aug, 2029 (4 years from now)
US10646481	VERTEX PHARMS	Pharmaceutical composition and administrations thereof	Aug, 2029 (4 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE)	Jan 31, 2017
New Indication(I-740)	Feb 21, 2017
New Indication(I-705)	Dec 30, 2017
Orphan Drug Exclusivity(ODE)	Jan 31, 2019
Orphan Drug Exclusivity(ODE-20)	Jan 31, 2019
New Patient Population(NPP)	May 03, 2026
Orphan Drug Exclusivity(ODE-186)	Feb 21, 2021
Orphan Drug Exclusivity(ODE-187)	Dec 29, 2021
Orphan Drug Exclusivity(ODE-188)	Mar 17, 2022
Orphan Drug Exclusivity(ODE-190)	May 17, 2024
Orphan Drug Exclusivity(ODE-189)	Jul 31, 2024
Orphan Drug Exclusivity(ODE-199)	Aug 15, 2025
Orphan Drug Exclusivity(ODE-236)	Apr 29, 2026
Orphan Drug Exclusivity(ODE-338)	Dec 21, 2027
Orphan Drug Exclusivity(ODE-435)	May 03, 2030

Drugs and Companies using IVACAFTOR ingredient

NCE-1 date: 01 February, 2016

Market Authorisation Date: 20 May, 2019

Treatment: Treatment of cf in a patient age 6 years and older who has one mutation in the cftr gene that is responsive to ivacaftor based on clinical and/or in vitro assay data using the composition recited in c...

Dosage: TABLET

KALYDECO family patents

97. Karbinal Er patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8062667	AYTU	Modified release formulations containing drug-ion exchange resin complexes	Mar, 2029 (4 years from now)

Drugs and Companies using CARBINOXAMINE MALEATE ingredient

Market Authorisation Date: 28 March, 2013

Treatment: NA

Dosage: SUSPENSION, EXTENDED RELEASE

KARBINAL ER family patents

98. Kazano patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8900638	TAKEDA PHARMS USA	Solid preparation comprising alogliptin and metformin hydrochloride	May, 2029 (4 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Combination(NC)	Jan 25, 2016
New Chemical Entity Exclusivity(NCE)	Jan 25, 2018
M(M-177)	Apr 05, 2019
M(M-300)	Jul 27, 2026

Drugs and Companies using ALOGLIPTIN BENZOATE; METFORMIN HYDROCHLORIDE ingredient

NCE-1 date: 25 January, 2017

Market Authorisation Date: 25 January, 2013

Treatment: NA

Dosage: TABLET

KAZANO family patents

99. Kengreal patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8759316	CHIESI	Maintenance of platelet inhibition during antiplatelet therapy	May, 2029 (4 years from now)
US9925265	CHIESI	Methods of treating or preventing stent thrombosis	May, 2029 (4 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE)	Jun 22, 2020

Drugs and Companies using CANGRELOR ingredient

NCE-1 date: 23 June, 2019

Market Authorisation Date: 22 June, 2015

Treatment: P2y12 platelet inhibitor for use as adjunct to percutaneous coronary intervention to reduce risk of various diseases/conditions in patients not treated with a p2y12 platelet inhibitor and not given a ...

Dosage: POWDER

KENGREAL family patents

100. Kerendia patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8436180	BAYER HLTHCARE	Substituted-4-aryl-1,4-dihydro-1,6-naphthyridinamides and use thereof	Apr, 2029 (4 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
M(M-279)	Sep 01, 2025
New Chemical Entity Exclusivity(NCE)	Jul 09, 2026

Drugs and Companies using FINERENONE ingredient

NCE-1 date: 09 July, 2025

Market Authorisation Date: 09 July, 2021

Treatment: NA

Dosage: TABLET

KERENDIA family patents

101. Kimyrsa patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8420592	MELINTA THERAP	Methods of treatment using single doses of oritavancin	Aug, 2029 (4 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE)	Aug 06, 2019
New Product(NP)	Mar 12, 2024
Generating Antibiotic Incentives Now(GAIN)	Aug 06, 2024

Drugs and Companies using ORITAVANCIN DIPHOSPHATE ingredient

NCE-1 date: 07 August, 2023

Market Authorisation Date: 12 March, 2021

Treatment: Treatment of acute bacterial skin and skin structure infections with a single dose of 1200mg oritavancin or its single dose equivalent

Dosage: POWDER

KIMYRSA family patents

102. Kisqali patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9416136	NOVARTIS	Pyrrolopyrimidine compounds and their uses	Aug, 2029 (4 years from now)
US8962630	NOVARTIS	Pyrrolopyrimidine compounds and their uses	Dec, 2029 (5 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Indication(I-783)	Jul 18, 2021
New Indication(I-784)	Jul 18, 2021
New Chemical Entity Exclusivity(NCE)	Mar 13, 2022
New Patient Population(NPP)	Dec 10, 2024
New Indication(I-950)	Sep 17, 2027

Drugs and Companies using RIBOCICLIB SUCCINATE ingredient

NCE-1 date: 13 March, 2021

Market Authorisation Date: 13 March, 2017

Treatment: In combination with fulvestrant as initial endocrine-based therapy or following disease progression on endocrine therapy, for the treatment of adult patients with hr-positive, her2-negative advanced o...

Dosage: TABLET

KISQALI family patents

103. Kisqali Femara Co-pack (copackaged) patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9416136	NOVARTIS	Pyrrolopyrimidine compounds and their uses	Aug, 2029 (4 years from now)
US8962630	NOVARTIS	Pyrrolopyrimidine compounds and their uses	Dec, 2029 (5 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE)	Mar 13, 2022
New Patient Population(NPP)	Dec 10, 2024
New Indication(I-951)	Sep 17, 2027

Drugs and Companies using LETROZOLE; RIBOCICLIB SUCCINATE ingredient

NCE-1 date: 13 March, 2021

Market Authorisation Date: 04 May, 2017

Treatment: As initial endocrine-based therapy for the treatment of adult patients with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative advanced or metastatic breast cance...

Dosage: TABLET

KISQALI FEMARA CO-PACK (COPACKAGED) family patents

104. Klisyri patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7851470	ALMIRALL	Composition and methods for modulating a kinase cascade	Feb, 2029 (4 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE)	Dec 14, 2025
New Dosing Schedule(D-192)	Jun 07, 2027

Drugs and Companies using TIRBANIBULIN ingredient

NCE-1 date: 14 December, 2024

Market Authorisation Date: 14 December, 2020

Treatment: Topical treatment of actinic keratosis of the face or scalp

Dosage: OINTMENT

KLISYRI family patents

105. Koselugo patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11813246	ASTRAZENECA	Pharmaceutical composition	Mar, 2029 (4 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE)	Apr 10, 2025
Orphan Drug Exclusivity(ODE-288)	Apr 10, 2027

Drugs and Companies using SELUMETINIB SULFATE ingredient

NCE-1 date: 10 April, 2024

Market Authorisation Date: 10 April, 2020

Treatment: NA

Dosage: CAPSULE

KOSELUGO family patents

106. Kyleena patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11850182	BAYER HLTHCARE	Inserter	Sep, 2029 (4 years from now)
US9615965	BAYER HLTHCARE	Inserter	Sep, 2029 (4 years from now)
US10561524	BAYER HLTHCARE	Inserter	Sep, 2029 (4 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Product(NP)	Sep 16, 2019

Drugs and Companies using LEVONORGESTREL ingredient

Market Authorisation Date: 16 September, 2016

Treatment: A method of preventing pregnancy by providing an intrauterine system (ius), holding an inserter handle with one hand, inserting the ius into the uterus, and moving a slider in the handle to release th...

Dosage: SYSTEM

KYLEENA family patents

107. Kynmobi patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10821074	SUMITOMO PHARMA AM	Sublingual and buccal film compositions	Aug, 2029 (4 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Product(NP)	May 21, 2023

Drugs and Companies using APOMORPHINE HYDROCHLORIDE ingredient

Market Authorisation Date: 21 May, 2020

Treatment: NA

Dosage: FILM

KYNMOBI family patents

108. Kyprolis patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
USRE47954	ONYX PHARMS AMGEN	Combination therapy with peptide epoxyketones	Oct, 2029 (4 years from now)
US9511109	ONYX PHARMS AMGEN	Combination therapy with peptide epoxyketones	Oct, 2029 (4 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE)	Jul 20, 2017
New Indication(I-712)	Jul 24, 2018
New Indication(I-722)	Jan 21, 2019
New Indication(I-723)	Jan 21, 2019
Orphan Drug Exclusivity(ODE)	Jul 20, 2019
Orphan Drug Exclusivity(ODE-27)	Jul 20, 2019
New Dosing Schedule(D-172)	Sep 28, 2021
New Indication(I-842)	Aug 20, 2023

Drugs and Companies using CARFILZOMIB ingredient

NCE-1 date: 20 July, 2016

Market Authorisation Date: 07 June, 2018

Treatment: Use in combination with lenalidomide plus dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma who have received one to three lines of therapy; Kyprolis is indicate...

Dosage: POWDER

KYPROLIS family patents

109. Lamictal Odt patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7919115	GLAXOSMITHKLINE LLC	Orally disintegrating tablet compositions of lamotrigine	Jan, 2029 (4 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
M(M-159)	May 18, 2018

Drugs and Companies using LAMOTRIGINE ingredient

Market Authorisation Date: 08 May, 2009

Treatment: NA

Dosage: TABLET, ORALLY DISINTEGRATING

LAMICTAL ODT family patents

110. Leqvio patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8106022	NOVARTIS	Carbohydrate conjugates as delivery agents for oligonucleotides	Dec, 2029 (5 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE)	Dec 22, 2026

Drugs and Companies using INCLISIRAN SODIUM ingredient

NCE-1 date: 22 December, 2025

Market Authorisation Date: 22 December, 2021

Treatment: As an adjunct to diet and statin therapy for the treatment of adults with primary hyperlipidemia, including heterozygous familial hypercholesterolemia (hefh), by inhibiting expression of the pcsk9 gen...

Dosage: SOLUTION

LEQVIO family patents

111. Lo Loestrin Fe patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7704984	APIL	Extended estrogen dosing contraceptive regimen	Feb, 2029 (4 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Product(NP)	Oct 21, 2013

Drugs and Companies using ETHINYL ESTRADIOL; NORETHINDRONE ACETATE ingredient

Market Authorisation Date: 21 October, 2010

Treatment: Lo loestrin fe is indicated for the prevention of pregnancy in women who elect to use oral contraceptives as a method of contraception

Dosage: TABLET

LO LOESTRIN FE family patents

112. Lo Minastrin Fe patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7704984	APIL	Extended estrogen dosing contraceptive regimen	Feb, 2029 (4 years from now)

Drugs and Companies using ETHINYL ESTRADIOL; NORETHINDRONE ACETATE ingredient

Market Authorisation Date: 24 July, 2013

Treatment: Prevention of pregnancy

Dosage: TABLET, CHEWABLE, TABLET

LO MINASTRIN FE family patents

113. Lonhala Magnair Kit patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10940110	SUMITOMO PHARMA AM	Method and system for the treatment of chronic COPD with nebulized anticholinergic administrations	Feb, 2029 (4 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Product(NP)	Dec 05, 2020

Drugs and Companies using GLYCOPYRROLATE ingredient

Market Authorisation Date: 05 December, 2017

Treatment: Long-term maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (copd)

Dosage: SOLUTION

LONHALA MAGNAIR KIT family patents

114. Lonsurf patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
USRE46284	TAIHO ONCOLOGY	Method of administrating an anticancer drug containing α, α, α-trifluorothymidine and thymidine phosphorylase inhibitor	Sep, 2029 (4 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE)	Sep 22, 2020
New Indication(I-794)	Feb 22, 2022
Orphan Drug Exclusivity(ODE-229)	Feb 22, 2026

Drugs and Companies using TIPIRACIL HYDROCHLORIDE; TRIFLURIDINE ingredient

NCE-1 date: 23 September, 2019

Market Authorisation Date: 22 September, 2015

Treatment: Treatment of metastatic colorectal cancer alone or with bevacizumab in patients previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-vegf biological thera...

Dosage: TABLET

LONSURF family patents

115. Lumify patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11833245	BAUSCH AND LOMB INC	Vasoconstriction compositions and methods of use	Jul, 2029 (4 years from now)
US11596600	BAUSCH AND LOMB INC	Vasoconstriction compositions and methods of use	Jul, 2029 (4 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Product(NP)	Dec 22, 2020

Drugs and Companies using BRIMONIDINE TARTRATE ingredient

Market Authorisation Date: 22 December, 2017

Treatment: Relieves redness of the eye due to minor eye irritations

Dosage: SOLUTION/DROPS

LUMIFY family patents

116. Lumify Preservative Free patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11596600	BAUSCH AND LOMB INC	Vasoconstriction compositions and methods of use	Jul, 2029 (4 years from now)

Drugs and Companies using BRIMONIDINE TARTRATE ingredient

Market Authorisation Date: 19 April, 2024

Treatment: Relieves redness of the eye due to minor eye irritations

Dosage: SOLUTION/DROPS

LUMIFY PRESERVATIVE FREE family patents

117. Lymphoseek Kit patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9439985	CARDINAL HEALTH 414	Compositions for radiolabeling diethylenetriaminepentaacetic acid (DTPA)-dextran	Jan, 2029 (4 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Indication(I-687)	Jun 13, 2017
New Chemical Entity Exclusivity(NCE)	Mar 13, 2018
Orphan Drug Exclusivity(ODE)	Jun 13, 2021
Orphan Drug Exclusivity(ODE-67)	Jun 13, 2021
New Patient Population(NPP)	May 19, 2024

Drugs and Companies using TECHNETIUM TC-99M TILMANOCEPT ingredient

NCE-1 date: 13 March, 2017

Market Authorisation Date: 13 March, 2013

Treatment: NA

Dosage: INJECTABLE

LYMPHOSEEK KIT family patents

118. Lynparza patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11633396	ASTRAZENECA	Immediate release pharmaceutical formulation of 4-[3-(4- cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H- phthalazin-1-one	Oct, 2029 (4 years from now)
US11975001	ASTRAZENECA	Immediate release pharmaceutical formulation of 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one	Oct, 2029 (4 years from now)
US12048695	ASTRAZENECA	Immediate release pharmaceutical formulation of 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one	Oct, 2029 (4 years from now)
US8475842	ASTRAZENECA	Immediate release pharmaceutical formulation of 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one	Dec, 2029 (5 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE)	Dec 19, 2019
New Product(NP)	Aug 17, 2020
New Indication(I-762)	Jan 12, 2021
New Indication(I-776)	Dec 19, 2021
Orphan Drug Exclusivity(ODE)	Dec 19, 2021
Orphan Drug Exclusivity(ODE-83)	Dec 19, 2021
New Indication(I-818)	Dec 27, 2022
New Indication(I-831)	May 08, 2023
New Indication(I-832)	May 19, 2023
Orphan Drug Exclusivity(ODE-180)	Aug 17, 2024
Orphan Drug Exclusivity(ODE-181)	Aug 17, 2024
New Indication(I-885)	Mar 11, 2025
Orphan Drug Exclusivity(ODE-226)	Dec 19, 2025
New Indication(I-914)	May 31, 2026
Orphan Drug Exclusivity(ODE-283)	Dec 27, 2026
Orphan Drug Exclusivity(ODE-306)	May 08, 2027

Drugs and Companies using OLAPARIB ingredient

NCE-1 date: 19 December, 2018

Market Authorisation Date: 17 August, 2017

Treatment: NA

Dosage: TABLET

LYNPARZA family patents

119. Milprosa patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10537584	FERRING PHARMS INC	Monolithic intravaginal rings comprising progesterone and methods of making and uses thereof	Feb, 2029 (4 years from now)
US10548904	FERRING PHARMS INC	Monolithic intravaginal rings comprising progesterone and methods of making and uses thereof	Feb, 2029 (4 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Product(NP)	Apr 29, 2023

Drugs and Companies using PROGESTERONE ingredient

Market Authorisation Date: 29 April, 2020

Treatment: Method of supporting embryo implantation and early pregnancy by supplementation of corpus luteal function as part of an assisted reproductive technology (art) treatment program for infertile women

Dosage: SYSTEM

MILPROSA family patents

120. Mirapex Er patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8679533	BOEHRINGER INGELHEIM	Pramipexole once-daily dosage form	Sep, 2029 (4 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Dosage Form(NDF)	Feb 19, 2013
New Indication(I-623)	Mar 19, 2013

Drugs and Companies using PRAMIPEXOLE DIHYDROCHLORIDE ingredient

Market Authorisation Date: 19 February, 2010

Treatment: Treatment of parkinson's disease

Dosage: TABLET, EXTENDED RELEASE

MIRAPEX ER family patents

121. Mirena patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11850182	BAYER HLTHCARE	Inserter	Sep, 2029 (4 years from now)
US9615965	BAYER HLTHCARE	Inserter	Sep, 2029 (4 years from now)
US10561524	BAYER HLTHCARE	Inserter	Sep, 2029 (4 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Indication(I-610)	Oct 01, 2012
New Dosing Schedule(D-181)	Aug 20, 2023

Drugs and Companies using LEVONORGESTREL ingredient

Market Authorisation Date: 06 December, 2000

Dosage: SYSTEM

MIRENA family patents

122. Mitosol patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7806265	MOBIUS THERAP	Apparatus and method for reconstituting a pharmaceutical and preparing the reconstituted pharmaceutical for transient application	Feb, 2029 (4 years from now)
US9649428	MOBIUS THERAP	Apparatus and method for reconstituting a pharmaceutical and preparing the reconstituted pharmaceutical for transient application	May, 2029 (4 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE)	Feb 07, 2019
Orphan Drug Exclusivity(ODE-21)	Feb 07, 2019

Drugs and Companies using MITOMYCIN ingredient

Market Authorisation Date: 07 February, 2012

Treatment: Mitosol is an antimetabolite indicated as an adjunct to ab externo glaucoma surgery. it is intended for topical application to the site of glaucoma filtration surgery

Dosage: FOR SOLUTION

MITOSOL family patents

123. Monoferric patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US10414831	PHARMACOSMOS	Stable iron oligosaccharide compound	Mar, 2029 (4 years from now)
US11851504	PHARMACOSMOS	Stable iron oligosaccharide compound	Mar, 2029 (4 years from now)
US12030962	PHARMACOSMOS	Stable iron oligosaccharide compound	Mar, 2029 (4 years from now)
US8815301	PHARMACOSMOS	Stable iron oligosaccharide compound	Aug, 2029 (4 years from now)

Drugs and Companies using FERRIC DERISOMALTOSE ingredient

Market Authorisation Date: 16 January, 2020

Treatment: Method of treatment of iron deficiency anemia in adult patients who have intolerance to oral iron or have had unsatisfactory response to oral iron, who have non-hemodialysis dependent chronic kidney d...

Dosage: SOLUTION

MONOFERRIC family patents

124. Moxeza patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8450311	HARROW EYE	Pharmaceutical compositions containing a fluoroquinolone antibiotic drug	May, 2029 (4 years from now)
US9114168	HARROW EYE	Pharmaceutical compositions containing a fluoroquinolone antibiotic drug	May, 2029 (4 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Product(NP)	Nov 19, 2013
Pediatric Exclusivity(PED)	May 19, 2014

Drugs and Companies using MOXIFLOXACIN HYDROCHLORIDE ingredient

Market Authorisation Date: 19 November, 2010

Treatment: NA

Dosage: SOLUTION/DROPS

MOXEZA family patents

125. Multaq patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9107900	SANOFI AVENTIS US	Use of dronedarone for the preparation of a medicament for use in the prevention of cardiovascular hospitalization or of morality	Apr, 2029 (4 years from now)
US8410167	SANOFI AVENTIS US	Use of dronedarone for the preparation of a medicament for use in the prevention of cardiovascular hospitalization or of mortality	Apr, 2029 (4 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE)	Jul 01, 2014

Drugs and Companies using DRONEDARONE HYDROCHLORIDE ingredient

NCE-1 date: 01 July, 2013

Market Authorisation Date: 01 July, 2009

Treatment: Reduction in risk of hospitalization in patients with coronary heart disease and a history of paroxysmal or persistent af and with one or more risk factors by administration twice a day with morning a...

Dosage: TABLET

MULTAQ family patents

126. Mycapssa patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9265812	CHIESI	Pharmaceutical compositions and related methods of delivery	Sep, 2029 (4 years from now)
US11986529	CHIESI	Pharmaceutical compositions and related methods of delivery	Sep, 2029 (4 years from now)
US8535695	CHIESI	Pharmaceutical compositions and related methods of delivery	Sep, 2029 (4 years from now)
US8329198	CHIESI	Pharmaceutical compositions and related methods of delivery	Sep, 2029 (4 years from now)
US11969471	CHIESI	Pharmaceutical compositions and related methods of delivery	Sep, 2029 (4 years from now)
US9566246	CHIESI	Pharmaceutical compositions and related methods of delivery	Sep, 2029 (4 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Product(NP)	Jun 26, 2023
Orphan Drug Exclusivity(ODE-474)	Jun 26, 2027

Drugs and Companies using OCTREOTIDE ACETATE ingredient

Market Authorisation Date: 26 June, 2020

Treatment: Use of oral octreotide for long-term maintenance treatment in acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide

Dosage: CAPSULE, DELAYED RELEASE

MYCAPSSA family patents

127. Mydayis patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8846100	TAKEDA PHARMS USA	Controlled dose drug delivery system	Aug, 2029 (4 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Product(NP)	Jun 20, 2020
M(M-248)	Sep 13, 2022
Pediatric Exclusivity(PED)	Mar 13, 2023

Drugs and Companies using AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE ingredient

Market Authorisation Date: 20 June, 2017

Treatment: NA

Dosage: CAPSULE, EXTENDED RELEASE

MYDAYIS family patents

128. Myrbetriq patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8772315 (Pediatric)	APGDI	Pharmaceutical composition for treating overactive bladder	Apr, 2029 (4 years from now)
US12097189	APGDI	Pharmaceutical composition for modified release	Sep, 2029 (4 years from now)
US10842780	APGDI	Pharmaceutical composition for modified release	Sep, 2029 (4 years from now)
US12059409	APGDI	Pharmaceutical composition for modified release	Sep, 2029 (4 years from now)
US11707451	APGDI	Pharmaceutical composition for modified release	Sep, 2029 (4 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE)	Jun 28, 2017
New Indication(I-777)	Apr 27, 2021
New Indication(I-855)	Mar 25, 2024
Pediatric Exclusivity(PED)	Sep 25, 2024

Drugs and Companies using MIRABEGRON ingredient

NCE-1 date: 26 September, 2023

Market Authorisation Date: 28 June, 2012

Treatment: Administration of an extended release tablet for the treatment of neurogenic detrusor overactivity (ndo) in pediatric patients aged 3 years and older and weighing 35 kg or more; Administration of an e...

Dosage: TABLET, EXTENDED RELEASE

MYRBETRIQ family patents

129. Namenda Xr patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8039009	ABBVIE	Modified release formulations of memantine oral dosage forms	Mar, 2029 (4 years from now)
US8039009 (Pediatric)	ABBVIE	Modified release formulations of memantine oral dosage forms	Sep, 2029 (4 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Dosage Form(NDF)	Jun 21, 2013
M(M-138)	Jul 03, 2017
Pediatric Exclusivity(PED)	Jan 03, 2018

Drugs and Companies using MEMANTINE HYDROCHLORIDE ingredient

Market Authorisation Date: 21 June, 2010

Treatment: Treatment of moderate to severe dementia of the alzheimer's type

Dosage: CAPSULE, EXTENDED RELEASE

NAMENDA XR family patents

130. Namzaric patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8039009	ABBVIE	Modified release formulations of memantine oral dosage forms	Mar, 2029 (4 years from now)
US8039009 (Pediatric)	ABBVIE	Modified release formulations of memantine oral dosage forms	Sep, 2029 (4 years from now)
US8058291	ABBVIE	Methods and compositions for the treatment of CNS-related conditions	Dec, 2029 (5 years from now)

Drugs and Companies using DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE ingredient

Market Authorisation Date: 18 July, 2016

Treatment: Memantine hcl/donepezil hcl combination for the treatment of moderate to severe dementia of the alzheimer's type

Dosage: CAPSULE, EXTENDED RELEASE

NAMZARIC family patents

131. Nerlynx patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9265784	PUMA BIOTECH	Antineoplastic combinations of 4-anilino-3-cyanoquinolines and capecitabine	Aug, 2029 (4 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE)	Jul 17, 2022
New Indication(I-823)	Feb 25, 2023
New Dosing Schedule(D-182)	Jun 28, 2024

Drugs and Companies using NERATINIB MALEATE ingredient

NCE-1 date: 17 July, 2021

Market Authorisation Date: 17 July, 2017

Treatment: Use in combination with capecitabine, for the treatment of adult patients with advanced or metastatic her2-positive breast cancer who have received two or more prior anti-her2 based regimens in the me...

Dosage: TABLET

NERLYNX family patents

132. Nesina patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8697125	TAKEDA PHARMS USA	Tablet preparation without causing a tableting trouble	Jun, 2029 (4 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE)	Jan 25, 2018
M(M-177)	Apr 05, 2019
M(M-300)	Jul 27, 2026

Drugs and Companies using ALOGLIPTIN BENZOATE ingredient

NCE-1 date: 25 January, 2017

Market Authorisation Date: 25 January, 2013

Treatment: NA

Dosage: TABLET

NESINA family patents

133. Neuraceq patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7907135	LIFE MOLECULAR	Image display and image displaying method for gradation correction	Mar, 2029 (4 years from now)
US7807135	LIFE MOLECULAR	Stilbene derivatives and their use for binding and imaging amyloid plaques	Mar, 2029 (4 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE)	Mar 21, 2019

Drugs and Companies using FLORBETABEN F-18 ingredient

NCE-1 date: 21 March, 2018

Market Authorisation Date: 19 March, 2014

Treatment: Neuraceq is a radioactive diagnostic agent for positron emission tomography (pet) imaging of the brain to estimate p-amyloid neuritic plaque density in adult patients with cognitive impairment

Dosage: SOLUTION

NEURACEQ family patents

134. Nexterone patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7635773	BAXTER HLTHCARE	Sulfoalkyl ether cyclodextrin compositions	Mar, 2029 (4 years from now)

Drugs and Companies using AMIODARONE HYDROCHLORIDE ingredient

Market Authorisation Date: 24 December, 2008

Treatment: NA

Dosage: INJECTABLE

NEXTERONE family patents

135. Nicorette patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8940772	HALEON US HOLDINGS	Nicotine lozenge composition	Apr, 2029 (4 years from now)
US8501164	HALEON US HOLDINGS	Nicotine lozenge compositions	Jun, 2029 (4 years from now)

Drugs and Companies using NICOTINE POLACRILEX ingredient

Market Authorisation Date: 18 May, 2009

Treatment: NA

Dosage: TROCHE/LOZENGE

NICORETTE family patents

136. Ninlaro patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8859504	TAKEDA PHARMS USA	Boronate ester compounds and pharmaceutical compositions thereof	Jun, 2029 (4 years from now)
US7442830	TAKEDA PHARMS USA	Proteasome inhibitors	Nov, 2029 (5 years from now)
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9175017	TAKEDA PHARMS USA	Boronate ester compounds and pharmaceutical compositions thereof	Jun, 2029 (4 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE)	Nov 20, 2020
Orphan Drug Exclusivity(ODE)	Nov 20, 2022
Orphan Drug Exclusivity(ODE-103)	Nov 20, 2022

Drugs and Companies using IXAZOMIB CITRATE ingredient

NCE-1 date: 21 November, 2019

Market Authorisation Date: 20 November, 2015

Treatment: Use in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy

Dosage: CAPSULE

NINLARO family patents

137. Nitrolingual Pumpspray patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7872049	POHL BOSKAMP	Long-term stable pharmaceutical preparation containing the active ingredient glyceryl trinitrate	Mar, 2029 (4 years from now)

Drugs and Companies using NITROGLYCERIN ingredient

Market Authorisation Date: 31 October, 1985

Treatment: Method of treating angina pectoris

Dosage: SPRAY, METERED

NITROLINGUAL PUMPSPRAY family patents

138. Nocdurna patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10137167	FERRING PHARMS INC	Methods comprising desmopressin	May, 2029 (4 years from now)
US11963995	FERRING PHARMS INC	Methods comprising desmopressin	May, 2029 (4 years from now)
US11020448	FERRING PHARMS INC	Methods comprising desmopressin	May, 2029 (4 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Product(NP)	Jun 21, 2021

Drugs and Companies using DESMOPRESSIN ACETATE ingredient

Market Authorisation Date: 21 June, 2018

Treatment: Treatment of nocturia due to nocturnal polyuria in adults, comprising monitoring a patient's serum sodium concentration

Dosage: TABLET

NOCDURNA family patents

139. Noxafil patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9750822	MERCK SHARP DOHME	Sulfoalkyl ether cyclodextrin compositions	Mar, 2029 (4 years from now)
US10117951	MERCK SHARP DOHME	Sulfoalkyl ether cyclodextrin compositions	Mar, 2029 (4 years from now)
US8410077	MERCK SHARP DOHME	Sulfoalkyl ether cyclodextrin compositions	Mar, 2029 (4 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE)	Sep 15, 2011
New Patient Population(NPP)	May 31, 2024
New Indication(I-881)	Jun 17, 2024
Orphan Drug Exclusivity(ODE-355)	Jun 17, 2028

Drugs and Companies using POSACONAZOLE ingredient

Market Authorisation Date: 13 March, 2014

Treatment: NA

Dosage: SOLUTION

NOXAFIL family patents

140. Nucynta Er patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8536130 (Pediatric)	COLLEGIUM PHARM INC	Use of 1 phenyl-3-dimethylamino-propane compounds for treating neuropathic pain	Mar, 2029 (4 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE)	Nov 20, 2013
New Dosage Form(NDF)	Aug 25, 2014
New Indication(I-656)	Aug 28, 2015

Drugs and Companies using TAPENTADOL HYDROCHLORIDE ingredient

NCE-1 date: 20 November, 2012

Market Authorisation Date: 25 August, 2011

Treatment: NA

Dosage: TABLET, EXTENDED RELEASE

NUCYNTA ER family patents

141. Nuzyra patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10124014	PARATEK PHARMS INC	Minocycline compounds and methods of use thereof	Mar, 2029 (4 years from now)
US9265740	PARATEK PHARMS INC	Minocycline compounds and methods of use thereof	Mar, 2029 (4 years from now)
US9724358	PARATEK PHARMS INC	Minocycline compounds and methods of use thereof	Mar, 2029 (4 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE)	Oct 02, 2023
Generating Antibiotic Incentives Now(GAIN)	Oct 02, 2028

Drugs and Companies using OMADACYCLINE TOSYLATE ingredient

NCE-1 date: 03 October, 2027

Market Authorisation Date: 02 October, 2018

Treatment: Treatment of bacterial skin and skin structure infection; Treatment of bacterial skin and skin structure infections

Dosage: TABLET; POWDER

NUZYRA family patents

142. Odomzo patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8178563	SUN PHARM	Compounds and compositions as hedgehog pathway modulators	Jul, 2029 (4 years from now)
US8063043	SUN PHARM	Salts of N-[6-cis-2,6-dimethylmorpholin-4-yl)pyridine-3-yl]-2-methyl-4′-(trifluoromethoxy)[1,1′-biphenyl]-3-carboxamide	Sep, 2029 (4 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE)	Jul 24, 2020

Drugs and Companies using SONIDEGIB PHOSPHATE ingredient

NCE-1 date: 25 July, 2019

Market Authorisation Date: 24 July, 2015

Treatment: Treatment of basal cell carcinoma

Dosage: CAPSULE

ODOMZO family patents

143. Ofev patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10105323	BOEHRINGER INGELHEIM	Pharmaceutical dosage form for immediate release of an indolinone derivative	Jun, 2029 (4 years from now)
US9907756	BOEHRINGER INGELHEIM	Capsule pharmaceutical dosage form comprising a suspension formulation of an indolinone derivative	Jun, 2029 (4 years from now)
US10105323 (Pediatric)	BOEHRINGER INGELHEIM	Pharmaceutical dosage form for immediate release of an indolinone derivative	Dec, 2029 (5 years from now)
US9907756 (Pediatric)	BOEHRINGER INGELHEIM	Capsule pharmaceutical dosage form comprising a suspension formulation of an indolinone derivative	Dec, 2029 (5 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE)	Oct 15, 2019
Orphan Drug Exclusivity(ODE)	Oct 15, 2021
Orphan Drug Exclusivity(ODE-77)	Oct 15, 2021
New Indication(I-805)	Sep 06, 2022
New Indication(I-825)	Mar 09, 2023
Orphan Drug Exclusivity(ODE-261)	Sep 06, 2026
Pediatric Exclusivity(PED)	Mar 06, 2027

Drugs and Companies using NINTEDANIB ESYLATE ingredient

NCE-1 date: 06 March, 2026

Market Authorisation Date: 15 October, 2014

Treatment: NA

Dosage: CAPSULE

OFEV family patents

144. Ofirmev patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9987238 (Pediatric)	MALLINCKRODT HOSP	Reduced dose intravenous acetaminophen	May, 2029 (4 years from now)
US9610265 (Pediatric)	MALLINCKRODT HOSP	Reduced dose intravenous acetaminophen	May, 2029 (4 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Product(NP)	Nov 02, 2013
M(M-196)	Jan 27, 2020
Pediatric Exclusivity(PED)	Jul 27, 2020

Drugs and Companies using ACETAMINOPHEN ingredient

Market Authorisation Date: 02 November, 2010

Treatment: NA

Dosage: SOLUTION

OFIRMEV family patents

145. Oleptro patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8133893	ANGELINI PHARMA	Trazodone and trazodone hydrochloride in purified form	Mar, 2029 (4 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Dosage Form(NDF)	Feb 02, 2013

Drugs and Companies using TRAZODONE HYDROCHLORIDE ingredient

Market Authorisation Date: 02 February, 2010

Treatment: NA

Dosage: TABLET, EXTENDED RELEASE

OLEPTRO family patents

146. Olumiant patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8420629	ELI LILLY AND CO	Azetidine and cyclobutane derivatives as JAK inhibitors	Mar, 2029 (4 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE)	May 31, 2023
New Indication(I-891)	May 10, 2025
New Indication(I-890)	Jun 13, 2025

Drugs and Companies using BARICITINIB ingredient

NCE-1 date: 31 May, 2022

Market Authorisation Date: 08 October, 2019

Treatment: Treatment of rheumatoid arthritis

Dosage: TABLET

OLUMIANT family patents

147. Olysio patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8148399	JANSSEN PRODS	Macrocyclic inhibitors of hepatitis C virus	Sep, 2029 (4 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Indication(I-697)	Nov 05, 2017
New Dosing Schedule(D-151)	Oct 05, 2018
New Indication(I-717)	Oct 05, 2018
New Chemical Entity Exclusivity(NCE)	Nov 22, 2018
M(M-171)	Feb 26, 2019
M(M-179)	May 20, 2019

Drugs and Companies using SIMEPREVIR SODIUM ingredient

NCE-1 date: 22 November, 2017

Market Authorisation Date: 22 November, 2013

Treatment: Method of treating hepatitis c

Dosage: CAPSULE

OLYSIO family patents

148. Omlonti patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8648097	VISIOX PHARMA	Pyridylaminoacetic acid compound	Oct, 2029 (4 years from now)
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8685986	VISIOX PHARMA	Medical composition for treatment or prophylaxis of glaucoma	Oct, 2029 (4 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE)	Sep 22, 2027

Drugs and Companies using OMIDENEPAG ISOPROPYL ingredient

NCE-1 date: 22 September, 2026

Market Authorisation Date: 22 September, 2022

Treatment: NA

Dosage: SOLUTION

OMLONTI family patents

149. Onexton patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9504704	BAUSCH	Topical pharmaceutical formulations containing a low concentration of benzoyl peroxide in suspension in water and a water-miscible organic solvent	Jun, 2029 (4 years from now)
US10220049	BAUSCH	Topical pharmaceutical formulations containing a low concentration of benzoyl peroxide in suspension in water and a water-miscible organic solvent	Jun, 2029 (4 years from now)
US9561208	BAUSCH	Topical pharmaceutical formulations containing a low concentration of benzoyl peroxide in suspension in water and a water-miscible organic solvent	Jun, 2029 (4 years from now)
US10137142	BAUSCH	Topical pharmaceutical formulations containing a low concentration of benzoyl peroxide in suspension in water and a water-miscible organic solvent	Jun, 2029 (4 years from now)
US8288434	BAUSCH	Topical pharmaceutical formulations containing a low concentration of benzoyl peroxide in suspension in water and a water-miscible organic solvent	Aug, 2029 (4 years from now)

Drugs and Companies using BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE ingredient

Market Authorisation Date: 23 October, 2008

Treatment: Treatment of acne; Topical treatment of acne vulgaris in patients 12 years or older

Dosage: GEL

ONEXTON family patents

150. Ongentys patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8168793	AMNEAL	Nitrocatechol derivatives as COMT inhibitors	Apr, 2029 (4 years from now)
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8524746	AMNEAL	Dosage regimen for COMT inhibitors	Jul, 2029 (4 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE)	Apr 24, 2025

Drugs and Companies using OPICAPONE ingredient

NCE-1 date: 24 April, 2024

Market Authorisation Date: 24 April, 2020

Treatment: Adjunctive treatment to levodopa/carbidopa in patients with parkinson’s disease experiencing off episodes

Dosage: CAPSULE

ONGENTYS family patents

151. Onpattro patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US10240152	ALNYLAM PHARMS INC	Compositions and methods for inhibiting expression of transthyretin	Oct, 2029 (4 years from now)
US8168775	ALNYLAM PHARMS INC	Compositions and methods for inhibiting expression of transthyretin	Oct, 2029 (4 years from now)
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11141378	ALNYLAM PHARMS INC	Lipid formulations for nucleic acid delivery	Apr, 2029 (4 years from now)
US8058069	ALNYLAM PHARMS INC	Lipid formulations for nucleic acid delivery	Apr, 2029 (4 years from now)
US9364435	ALNYLAM PHARMS INC	Lipid formulations for nucleic acid delivery	Apr, 2029 (4 years from now)
US8822668	ALNYLAM PHARMS INC	Lipid formulations for nucleic acid delivery	Apr, 2029 (4 years from now)
US8492359	ALNYLAM PHARMS INC	Lipid formulations for nucleic acid delivery	Apr, 2029 (4 years from now)
US8741866	ALNYLAM PHARMS INC	Compositions and methods for inhibiting expression of transthyretin	Oct, 2029 (4 years from now)
US9234196	ALNYLAM PHARMS INC	Compositions and methods for inhibiting expression of transthyretin	Oct, 2029 (4 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE)	Aug 10, 2023
Orphan Drug Exclusivity(ODE-197)	Aug 10, 2025
M(M-270)	Jan 13, 2026

Drugs and Companies using PATISIRAN SODIUM ingredient

NCE-1 date: 10 August, 2022

Market Authorisation Date: 10 August, 2018

Treatment: Treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis

Dosage: SOLUTION

ONPATTRO family patents

152. Onureg patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US12053482	BRISTOL	Oral formulations of cytidine analogs and methods of use thereof	May, 2029 (4 years from now)
US11571436	BRISTOL	Oral formulations of cytidine analogs and methods of use thereof	May, 2029 (4 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Product(NP)	Sep 01, 2023
Orphan Drug Exclusivity(ODE-320)	Sep 01, 2027

Drugs and Companies using AZACITIDINE ingredient

Market Authorisation Date: 01 September, 2020

Treatment: Continued treatment of adults with acute myeloid leukemia who achieved first complete remission (cr) or cr with incomplete blood count recovery following intensive induction chemotherapy and are not a...

Dosage: TABLET

ONUREG family patents

153. Onyda Xr patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8062667	TRIS PHARMA INC	Modified release formulations containing drug-ion exchange resin complexes	Mar, 2029 (4 years from now)

Drugs and Companies using CLONIDINE HYDROCHLORIDE ingredient

Market Authorisation Date: 24 May, 2024

Treatment: NA

Dosage: SUSPENSION, EXTENDED RELEASE

ONYDA XR family patents

154. Onzetra Xsail patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10076615	CURRAX	Nasal delivery	Jul, 2029 (4 years from now)
US8550073	CURRAX	Nasal delivery	Oct, 2029 (4 years from now)

Drugs and Companies using SUMATRIPTAN SUCCINATE ingredient

Market Authorisation Date: 27 January, 2016

Treatment: Method of delivering sumatriptan to a nasal cavity

Dosage: POWDER

ONZETRA XSAIL family patents

155. Opana Er patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7851482	ENDO PHARMS	Method for making analgesics	Jul, 2029 (4 years from now)
US8871779	ENDO PHARMS	Process for preparing morphinan-6-one products with low levels of α,β-unsaturated ketone compounds	Nov, 2029 (5 years from now)

Drugs and Companies using OXYMORPHONE HYDROCHLORIDE ingredient

Market Authorisation Date: 09 December, 2011

Treatment: NA

Dosage: TABLET, EXTENDED RELEASE

OPANA ER family patents

156. Opana Er patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8871779	ENDO OPERATIONS	Process for preparing morphinan-6-one products with low levels of α,β-unsaturated ketone compounds	Nov, 2029 (5 years from now)

Drugs and Companies using OXYMORPHONE HYDROCHLORIDE ingredient

Market Authorisation Date: 22 June, 2006

Treatment: NA

Dosage: TABLET, EXTENDED RELEASE

OPANA ER family patents

157. Opsumit patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8268847	ACTELION	Therapeutic compositions comprising a specific endothelin receptor antagonist and a PDE5 inhibitor	Apr, 2029 (4 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE)	Oct 18, 2018
Orphan Drug Exclusivity(ODE)	Oct 18, 2020
Orphan Drug Exclusivity(ODE-54)	Oct 18, 2020

Drugs and Companies using MACITENTAN ingredient

NCE-1 date: 18 October, 2017

Market Authorisation Date: 18 October, 2013

Treatment: Method of treating pulmonary hypertension comprising administering macitentan in combination with a compound having phosphodiesterase-5 inhibitory properties

Dosage: TABLET

OPSUMIT family patents

158. Opsynvi patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8268847	ACTELION	Therapeutic compositions comprising a specific endothelin receptor antagonist and a PDE5 inhibitor	Apr, 2029 (4 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Product(NP)	Mar 22, 2027
Orphan Drug Exclusivity(ODE-475)	Mar 22, 2031

Drugs and Companies using MACITENTAN; TADALAFIL ingredient

Market Authorisation Date: 22 March, 2024

Treatment: Method of treating pulmonary arterial hypertension comprising administering a combination of macitentan and tadalafil

Dosage: TABLET

OPSYNVI family patents

159. Orbactiv patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8420592	MELINTA THERAP	Methods of treatment using single doses of oritavancin	Aug, 2029 (4 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE)	Aug 06, 2019
Generating Antibiotic Incentives Now(GAIN)	Aug 06, 2024

Drugs and Companies using ORITAVANCIN DIPHOSPHATE ingredient

NCE-1 date: 07 August, 2023

Market Authorisation Date: 06 August, 2014

Treatment: Treatment of bacterial skin and skin structure infections using a single dose

Dosage: POWDER

ORBACTIV family patents

160. Oriahnn (copackaged) patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7419983	ABBVIE	Gonadotropin-releasing hormone receptor antagonists and methods related thereto	Jul, 2029 (4 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Product(NP)	May 29, 2023
New Chemical Entity Exclusivity(NCE)	Jul 23, 2023

Drugs and Companies using ELAGOLIX SODIUM,ESTRADIOL,NORETHINDRONE ACETATE; ELAGOLIX SODIUM ingredient

NCE-1 date: 23 July, 2022

Market Authorisation Date: 29 May, 2020

Treatment: NA

Dosage: CAPSULE

ORIAHNN (COPACKAGED) family patents

161. Orilissa patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7419983	ABBVIE	Gonadotropin-releasing hormone receptor antagonists and methods related thereto	Jul, 2029 (4 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE)	Jul 23, 2023

Drugs and Companies using ELAGOLIX SODIUM ingredient

NCE-1 date: 23 July, 2022

Market Authorisation Date: 23 July, 2018

Treatment: Management of moderate to severe pain associated with endometriosis

Dosage: TABLET

ORILISSA family patents

162. Orkambi patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8846718	VERTEX PHARMS INC	Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxo1-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid	Jul, 2029 (4 years from now)
US10646481	VERTEX PHARMS INC	Pharmaceutical composition and administrations thereof	Aug, 2029 (4 years from now)
US11564916	VERTEX PHARMS INC	Pharmaceutical composition and administrations thereof	Aug, 2029 (4 years from now)
US9192606	VERTEX PHARMS INC	Dosage units of 3-(6-(1-(2,2-difluorobenzo[d] [1,3] dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid	Sep, 2029 (4 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Patient Population(NPP)	Sep 02, 2025
Pediatric Exclusivity(PED)	Jan 02, 2023
New Chemical Entity Exclusivity(NCE)	Jul 02, 2020
M(M-218)	Jan 25, 2021
New Product(NP)	Aug 07, 2021
Orphan Drug Exclusivity(ODE-93)	Jul 02, 2022
Orphan Drug Exclusivity(ODE)	Sep 28, 2023
Orphan Drug Exclusivity(ODE-123)	Sep 28, 2023
Orphan Drug Exclusivity(ODE-195)	Aug 07, 2025
New Strength(NS)	Sep 02, 2025
Generating Antibiotic Incentives Now(GAIN)	Jan 02, 2028
Orphan Drug Exclusivity(ODE-408)	Sep 02, 2029

Drugs and Companies using IVACAFTOR; LUMACAFTOR ingredient

NCE-1 date: 03 July, 2019

Market Authorisation Date: 02 September, 2022

Treatment: Treatment of cystic fibrosis in a patient age 2-5 years who is homozygous for the f508del mutation in the cftr gene using lumacaftor form i and ivacaftor; Treatment of cf in a patient age 6 years and ...

Dosage: GRANULE; TABLET

ORKAMBI family patents

163. Oseni patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8637079	TAKEDA PHARMS USA	Solid preparation comprising alogliptin and pioglitazone	Jun, 2029 (4 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Combination(NC)	Jan 25, 2016
New Chemical Entity Exclusivity(NCE)	Jan 25, 2018
M(M-177)	Apr 05, 2019

Drugs and Companies using ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE ingredient

NCE-1 date: 25 January, 2017

Market Authorisation Date: 25 January, 2013

Treatment: NA

Dosage: TABLET

OSENI family patents

164. Otiprio patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9603796	ALK ABELLO	Controlled release antimicrobial compositions and methods for the treatment of otic disorders	Apr, 2029 (4 years from now)
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11369566	ALK ABELLO	Controlled release antimicrobial compositions and methods for the treatment of otic disorders	Apr, 2029 (4 years from now)
US9205048	ALK ABELLO	Controlled release antimicrobial compositions and methods for the treatment of otic disorders	Apr, 2029 (4 years from now)
US9233068	ALK ABELLO	Controlled release antimicrobial compositions and methods for the treatment of OTIC disorders	Dec, 2029 (5 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Product(NP)	Dec 10, 2018
New Indication(I-770)	Mar 02, 2021

Drugs and Companies using CIPROFLOXACIN ingredient

Market Authorisation Date: 10 December, 2015

Treatment: Treatment of pediatric patients with otitis media with effusion undergoing tympanostomy tube placement; The treatment of acute otitis externa in patients 6 months of age and older due to pseudomonas a...

Dosage: INJECTABLE, SUSPENSION

OTIPRIO family patents

165. Otrexup patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11684723	OTTER PHARMS	Injector safety device	Mar, 2029 (4 years from now)
US9867949	OTTER PHARMS	Injector safety device	Mar, 2029 (4 years from now)
US10709844	OTTER PHARMS	Injector safety device	Mar, 2029 (4 years from now)

Drugs and Companies using METHOTREXATE ingredient

Market Authorisation Date: 07 November, 2014

Treatment: NA

Dosage: SOLUTION

OTREXUP family patents

166. Oxlumo patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8106022	ALNYLAM PHARMS INC	Carbohydrate conjugates as delivery agents for oligonucleotides	Dec, 2029 (5 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Indication(I-901)	Oct 06, 2025
New Chemical Entity Exclusivity(NCE)	Nov 23, 2025
Orphan Drug Exclusivity(ODE-339)	Nov 23, 2027
Orphan Drug Exclusivity(ODE-415)	Oct 06, 2029

Drugs and Companies using LUMASIRAN SODIUM ingredient

NCE-1 date: 23 November, 2024

Market Authorisation Date: 23 November, 2020

Treatment: Treatment of primary hyperoxaluria type 1 (ph1)

Dosage: SOLUTION

OXLUMO family patents

167. Pennsaid patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8741956	HORIZON	Treatment of pain with topical diclofenac	Jul, 2029 (4 years from now)
US8618164	HORIZON	Treatment of pain with topical diclofenac compounds	Jul, 2029 (4 years from now)
US9415029	HORIZON	Treatment of pain with topical diclofenac	Jul, 2029 (4 years from now)
US9370501	HORIZON	Treatment of pain with topical diclofenac	Jul, 2029 (4 years from now)
US9375412	HORIZON	Treatment of pain with topical diclofenac	Jul, 2029 (4 years from now)
US8217078	HORIZON	Treatment of pain with topical diclofenac	Jul, 2029 (4 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Dosage Form(NDF)	Nov 04, 2012
New Product(NP)	Jan 16, 2017

Drugs and Companies using DICLOFENAC SODIUM ingredient

Market Authorisation Date: 16 January, 2014

Treatment: Combination use of topical diclofenac on the knee and administration of an oral nsaid.; Use of topical diclofenac on the knee and a second topical prescription medication on the same knee; Use of topi...

Dosage: SOLUTION

PENNSAID family patents

168. Pennsaid patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8741956	NUVO PHARMS INC	Treatment of pain with topical diclofenac	Jul, 2029 (4 years from now)
US8618164	NUVO PHARMS INC	Treatment of pain with topical diclofenac compounds	Jul, 2029 (4 years from now)
US8217078	NUVO PHARMS INC	Treatment of pain with topical diclofenac	Jul, 2029 (4 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Dosage Form(NDF)	Nov 04, 2012
New Product(NP)	Jan 16, 2017

Drugs and Companies using DICLOFENAC SODIUM ingredient

Market Authorisation Date: 04 November, 2009

Dosage: SOLUTION

PENNSAID family patents

169. Piqray patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8476268	NOVARTIS	Pyrrolidine-1,2-dicarboxamide derivatives	Sep, 2029 (4 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE)	May 24, 2024
New Indication(I-937)	Jan 18, 2027

Drugs and Companies using ALPELISIB ingredient

NCE-1 date: 25 May, 2023

Market Authorisation Date: 24 May, 2019

Treatment: NA

Dosage: TABLET

PIQRAY family patents

170. Prestalia patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7846961	ADHERA	α crystalline form of the arginine salt of perindopril, a process for its preparation and pharmaceutical compositions containing it	Oct, 2029 (4 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Product(NP)	Jan 21, 2018

Drugs and Companies using AMLODIPINE BESYLATE; PERINDOPRIL ARGININE ingredient

Market Authorisation Date: 21 January, 2015

Treatment: Treatment of hypertension

Dosage: TABLET

PRESTALIA family patents

171. Prevymis patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
USRE46791	MSD	Substituted dihydroquinazolines	Jan, 2029 (4 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE)	Nov 08, 2022
ODE(ODE)	Jun 05, 2030
Orphan Drug Exclusivity(ODE-165)	Nov 08, 2024
New Indication(I-916)	Jun 05, 2026
New Dosing Schedule(D-189)	Aug 02, 2026
New Product(NP)	Aug 30, 2027
New Patient Population(NPP)	Aug 30, 2027
Orphan Drug Exclusivity(ODE-423)	Jun 05, 2030

Drugs and Companies using LETERMOVIR ingredient

Market Authorisation Date: 30 August, 2024

Treatment: NA

Dosage: PELLETS

PREVYMIS family patents

172. Prevymis patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
USRE46791	MERCK SHARP DOHME	Substituted dihydroquinazolines	Jan, 2029 (4 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE)	Nov 08, 2022
ODE(ODE)	Jun 05, 2030
Orphan Drug Exclusivity(ODE-165)	Nov 08, 2024
New Indication(I-916)	Jun 05, 2026
New Dosing Schedule(D-189)	Aug 02, 2026
New Product(NP)	Aug 30, 2027
New Patient Population(NPP)	Aug 30, 2027
Orphan Drug Exclusivity(ODE-423)	Jun 05, 2030

Drugs and Companies using LETERMOVIR ingredient

NCE-1 date: 08 November, 2021

Market Authorisation Date: 08 November, 2017

Treatment: NA

Dosage: TABLET; SOLUTION

PREVYMIS family patents

173. Prezcobix patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8148374	JANSSEN PRODS	Modulators of pharmacokinetic properties of therapeutics	Sep, 2029 (4 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE)	Aug 27, 2017

Drugs and Companies using COBICISTAT; DARUNAVIR ingredient

NCE-1 date: 27 August, 2016

Market Authorisation Date: 29 January, 2015

Treatment: Treatment of hiv infection in adults and pediatric patients weighing at least 40kg using a composition containing a pharmacokinetic enhancer that inhibits cytochrome p450 monooxygenase

Dosage: TABLET

PREZCOBIX family patents

174. Pylarify patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9861713	PROGENICS PHARMS INC	PSMA-binding agents and uses thereof	Jul, 2029 (4 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE)	May 26, 2026

Drugs and Companies using PIFLUFOLASTAT F-18 ingredient

NCE-1 date: 26 May, 2025

Market Authorisation Date: 26 May, 2021

Treatment: Method of positron emission tomography (pet) in men with prostate cancer

Dosage: SOLUTION

PYLARIFY family patents

175. Qbrexza patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8618160	JOURNEY	Topical glycopyrrolate formulations	Dec, 2029 (5 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Product(NP)	Jun 28, 2021

Drugs and Companies using GLYCOPYRRONIUM TOSYLATE ingredient

Market Authorisation Date: 28 June, 2018

Treatment: Topical treatment of primary axillary hyperhidrosis in adults and pediatric patients 9 years of age and older

Dosage: CLOTH

QBREXZA family patents

176. Qelbree patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11324753	SUPERNUS PHARMS	Method of treatment of attention deficit/hyperactivity disorder (ADHD)	Sep, 2029 (4 years from now)
US11458143	SUPERNUS PHARMS	Method of treatment of attention deficit/hyperactivity disorder (ADHD)	Sep, 2029 (4 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Patient Population(NPP)	Apr 29, 2025
New Chemical Entity Exclusivity(NCE)	Apr 02, 2026

Drugs and Companies using VILOXAZINE HYDROCHLORIDE ingredient

NCE-1 date: 02 April, 2025

Market Authorisation Date: 02 April, 2021

Treatment: For the treatment of attention deficit hyperactivity disorder (adhd)

Dosage: CAPSULE, EXTENDED RELEASE

QELBREE family patents

177. Qsymia patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8580298	VIVUS LLC	Low dose topiramate/phentermine composition and methods of use thereof	May, 2029 (4 years from now)
US8580299	VIVUS LLC	Escalating dosing regimen for effecting weight loss and treating obesity	Jun, 2029 (4 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Combination(NC)	Jul 17, 2015
New Patient Population(NPP)	Jun 24, 2025

Drugs and Companies using PHENTERMINE HYDROCHLORIDE; TOPIRAMATE ingredient

Market Authorisation Date: 17 July, 2012

Treatment: For chronic weight management in adults with bmi >=30 kg/m2, and patients age 12-17 with bmi >=30 kg/m2 and in the 95th percentile or greater (standardized for age and sex), each having a weight-relat...

Dosage: CAPSULE, EXTENDED RELEASE

QSYMIA family patents

178. Qtern patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7919598	ASTRAZENECA AB	Crystal structures of SGLT2 inhibitors and processes for preparing same	Dec, 2029 (5 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE)	Jan 08, 2019
M(M-175)	Apr 05, 2019
New Combination(NC)	Feb 27, 2020
New Indication(I-804)	May 02, 2022
New Strength(NS)	May 02, 2022

Drugs and Companies using DAPAGLIFLOZIN; SAXAGLIPTIN HYDROCHLORIDE ingredient

NCE-1 date: 08 January, 2018

Market Authorisation Date: 02 May, 2019

Treatment: NA

Dosage: TABLET

QTERN family patents

179. Qternmet Xr patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7919598	ASTRAZENECA AB	Crystal structures of SGLT2 inhibitors and processes for preparing same	Dec, 2029 (5 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Product(NP)	May 02, 2022

Drugs and Companies using DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE ingredient

Market Authorisation Date: 02 May, 2019

Treatment: NA

Dosage: TABLET, EXTENDED RELEASE

QTERNMET XR family patents

180. Quartette patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8415332	TEVA BRANDED PHARM	Methods of hormonal treatment utilizing ascending-dose extended cycle regimens	Mar, 2029 (4 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Product(NP)	Mar 28, 2016

Drugs and Companies using ETHINYL ESTRADIOL; LEVONORGESTREL ingredient

Market Authorisation Date: 28 March, 2013

Treatment: NA

Dosage: TABLET

QUARTETTE family patents

181. Quillivant Xr patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8062667	NEXTWAVE	Modified release formulations containing drug-ion exchange resin complexes	Mar, 2029 (4 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Dosage Form(NDF)	Sep 27, 2015

Drugs and Companies using METHYLPHENIDATE HYDROCHLORIDE ingredient

Market Authorisation Date: 27 September, 2012

Treatment: NA

Dosage: FOR SUSPENSION, EXTENDED RELEASE

QUILLIVANT XR family patents

182. Rasuvo patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8664231	MEDEXUS	Concentrated methotrexate solutions	Jun, 2029 (4 years from now)

Drugs and Companies using METHOTREXATE ingredient

Market Authorisation Date: 10 July, 2014

Treatment: Subcutaneous injection of methotrexate

Dosage: SOLUTION

RASUVO family patents

183. Relistor patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8420663	SALIX	Peripheral opioid receptor antagonists and uses thereof	Sep, 2029 (4 years from now)
US9724343	SALIX	Peripheral opioid receptor antagonists and uses thereof	Sep, 2029 (4 years from now)
US9492445	SALIX	Peripheral opioid receptor antagonists and uses thereof	Sep, 2029 (4 years from now)
US9180125	SALIX	Peripheral opioid receptor antagonists and uses thereof	Sep, 2029 (4 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE)	Apr 24, 2013
New Product(NP)	Jul 19, 2019

Drugs and Companies using METHYLNALTREXONE BROMIDE ingredient

Market Authorisation Date: 19 July, 2016

Treatment: Treatment of opioid-induced constipation

Dosage: TABLET

RELISTOR family patents

184. Relistor patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9492445	SALIX PHARMS	Peripheral opioid receptor antagonists and uses thereof	Sep, 2029 (4 years from now)
US8822490	SALIX PHARMS	Peripheral opioid receptor antagonists and uses thereof	Sep, 2029 (4 years from now)
US9180125	SALIX PHARMS	Peripheral opioid receptor antagonists and uses thereof	Sep, 2029 (4 years from now)
US8420663	SALIX PHARMS	Peripheral opioid receptor antagonists and uses thereof	Sep, 2029 (4 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE)	Apr 24, 2013
New Product(NP)	Jul 19, 2019

Drugs and Companies using METHYLNALTREXONE BROMIDE ingredient

NCE-1 date: 24 April, 2012

Market Authorisation Date: 27 September, 2010

Treatment: Treatment of opioid-induced constipation

Dosage: SOLUTION

RELISTOR family patents

185. Remodulin patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7999007	UNITED THERAP	Buffer solutions having selective bactericidal activity against gram negative bacteria and methods of using same	Mar, 2029 (4 years from now)

Drugs and Companies using TREPROSTINIL ingredient

Market Authorisation Date: 28 September, 2023

Treatment: Administration of remodulin diluted for intravenous infusion with sterile diluent for flolan or sterile diluent for epoprostenol sodium prior to administration

Dosage: INJECTABLE

REMODULIN family patents

186. Rexulti patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
USRE48059 (Pediatric)	OTSUKA	Piperazine-substituted benzothiophenes for treatment of mental disorders	Jun, 2029 (4 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
M(M-186)	Sep 23, 2019
New Chemical Entity Exclusivity(NCE)	Jul 10, 2020
New Patient Population(NPP)	Dec 27, 2024
New Indication(I-913)	May 10, 2026
Pediatric Exclusivity(PED)	Nov 10, 2026
M(M-14)	May 08, 2027

Drugs and Companies using BREXPIPRAZOLE ingredient

NCE-1 date: 10 November, 2025

Market Authorisation Date: 10 July, 2015

Treatment: NA

Dosage: TABLET

REXULTI family patents

187. Rezurock patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8357693	KADMON PHARMS LLC	Pharmacokinetically improved compounds	Oct, 2029 (4 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE)	Jul 16, 2026
Orphan Drug Exclusivity(ODE-362)	Jul 16, 2028

Drugs and Companies using BELUMOSUDIL MESYLATE ingredient

NCE-1 date: 16 July, 2025

Market Authorisation Date: 16 July, 2021

Treatment: For the treatment of chronic graft versus hold disease

Dosage: TABLET

REZUROCK family patents

188. Rozlytrek patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8299057	GENENTECH INC	Substituted indazole derivatives active as kinase inhibitors	Mar, 2029 (4 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE)	Aug 15, 2024
Orphan Drug Exclusivity(ODE-265)	Aug 15, 2026
Orphan Drug Exclusivity(ODE-313)	Aug 15, 2026
New Product(NP)	Oct 20, 2026
New Patient Population(NPP)	Oct 20, 2026
Orphan Drug Exclusivity(ODE-448)	Oct 20, 2030

Drugs and Companies using ENTRECTINIB ingredient

NCE-1 date: 16 August, 2023

Market Authorisation Date: 15 August, 2019

Treatment: NA

Dosage: CAPSULE

ROZLYTREK family patents

189. Rukobia patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8168615	VIIV HLTHCARE	Prodrugs of piperazine and substituted piperidine antiviral agents	Jul, 2029 (4 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE)	Jul 02, 2025

Drugs and Companies using FOSTEMSAVIR TROMETHAMINE ingredient

NCE-1 date: 02 July, 2024

Market Authorisation Date: 02 July, 2020

Treatment: NA

Dosage: TABLET, EXTENDED RELEASE

RUKOBIA family patents

190. Ryzodeg 70/30 patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7615532	NOVO	Insulin derivatives	Jun, 2029 (4 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Patient Population(NPP)	Dec 16, 2019
New Chemical Entity Exclusivity(NCE)	Sep 25, 2020

Drugs and Companies using INSULIN ASPART; INSULIN DEGLUDEC ingredient

NCE-1 date: 26 September, 2019

Market Authorisation Date: 25 September, 2015

Treatment: NA

Dosage: SOLUTION

RYZODEG 70/30 family patents

191. Savella patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7994220	ABBVIE	Milnacipran for the long-term treatment of fibromyalgia syndrome	Sep, 2029 (4 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE)	Jan 14, 2014

Drugs and Companies using MILNACIPRAN HYDROCHLORIDE ingredient

NCE-1 date: 14 January, 2013

Market Authorisation Date: 14 January, 2009

Treatment: Management of fibromyalgia

Dosage: TABLET

SAVELLA family patents

192. Scenesse patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8334265	CLIVUNEL INC	Method of treatment of photodermatoses	Mar, 2029 (4 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE)	Oct 08, 2024
Orphan Drug Exclusivity(ODE-270)	Oct 08, 2026

Drugs and Companies using AFAMELANOTIDE ingredient

NCE-1 date: 09 October, 2023

Market Authorisation Date: 08 October, 2019

Treatment: Increase pain-free light exposure in adult patients with a history of phototoxic reactions from erythropoietic protoporphyria (epp)

Dosage: IMPLANT

SCENESSE family patents

193. Sesquient patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8410077	LUPIN	Sulfoalkyl ether cyclodextrin compositions	Mar, 2029 (4 years from now)
US9750822	LUPIN	Sulfoalkyl ether cyclodextrin compositions	Mar, 2029 (4 years from now)
US9200088	LUPIN	Sulfoalkyl ether cyclodextrin compositions	Mar, 2029 (4 years from now)
US7635773	LUPIN	Sulfoalkyl ether cyclodextrin compositions	Mar, 2029 (4 years from now)

Drugs and Companies using FOSPHENYTOIN SODIUM ingredient

Market Authorisation Date: 05 November, 2020

Treatment: NA

Dosage: SOLUTION

SESQUIENT family patents

194. Seysara patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8513223	ALMIRALL	Substituted tetracycline compounds for treatment of inflammatory skin disorders	Dec, 2029 (5 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE)	Oct 01, 2023

Drugs and Companies using SARECYCLINE HYDROCHLORIDE ingredient

NCE-1 date: 01 October, 2022

Market Authorisation Date: 01 October, 2018

Treatment: A method for treating a patient 9 years of age and older suffering from an inflammatory skin disorder of non-nodular moderate to severe acne vulgaris comprising administering an effective amount of sa...

Dosage: TABLET

SEYSARA family patents

195. Silenor patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9532971	CURRAX	Low-dose doxepin formulations and methods of making and using the same	Jun, 2029 (4 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Product(NP)	Mar 17, 2013

Drugs and Companies using DOXEPIN HYDROCHLORIDE ingredient

Market Authorisation Date: 17 March, 2010

Treatment: NA

Dosage: TABLET

SILENOR family patents

196. Sirturo patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8546428	JANSSEN THERAP	Fumarate salt of (alpha S, beta R)-6-bromo-alpha-[2-(dimethylamino)ethyl]-2-methoxy-alpha-1-naphthalenyl-beta-phenyl-3-quinolineethanol	Mar, 2029 (4 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE)	Dec 28, 2017
Orphan Drug Exclusivity(ODE)	Dec 28, 2019
Orphan Drug Exclusivity(ODE-38)	Dec 28, 2019
New Patient Population(NPP)	Aug 09, 2022
Orphan Drug Exclusivity(ODE-251)	Aug 09, 2026
Orphan Drug Exclusivity(ODE-307)	May 27, 2027
M(M-306)	Jun 21, 2027

Drugs and Companies using BEDAQUILINE FUMARATE ingredient

NCE-1 date: 28 December, 2016

Market Authorisation Date: 27 May, 2020

Treatment: Treatment of pulmonary multi-drug resistant tuberculosis

Dosage: TABLET

SIRTURO family patents

197. Skyclarys patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9670147	REATA PHARMS	Antioxidant inflammation modulators: oleanolic acid derivatives with amino and other modifications at C-17	Apr, 2029 (4 years from now)
US8124799	REATA PHARMS	Antioxidant inflammation modulators: oleanolic acid derivatives with amino and other modifications at C-17	Dec, 2029 (5 years from now)
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8440854	REATA PHARMS	Antioxidant inflammation modulators: oleanolic acid derivatives with amino acid and other modifications at C-17	Apr, 2029 (4 years from now)
US11919838	REATA PHARMS	Antioxidant inflammation modulators: oleanolic acid derivatives with amino and other modifications at C-17	Apr, 2029 (4 years from now)
US11091430	REATA PHARMS	Antioxidant inflammation modulators: oleanolic acid derivatives with amino and other modifications at c-17	Apr, 2029 (4 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE)	Feb 28, 2028
Orphan Drug Exclusivity(ODE-427)	Feb 28, 2030

Drugs and Companies using OMAVELOXOLONE ingredient

NCE-1 date: 28 February, 2027

Market Authorisation Date: 28 February, 2023

Treatment: Method of treating friedrich's ataxia by activating the nrf2 pathway which reduces oxidative stress; Treatment of friedreich's ataxia in adults and adolescents aged 16 years and older

Dosage: CAPSULE

SKYCLARYS family patents

198. Skyla patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11850182	BAYER HLTHCARE	Inserter	Sep, 2029 (4 years from now)
US10561524	BAYER HLTHCARE	Inserter	Sep, 2029 (4 years from now)
US9615965	BAYER HLTHCARE	Inserter	Sep, 2029 (4 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Product(NP)	Jan 09, 2016

Drugs and Companies using LEVONORGESTREL ingredient

Market Authorisation Date: 09 January, 2013

Dosage: SYSTEM

SKYLA family patents

199. Soliqua 100/33 patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9526764	SANOFI-AVENTIS US	Combination of an insulin and a GLP-1-agonist	Oct, 2029 (4 years from now)
US10117909	SANOFI-AVENTIS US	Combination of an insulin and a GLP-1 agonist	Oct, 2029 (4 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Combination(NC)	Nov 21, 2019
New Chemical Entity Exclusivity(NCE)	Jul 27, 2021

Drugs and Companies using INSULIN GLARGINE; LIXISENATIDE ingredient

NCE-1 date: 27 July, 2020

Market Authorisation Date: 21 November, 2016

Treatment: NA

Dosage: SOLUTION

SOLIQUA 100/33 family patents

200. Soluprep S patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8623935	3M HEALTH CARE	Antimicrobial compositions	Jul, 2029 (4 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Product(NP)	Aug 08, 2021
M(M-292)	Jan 20, 2026

Drugs and Companies using CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL ingredient

Market Authorisation Date: 08 August, 2018

Treatment: For the preparation of skin prior to surgery; Helps reduce bacteria that can potentially cause skin infection

Dosage: SOLUTION

SOLUPREP S family patents

201. Sovaldi patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7964580	GILEAD SCIENCES INC	NA	Mar, 2029 (4 years from now)
US8633309	GILEAD SCIENCES INC	Nucleoside phosphoramidates	Mar, 2029 (4 years from now)
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8889159	GILEAD SCIENCES INC	Compositions and methods for treating hepatitis C virus	Mar, 2029 (4 years from now)
US9549941	GILEAD SCIENCES INC	Compositions and methods for treating hepatitis C virus	Mar, 2029 (4 years from now)
US7964580 (Pediatric)	GILEAD SCIENCES INC	NA	Sep, 2029 (4 years from now)
US8633309 (Pediatric)	GILEAD SCIENCES INC	Nucleoside phosphoramidates	Sep, 2029 (4 years from now)
US8889159 (Pediatric)	GILEAD SCIENCES INC	Compositions and methods for treating hepatitis C virus	Sep, 2029 (4 years from now)
US9549941 (Pediatric)	GILEAD SCIENCES INC	Compositions and methods for treating hepatitis C virus	Sep, 2029 (4 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE)	Dec 06, 2018
New Patient Population(NPP)	Apr 07, 2020
Orphan Drug Exclusivity(ODE)	Apr 07, 2024
ODE(ODE)	Aug 28, 2026
Orphan Drug Exclusivity(ODE-135)	Apr 07, 2024
Pediatric Exclusivity(PED)	Oct 07, 2024
Orphan Drug Exclusivity(ODE-258)	Aug 28, 2026

Drugs and Companies using SOFOSBUVIR ingredient

NCE-1 date: 08 October, 2023

Market Authorisation Date: 28 August, 2019

Treatment: For the treatment of hepatitis c; For the treatment of genotype 1, 2, 3 or 4 chronic hepatitis c virus (hcv) infection as a component of a combination antiviral treatment regimen with ribavirin

Dosage: TABLET; PELLETS

SOVALDI family patents

202. Spy Agent Green Kit patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8647605	NOVADAQ TECH	Real time imaging during solid organ transplant	Feb, 2029 (4 years from now)
US8406860	NOVADAQ TECH	Method for evaluating blush in myocardial tissue	Apr, 2029 (4 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Product(NP)	Nov 21, 2021
New Indication(I-911)	Jun 05, 2026

Drugs and Companies using INDOCYANINE GREEN ingredient

Market Authorisation Date: 21 November, 2018

Treatment: Visualization of vessels, blood flow and tissue perfusion of transplanted organ or attached vessel in vascular, gastrointestinal, organ transplant, and plastic, micro- and reconstructive, including mi...

Dosage: POWDER

SPY AGENT GREEN KIT family patents

203. Stribild patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8148374	GILEAD SCIENCES INC	Modulators of pharmacokinetic properties of therapeutics	Sep, 2029 (4 years from now)
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9891239	GILEAD SCIENCES INC	Modulators of pharmacokinetic properties of therapeutics	Sep, 2029 (4 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Product(NP)	Aug 27, 2015
New Chemical Entity Exclusivity(NCE)	Aug 27, 2017
New Indication(I-704)	Dec 17, 2017
New Patient Population(NPP)	Jan 27, 2020

Drugs and Companies using COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE ingredient

NCE-1 date: 27 August, 2016

Market Authorisation Date: 27 August, 2012

Treatment: Treatment of hiv infection; Treatment of hiv infection using a composition containing a pharmacokinetic enhancer that inhibits cytochrome p450 monooxygenase

Dosage: TABLET

STRIBILD family patents

204. Suboxone patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9687454	INDIVIOR	Sublingual and buccal film compositions	Aug, 2029 (4 years from now)
US11135216	INDIVIOR	Sublingual and buccal film compositions	Aug, 2029 (4 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Dosage Form(NDF)	Aug 30, 2013

Drugs and Companies using BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE ingredient

Market Authorisation Date: 30 August, 2010

Treatment: Treatment of opioid dependence/sublingual or buccal application; Treating opioid use disorder

Dosage: FILM

SUBOXONE family patents

205. Suprenza patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8440170	CITIUS PHARMS	Orally disintegrating tablets with speckled appearance	Mar, 2029 (4 years from now)

Drugs and Companies using PHENTERMINE HYDROCHLORIDE ingredient

Market Authorisation Date: 13 June, 2011

Treatment: NA

Dosage: TABLET, ORALLY DISINTEGRATING

SUPRENZA family patents

206. Symbicort patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8616196	ASTRAZENECA	Inhalation device and a method for assembling said inhalation device	Apr, 2029 (4 years from now)
US8528545 (Pediatric)	ASTRAZENECA	Inhaler device that reduces the risk for miscounting a dosage	Apr, 2029 (4 years from now)
US8616196 (Pediatric)	ASTRAZENECA	Inhalation device and a method for assembling said inhalation device	Oct, 2029 (4 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Indication(I-582)	Feb 27, 2012
New Patient Population(NPP)	Jan 27, 2020
Pediatric Exclusivity(PED)	Jul 27, 2020
M(M-210)	Sep 11, 2020
M(M-214)	Dec 20, 2020

Drugs and Companies using BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE ingredient

Market Authorisation Date: 21 July, 2006

Treatment: NA

Dosage: AEROSOL, METERED

SYMBICORT family patents

207. Symdeko (copackaged) patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11564916	VERTEX PHARMS INC	Pharmaceutical composition and administrations thereof	Aug, 2029 (4 years from now)
US10646481	VERTEX PHARMS INC	Pharmaceutical composition and administrations thereof	Aug, 2029 (4 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Patient Population(NPP)	Jun 21, 2022
New Chemical Entity Exclusivity(NCE)	Feb 12, 2023
Orphan Drug Exclusivity(ODE-173)	Feb 12, 2025
Orphan Drug Exclusivity(ODE-247)	Jun 21, 2026
Orphan Drug Exclusivity(ODE-335)	Dec 21, 2027

Drugs and Companies using IVACAFTOR; IVACAFTOR, TEZACAFTOR ingredient

NCE-1 date: 12 February, 2022

Market Authorisation Date: 21 June, 2019

Treatment: Treatment of cf in a patient age 6 years and older who is homozygous for f508del or has at least one cftr gene mutation responsive to tez/iva based on in vitro data and/or clinical evidence using the ...

Dosage: TABLET

SYMDEKO (COPACKAGED) family patents

208. Symtuza patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8148374	JANSSEN PRODS	Modulators of pharmacokinetic properties of therapeutics	Sep, 2029 (4 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE)	Nov 05, 2020
New Combination(NC)	Jul 17, 2021

Drugs and Companies using COBICISTAT; DARUNAVIR; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE ingredient

NCE-1 date: 06 November, 2019

Market Authorisation Date: 17 July, 2018

Treatment: Treatment of hiv-1 infection using a composition containing a pharmacokinetic enhancer that inhibits cytochrome p450 monooxygenase in adults who are virologically suppressed on a stable antiretroviral...

Dosage: TABLET

SYMTUZA family patents

209. Synjardy patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7579449 (Pediatric)	BOEHRINGER INGELHEIM	Glucopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture	Feb, 2029 (4 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Product(NP)	Aug 26, 2018
M(M-174)	Mar 18, 2019
New Chemical Entity Exclusivity(NCE)	Aug 01, 2019
New Indication(I-739)	Dec 02, 2019
New Patient Population(NPP)	Jun 20, 2026
Pediatric Exclusivity(PED)	Dec 20, 2026

Drugs and Companies using EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE ingredient

NCE-1 date: 20 December, 2025

Market Authorisation Date: 26 August, 2015

Treatment: NA

Dosage: TABLET

SYNJARDY family patents

210. Synjardy Xr patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7579449 (Pediatric)	BOEHRINGER INGELHEIM	Glucopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture	Feb, 2029 (4 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE)	Aug 01, 2019
New Indication(I-739)	Dec 02, 2019
M(M-296)	Jun 20, 2026
Pediatric Exclusivity(PED)	Dec 20, 2026

Drugs and Companies using EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE ingredient

NCE-1 date: 20 December, 2025

Market Authorisation Date: 09 December, 2016

Treatment: NA

Dosage: TABLET, EXTENDED RELEASE

SYNJARDY XR family patents

211. Tabrecta patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8901123	NOVARTIS PHARM	Salts of 2-fluoro-N-methyl-4-[7-(quinolin-6-yl-methyl)-imidazo[1,2-B][1,2,4]triazin-2-yl]benzamide and processes related to preparing the same	May, 2029 (4 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE)	May 06, 2025
Orphan Drug Exclusivity(ODE-291)	May 06, 2027

Drugs and Companies using CAPMATINIB HYDROCHLORIDE ingredient

NCE-1 date: 06 May, 2024

Market Authorisation Date: 06 May, 2020

Treatment: Use for the treatment of patients with metastatic non-small cell lung cancer (nsclc) with a mesenchymal-epithelial transition (met) exon 14 skipping mutation

Dosage: TABLET

TABRECTA family patents

212. Tafinlar patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9233956	NOVARTIS	Benzene sulfonamide thiazole and oxazole compounds	May, 2029 (4 years from now)
US9233956 (Pediatric)	NOVARTIS	Benzene sulfonamide thiazole and oxazole compounds	Nov, 2029 (4 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Indication(I-678)	Jan 08, 2017
New Chemical Entity Exclusivity(NCE)	May 29, 2018
M(M-170)	Nov 20, 2018
Orphan Drug Exclusivity(ODE)	May 29, 2020
Orphan Drug Exclusivity(ODE-47)	May 29, 2020
New Indication(I-745)	Jun 22, 2020
Orphan Drug Exclusivity(ODE-58)	Jan 09, 2021
New Indication(I-778)	Apr 30, 2021
New Indication(I-781)	May 04, 2021
M(M-246)	Oct 06, 2022
Orphan Drug Exclusivity(ODE-147)	Jun 22, 2024
Orphan Drug Exclusivity(ODE-182)	Apr 30, 2025
Orphan Drug Exclusivity(ODE-183)	May 04, 2025
New Indication(I-894)	Jun 22, 2025
Pediatric Exclusivity(PED)	Sep 16, 2026
New Indication(I-908)	Mar 16, 2026
New Product(NP)	Mar 16, 2026
Orphan Drug Exclusivity(ODE-428)	Mar 16, 2030

Drugs and Companies using DABRAFENIB MESYLATE ingredient

NCE-1 date: 22 December, 2024

Market Authorisation Date: 29 May, 2013

Treatment: Tafinlar is indicated, in combination with trametinib, for the treatment of patients with unresectable or metastatic melanoma with braf v600e or v600k mutations, as detected by an fda-approved test.

Dosage: CAPSULE

TAFINLAR family patents

213. Talzenna patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8420650	PFIZER	Dihydropyridophthalazinone inhibitors of poly(ADP-ribose)polymerase (PARP)	Jul, 2029 (4 years from now)
US8012976	PFIZER	Dihydropyridophthalazinone inhibitors of poly(ADP-ribose)polymerase (PARP)	Oct, 2029 (4 years from now)
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9820985	PFIZER	Dihydropyridophthalazinone inhibitors of poly(ADP-ribose)polymerase (PARP)	Jul, 2029 (4 years from now)
US10780088	PFIZER	Dihydropyridophthalazinone inhibitors of poly(ADP-ribose)polymerase (PARP)	Jul, 2029 (4 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE)	Oct 16, 2023
New Indication(I-920)	Jun 20, 2026

Drugs and Companies using TALAZOPARIB TOSYLATE ingredient

NCE-1 date: 16 October, 2022

Market Authorisation Date: 20 June, 2023

Treatment: Treatment of adult patients with deleterious or suspected deleterious germline breast cancer susceptibility gene (brca)-mutated (gbrcam) human epidermal growth factor receptor 2 (her2)-negative locall...

Dosage: CAPSULE

TALZENNA family patents

214. Tarpeyo patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8491932	CALLIDITAS	Compositions for the oral delivery of corticosteroids	May, 2029 (4 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Product(NP)	Dec 15, 2024
Orphan Drug Exclusivity(ODE-389)	Dec 15, 2028
Orphan Drug Exclusivity(ODE-464)	Dec 20, 2030

Drugs and Companies using BUDESONIDE ingredient

Market Authorisation Date: 15 December, 2021

Treatment: Reduction in loss of kidney function in adults with primary immunoglobulin a nephropathy (igan) who are at risk of disease progression

Dosage: CAPSULE, DELAYED RELEASE

TARPEYO family patents

215. Tasigna patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8163904 (Pediatric)	NOVARTIS	Salts of 4-methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-Benzamide	Feb, 2029 (4 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE)	Oct 29, 2012
New Indication(I-627)	Jun 17, 2014
Orphan Drug Exclusivity(ODE)	Oct 29, 2014
New Dosing Schedule(D-170)	Dec 22, 2020
New Patient Population(NPP)	Mar 22, 2021
Orphan Drug Exclusivity(ODE-171)	Mar 22, 2025
Orphan Drug Exclusivity(ODE-172)	Mar 22, 2025
Orphan Drug Exclusivity(ODE-380)	Sep 23, 2028
Pediatric Exclusivity(PED)	Mar 23, 2029

Drugs and Companies using NILOTINIB HYDROCHLORIDE ingredient

NCE-1 date: 23 March, 2028

Market Authorisation Date: 22 March, 2018

Treatment: NA

Dosage: CAPSULE

TASIGNA family patents

216. Tavneos patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8906938	CHEMOCENTRYX	C5aR antagonists	Dec, 2029 (5 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE)	Oct 07, 2026
Orphan Drug Exclusivity(ODE-377)	Oct 07, 2028

Drugs and Companies using AVACOPAN ingredient

NCE-1 date: 07 October, 2025

Market Authorisation Date: 07 October, 2021

Treatment: NA

Dosage: CAPSULE

TAVNEOS family patents

217. Technivie patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8642538	ABBVIE	Macrocyclic hepatitis C serine protease inhibitors	Sep, 2029 (4 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Indication(I-743)	Jul 24, 2018
New Product(NP)	Jul 24, 2018
New Chemical Entity Exclusivity(NCE)	Dec 19, 2019

Drugs and Companies using OMBITASVIR; PARITAPREVIR; RITONAVIR ingredient

NCE-1 date: 19 December, 2018

Market Authorisation Date: 24 July, 2015

Treatment: Treatment of hcv infection using paritaprevir

Dosage: TABLET

TECHNIVIE family patents

218. Tekamlo patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8613949	NOVARTIS	Galenical formulations of organic compounds	Dec, 2029 (5 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE)	Mar 05, 2012
New Combination(NC)	Aug 26, 2013

Drugs and Companies using ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE ingredient

NCE-1 date: 06 March, 2011

Market Authorisation Date: 26 August, 2010

Treatment: NA

Dosage: TABLET

TEKAMLO family patents

219. Tepmetko patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8329692	EMD SERONO INC	Pyrimidinyl pyridazinone derivatives	Oct, 2029 (4 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE)	Feb 03, 2026
Orphan Drug Exclusivity(ODE-325)	Feb 03, 2028

Drugs and Companies using TEPOTINIB HYDROCHLORIDE ingredient

NCE-1 date: 03 February, 2025

Market Authorisation Date: 03 February, 2021

Treatment: NA

Dosage: TABLET

TEPMETKO family patents

220. Tiglutik Kit patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8765150	ITALFARMACO SA	Riluzole aqueous suspensions	Mar, 2029 (4 years from now)

Drugs and Companies using RILUZOLE ingredient

Market Authorisation Date: 05 September, 2018

Treatment: A method of treating amyotrophic lateral sclerosis in a patient in need of such treatment, said method comprising administering to said patient an effective amount of a suspension according to claim 1

Dosage: SUSPENSION

TIGLUTIK KIT family patents

221. Tivicay patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9242986	VIIV HLTHCARE	Synthesis of carbamoylpyridone HIV integrase inhibitors and intermediates	Dec, 2029 (5 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
M(M-166)	Jul 30, 2018
New Chemical Entity Exclusivity(NCE)	Aug 12, 2018
New Indication(I-758)	Nov 21, 2020

Drugs and Companies using DOLUTEGRAVIR SODIUM ingredient

NCE-1 date: 12 August, 2017

Market Authorisation Date: 09 June, 2016

Treatment: NA

Dosage: TABLET

TIVICAY family patents

222. Tivicay Pd patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9242986	VIIV HLTHCARE	Synthesis of carbamoylpyridone HIV integrase inhibitors and intermediates	Dec, 2029 (5 years from now)

Drugs and Companies using DOLUTEGRAVIR SODIUM ingredient

Market Authorisation Date: 12 June, 2020

Treatment: NA

Dosage: TABLET, FOR SUSPENSION

TIVICAY PD family patents

223. Tlando patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8778922	VERITY	Steroidal compositions	Jan, 2029 (4 years from now)
US11304960	VERITY	Steroidal compositions	Jan, 2029 (4 years from now)
US8865695	VERITY	Steroidal compositions	Jan, 2029 (4 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Product(NP)	Mar 28, 2025

Drugs and Companies using TESTOSTERONE UNDECANOATE ingredient

Market Authorisation Date: 28 March, 2022

Treatment: Testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone; Primary hypogonadism (congenital or acquired); Hypogonadotropic hypog...

Dosage: CAPSULE

TLANDO family patents

224. Tradjenta patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9486526	BOEHRINGER INGELHEIM	Treatment for diabetes in patients inappropriate for metformin therapy	Aug, 2029 (4 years from now)
US10034877	BOEHRINGER INGELHEIM	Treatment for diabetes in patients inappropriate for metformin therapy	Aug, 2029 (4 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
M(M-118)	Aug 13, 2015
M(M-121)	Aug 13, 2015
New Chemical Entity Exclusivity(NCE)	May 02, 2016
M(M-258)	Jul 03, 2022
M(M-252)	Mar 30, 2023
M(M-295)	Jun 20, 2026
Pediatric Exclusivity(PED)	Dec 20, 2026

Drugs and Companies using LINAGLIPTIN ingredient

NCE-1 date: 20 December, 2025

Market Authorisation Date: 02 May, 2011

Treatment: Method of treating type 2 diabetes mellitus in patients with severe chronic renal impairment and who are ineligible for metformin therapy by administering linagliptin; Treatment of type 2 diabetes mel...

Dosage: TABLET

TRADJENTA family patents

225. Travatan Z patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8268299	SANDOZ	Self preserved aqueous pharmaceutical compositions	Oct, 2029 (4 years from now)

Drugs and Companies using TRAVOPROST ingredient

Market Authorisation Date: 21 September, 2006

Treatment: NA

Dosage: SOLUTION/DROPS

TRAVATAN Z family patents

226. Treanda patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8445524	CEPHALON	Solid forms of bendamustine hydrochloride	Mar, 2029 (4 years from now)
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8883836	CEPHALON	Solid forms of bendamustine hydrochloride	Mar, 2029 (4 years from now)
US8669279	CEPHALON	Solid forms of bendamustine hydrochloride	Mar, 2029 (4 years from now)
US9533955	CEPHALON	Solid forms of bendamustine hydrochloride	Mar, 2029 (4 years from now)
US8344006	CEPHALON	Liquid formulations of bendamustine	Sep, 2029 (4 years from now)
US9533955 (Pediatric)	CEPHALON	Solid forms of bendamustine hydrochloride	Sep, 2029 (4 years from now)
US8445524 (Pediatric)	CEPHALON	Solid forms of bendamustine hydrochloride	Sep, 2029 (4 years from now)
US8669279 (Pediatric)	CEPHALON	Solid forms of bendamustine hydrochloride	Sep, 2029 (4 years from now)
US8883836 (Pediatric)	CEPHALON	Solid forms of bendamustine hydrochloride	Sep, 2029 (4 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Indication(I-580)	Oct 31, 2011
New Chemical Entity Exclusivity(NCE)	Mar 20, 2013
Pediatric Exclusivity(PED)	May 01, 2016
Orphan Drug Exclusivity(ODE)	Oct 31, 2015
ODE(ODE)	Dec 07, 2022

Drugs and Companies using BENDAMUSTINE HYDROCHLORIDE ingredient

NCE-1 date: 02 May, 2015

Market Authorisation Date: 01 May, 2009

Treatment: For use in the treatment of patients with chronic lymphocytic leukemia (cll) and/or indolent b-cell non-hodgkin lymphoma (nhl); For use in the treatment of patients with chronic lymphocytic leukemia (...

Dosage: POWDER; SOLUTION

TREANDA family patents

227. Trelstar patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10166181	VERITY	Slow release pharmaceutical composition made of microgranules	Jun, 2029 (4 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Product(NP)	Mar 10, 2013

Drugs and Companies using TRIPTORELIN PAMOATE ingredient

Market Authorisation Date: 10 March, 2010

Treatment: NA

Dosage: INJECTABLE

TRELSTAR family patents

228. Tresiba patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7615532	NOVO	Insulin derivatives	Jun, 2029 (4 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Patient Population(NPP)	Dec 16, 2019
New Chemical Entity Exclusivity(NCE)	Sep 25, 2020

Drugs and Companies using INSULIN DEGLUDEC ingredient

NCE-1 date: 26 September, 2019

Market Authorisation Date: 21 November, 2018

Treatment: NA

Dosage: SOLUTION

TRESIBA family patents

229. Triesence patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8211880	HARROW EYE	Low viscosity, highly flocculated triamcinolone acetonide suspensions for intravitreal injection	Mar, 2029 (4 years from now)
US8128960	HARROW EYE	Low viscosity, highly flocculated triamcinolone acetonide suspensions for intravitreal injection	Dec, 2029 (5 years from now)

Drugs and Companies using TRIAMCINOLONE ACETONIDE ingredient

Market Authorisation Date: 29 November, 2007

Treatment: Treatment of ophthalmic disorders

Dosage: INJECTABLE

TRIESENCE family patents

230. Triferic patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7816404	ROCKWELL MEDICAL INC	Methods for the preparation and use of ferric pyrophosphate citrate chelate compositions	Apr, 2029 (4 years from now)

Drugs and Companies using FERRIC PYROPHOSPHATE CITRATE ingredient

Market Authorisation Date: 25 April, 2016

Treatment: Method of iron administration to treat patients in need of iron replacement

Dosage: POWDER; SOLUTION

TRIFERIC family patents

231. Triferic Avnu patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7816404	ROCKWELL MEDICAL INC	Methods for the preparation and use of ferric pyrophosphate citrate chelate compositions	Apr, 2029 (4 years from now)

Drugs and Companies using FERRIC PYROPHOSPHATE CITRATE ingredient

Market Authorisation Date: 27 March, 2020

Treatment: Method of iron administration to treat patients in need of iron replacement therapy

Dosage: SOLUTION

TRIFERIC AVNU family patents

232. Trijardy Xr patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7579449 (Pediatric)	BOEHRINGER INGELHEIM	Glucopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture	Feb, 2029 (4 years from now)
US9415016	BOEHRINGER INGELHEIM	DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation	Apr, 2029 (4 years from now)
US10022379	BOEHRINGER INGELHEIM	DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation	Apr, 2029 (4 years from now)
US8551957	BOEHRINGER INGELHEIM	Pharmaceutical composition comprising a glucopyranosyl-substituted benzene derivate	Oct, 2029 (4 years from now)

Drugs and Companies using EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE ingredient

Market Authorisation Date: 27 January, 2020

Treatment: Method of treating type 2 diabetes using a pharmaceutical composition comprising linagliptin, metformin, empagliflozin and a basic amino acid; Method of treating type 2 diabetes mellitus using a pharm...

Dosage: TABLET, EXTENDED RELEASE

TRIJARDY XR family patents

233. Trikafta (copackaged) patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11564916	VERTEX PHARMS INC	Pharmaceutical composition and administrations thereof	Aug, 2029 (4 years from now)
US10646481	VERTEX PHARMS INC	Pharmaceutical composition and administrations thereof	Aug, 2029 (4 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Patient Population(NPP)	Jun 08, 2024
New Chemical Entity Exclusivity(NCE)	Oct 21, 2024
New Product(NP)	Apr 26, 2026
Orphan Drug Exclusivity(ODE-275)	Oct 21, 2026
Orphan Drug Exclusivity(ODE-323)	Dec 21, 2027
Orphan Drug Exclusivity(ODE-357)	Jun 08, 2028
Orphan Drug Exclusivity(ODE-433)	Apr 26, 2030

Drugs and Companies using ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR ingredient

NCE-1 date: 22 October, 2023

Market Authorisation Date: 26 April, 2023

Treatment: Treatment of cf in patients aged 2 to <6 years who have in the cftr gene at least one f508del mutation or a mutation that is responsive based on in vitro data comprising administering the composition ...

Dosage: GRANULES; TABLET

TRIKAFTA (COPACKAGED) family patents

234. Triptodur Kit patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10166181	AZURITY	Slow release pharmaceutical composition made of microgranules	Jun, 2029 (4 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Product(NP)	Jun 29, 2020
Orphan Drug Exclusivity(ODE)	Jun 29, 2024
Orphan Drug Exclusivity(ODE-149)	Jun 29, 2024

Drugs and Companies using TRIPTORELIN PAMOATE ingredient

Market Authorisation Date: 29 June, 2017

Treatment: NA

Dosage: FOR SUSPENSION, EXTENDED RELEASE

TRIPTODUR KIT family patents

235. Triumeq patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9242986	VIIV HLTHCARE	Synthesis of carbamoylpyridone HIV integrase inhibitors and intermediates	Dec, 2029 (5 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Dosing Schedule(D-147)	Mar 23, 2018
New Chemical Entity Exclusivity(NCE)	Aug 12, 2018
M(M-294)	Jun 15, 2026
Pediatric Exclusivity(PED)	Dec 15, 2026

Drugs and Companies using ABACAVIR SULFATE; DOLUTEGRAVIR SODIUM; LAMIVUDINE ingredient

NCE-1 date: 15 December, 2025

Market Authorisation Date: 22 August, 2014

Treatment: NA

Dosage: TABLET

TRIUMEQ family patents

236. Triumeq Pd patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9242986	VIIV HLTHCARE	Synthesis of carbamoylpyridone HIV integrase inhibitors and intermediates	Dec, 2029 (5 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Patient Population(NPP)	Jun 15, 2026
Pediatric Exclusivity(PED)	Dec 15, 2026

Drugs and Companies using ABACAVIR SULFATE; DOLUTEGRAVIR SODIUM; LAMIVUDINE ingredient

Market Authorisation Date: 30 March, 2022

Treatment: NA

Dosage: TABLET, FOR SUSPENSION

TRIUMEQ PD family patents

237. Truseltiq patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8552002	HELSINN HLTHCARE	Compounds and compositions as protein kinase inhibitors	Aug, 2029 (4 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE)	May 28, 2026
Orphan Drug Exclusivity(ODE-353)	May 28, 2028

Drugs and Companies using INFIGRATINIB PHOSPHATE ingredient

NCE-1 date: 28 May, 2025

Market Authorisation Date: 28 May, 2021

Treatment: NA

Dosage: CAPSULE

TRUSELTIQ family patents

238. Tryvio patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8324232	IDORSIA	4-pyrimidinesulfamide derivative	Sep, 2029 (4 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE)	Mar 22, 2029

Drugs and Companies using APROCITENTAN ingredient

NCE-1 date: 22 March, 2028

Market Authorisation Date: 19 March, 2024

Treatment: Treatment of hypertension in combination with other antihypertensive drugs, to lower blood pressure in adult patients who are not adequately controlled on other drugs

Dosage: TABLET

TRYVIO family patents

239. Tudorza Pressair patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10085974	COVIS	Dosage and formulation	Mar, 2029 (4 years from now)
US11000517	COVIS	Dosage and formulation	Mar, 2029 (4 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE)	Jul 23, 2017
M(M-256)	Mar 29, 2022

Drugs and Companies using ACLIDINIUM BROMIDE ingredient

NCE-1 date: 23 July, 2016

Market Authorisation Date: 23 July, 2012

Treatment: Maintenance treatment of chronic obstructive pulmonary disease (copd)

Dosage: POWDER, METERED

TUDORZA PRESSAIR family patents

240. Tuzistra Xr patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8062667	TRIS PHARMA INC	Modified release formulations containing drug-ion exchange resin complexes	Mar, 2029 (4 years from now)

Drugs and Companies using CHLORPHENIRAMINE POLISTIREX; CODEINE POLISTIREX ingredient

Market Authorisation Date: 30 April, 2015

Treatment: NA

Dosage: SUSPENSION, EXTENDED RELEASE

TUZISTRA XR family patents

241. Tybost patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8148374	GILEAD SCIENCES INC	Modulators of pharmacokinetic properties of therapeutics	Sep, 2029 (4 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE)	Aug 27, 2017
New Product(NP)	Sep 24, 2017
New Patient Population(NPP)	Aug 22, 2022
Orphan Drug Exclusivity(ODE-260)	Aug 22, 2026

Drugs and Companies using COBICISTAT ingredient

NCE-1 date: 27 August, 2016

Market Authorisation Date: 24 September, 2014

Treatment: Treatment of hiv infection using a composition containing a pharmacokinetic enhancer that inhibits cytochrome p450 monooxygenase

Dosage: TABLET

TYBOST family patents

242. Tygacil patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7879828	PF PRISM CV	Tigecycline compositions and methods of preparation	Feb, 2029 (4 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Indication(I-586)	Mar 20, 2012
New Indication(I-587)	Mar 20, 2012
New Indication(I-588)	Mar 20, 2012

Drugs and Companies using TIGECYCLINE ingredient

Market Authorisation Date: 15 June, 2005

Treatment: NA

Dosage: POWDER

TYGACIL family patents

243. Tykerb patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8821927	NOVARTIS	Pharmaceutical composition	Sep, 2029 (4 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE)	Mar 13, 2012
New Indication(I-620)	Jan 29, 2013
M(M-235)	Dec 06, 2021

Drugs and Companies using LAPATINIB DITOSYLATE ingredient

NCE-1 date: 14 March, 2011

Market Authorisation Date: 13 March, 2007

Treatment: NA

Dosage: TABLET

TYKERB family patents

244. Uptravi patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9173881	ACTELION	Therapeutic compositions containing macitentan	Aug, 2029 (4 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE)	Dec 21, 2020
Orphan Drug Exclusivity(ODE)	Dec 21, 2022
Orphan Drug Exclusivity(ODE-106)	Dec 21, 2022

Drugs and Companies using SELEXIPAG ingredient

NCE-1 date: 22 December, 2019

Market Authorisation Date: 21 December, 2015

Treatment: Method of treating pulmonary arterial hypertension comprising administering selexipag in combination with the endothelin receptor antagonist macitentan

Dosage: TABLET; POWDER

UPTRAVI family patents

245. Valchlor patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7872050	HELSINN	Stabilized compositions of volatile alkylating agents and methods of using thereof	Jul, 2029 (4 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Dosage Form(NDF)	Aug 23, 2016
Orphan Drug Exclusivity(ODE)	Aug 23, 2020
Orphan Drug Exclusivity(ODE-51)	Aug 23, 2020

Drugs and Companies using MECHLORETHAMINE HYDROCHLORIDE ingredient

Market Authorisation Date: 23 August, 2013

Treatment: Alkylating drug indicated for the topical treatment of stage ia and ib mycosis fungoides-type cutaneous t-cell lymphoma in patients who have received prior skin directed therapy

Dosage: GEL

VALCHLOR family patents

246. Valtoco patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8895546	NEURELIS INC	Administration of benzodiazepine compositions	Mar, 2029 (4 years from now)
US11793786	NEURELIS INC	Administration of benzodiazepine compositions	Mar, 2029 (4 years from now)
US11241414	NEURELIS INC	Administration of benzodiazepine compositions	Mar, 2029 (4 years from now)
US9763876	NEURELIS INC	Administration of benzodiazepine compositions	Mar, 2029 (4 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Product(NP)	Jan 10, 2023
Orphan Drug Exclusivity(ODE-279)	Jan 10, 2027

Drugs and Companies using DIAZEPAM ingredient

Market Authorisation Date: 10 January, 2020

Treatment: Nasal administration of diazepam for treatment of intermittent, stereotypic episodes of frequent seizure activity in patients 6 years of age and older

Dosage: SPRAY

VALTOCO family patents

247. Vanflyta patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7968543	DAIICHI SANKYO INC	Methods of administering N-(5-tert-butyl-isoxazol-3-yl)-N′-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea to treat proliferative disease	Aug, 2029 (4 years from now)
US8865710	DAIICHI SANKYO INC	Methods of treating proliferative diseases	Aug, 2029 (4 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE)	Jul 20, 2028
Orphan Drug Exclusivity(ODE-437)	Jul 20, 2030

Drugs and Companies using QUIZARTINIB DIHYDROCHLORIDE ingredient

NCE-1 date: 21 July, 2027

Market Authorisation Date: 20 July, 2023

Treatment: Combination with standard cytarabine and anthracycline induction and cytarabine consolidation, and as maintenance monotherapy following consolidation chemotherapy, for adult patients with newly diagno...

Dosage: TABLET

VANFLYTA family patents

248. Vantrela Er patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8445018	TEVA BRANDED PHARM	Abuse resistant drug formulation	Jul, 2029 (4 years from now)

Drugs and Companies using HYDROCODONE BITARTRATE ingredient

Market Authorisation Date: 17 January, 2017

Treatment: NA

Dosage: TABLET, EXTENDED RELEASE

VANTRELA ER family patents

249. Varubi patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8470842	TERSERA	Hydrochloride salts of 8-[{1-(3,5-Bis-trifluoromethyl)phenyl)-ethoxy}-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one and preparation process therefor	Jan, 2029 (4 years from now)
US8361500	TERSERA	Tablet formulations containing 8-[{1-(3,5-Bis-(trifluoromethyl)phenyl)-ethoxy}-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one salts and tablets made therefrom	Oct, 2029 (4 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE)	Sep 01, 2020

Drugs and Companies using ROLAPITANT HYDROCHLORIDE ingredient

NCE-1 date: 02 September, 2019

Market Authorisation Date: 25 October, 2017

Treatment: Prevention of delayed nausea and vomiting associated with emetogenic cancer chemotherapy

Dosage: EMULSION; TABLET

VARUBI family patents

250. Veklury patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8318682	GILEAD SCIENCES INC	1′substituted carba-nucleoside analogs for antiviral treatment	Apr, 2029 (4 years from now)
USRE46762	GILEAD SCIENCES INC	1′-substituted carba-nucleoside analogs for antiviral treatment	Apr, 2029 (4 years from now)
US8008264	GILEAD SCIENCES INC	1′-substituted carba-nucleoside analogs for antiviral treatment	Sep, 2029 (4 years from now)
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
USRE46762 (Pediatric)	GILEAD SCIENCES INC	1′-substituted carba-nucleoside analogs for antiviral treatment	Oct, 2029 (4 years from now)
US8318682 (Pediatric)	GILEAD SCIENCES INC	1′substituted carba-nucleoside analogs for antiviral treatment	Oct, 2029 (4 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Dosing Schedule(D-183)	Jan 21, 2025
New Patient Population(NPP)	Apr 25, 2025
New Chemical Entity Exclusivity(NCE)	Oct 22, 2025
M(M-301)	Jul 13, 2026
Pediatric Exclusivity(PED)	Jan 13, 2027

Drugs and Companies using REMDESIVIR ingredient

NCE-1 date: 13 January, 2026

Market Authorisation Date: 22 October, 2020

Treatment: NA

Dosage: SOLUTION; POWDER

VEKLURY family patents

251. Velphoro patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10695367 (Pediatric)	VIFOR FRESENIUS	Pharmaceutical compositions	May, 2029 (4 years from now)
US11013761 (Pediatric)	VIFOR FRESENIUS	Pharmaceutical compositions	May, 2029 (4 years from now)
US10682376 (Pediatric)	VIFOR FRESENIUS	Pharmaceutical compositions	May, 2029 (4 years from now)
US10933090 (Pediatric)	VIFOR FRESENIUS	Pharmaceutical compositions	May, 2029 (4 years from now)
US10925897 (Pediatric)	VIFOR FRESENIUS	Pharmaceutical compositions	May, 2029 (4 years from now)
US10925896 (Pediatric)	VIFOR FRESENIUS	Pharmaceutical compositions	May, 2029 (4 years from now)
US11013762 (Pediatric)	VIFOR FRESENIUS	Pharmaceutical compositions	May, 2029 (4 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Product(NP)	Nov 27, 2016
New Patient Population(NPP)	Jul 01, 2027
Pediatric Exclusivity(PED)	Jan 01, 2028

Drugs and Companies using FERRIC OXYHYDROXIDE ingredient

Market Authorisation Date: 27 November, 2013

Treatment: NA

Dosage: TABLET, CHEWABLE

VELPHORO family patents

252. Velsipity patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9126932	PFIZER	Substituted 1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid derivatives useful in the treatment of autoimmune and inflammatory disorders	Jul, 2029 (4 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE)	Oct 12, 2028

Drugs and Companies using ETRASIMOD ARGININE ingredient

NCE-1 date: 13 October, 2027

Market Authorisation Date: 12 October, 2023

Treatment: A method for treating ulcerative colitis by administering a therapeutically effective amount of estrasimod arginine

Dosage: TABLET

VELSIPITY family patents

253. Verkazia patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9132071	HARROW EYE	Compositions containing quaternary ammonium compounds	Jun, 2029 (4 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Product(NP)	Jun 23, 2024
Orphan Drug Exclusivity(ODE-358)	Jun 23, 2028

Drugs and Companies using CYCLOSPORINE ingredient

Market Authorisation Date: 23 June, 2021

Treatment: NA

Dosage: EMULSION

VERKAZIA family patents

254. Viberzi patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7741356	ABBVIE	Compounds as opioid receptor modulators	May, 2029 (4 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE)	May 27, 2020

Drugs and Companies using ELUXADOLINE ingredient

NCE-1 date: 28 May, 2019

Market Authorisation Date: 27 May, 2015

Treatment: NA

Dosage: TABLET

VIBERZI family patents

255. Viekira Pak (copackaged) patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8188104	ABBVIE	Anti-infective agents and uses thereof	May, 2029 (4 years from now)
US8642538	ABBVIE	Macrocyclic hepatitis C serine protease inhibitors	Sep, 2029 (4 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Dosing Schedule(D-163)	Apr 22, 2019
New Chemical Entity Exclusivity(NCE)	Dec 19, 2019

Drugs and Companies using DASABUVIR SODIUM; OMBITASVIR, PARITAPREVIR, RITONAVIR ingredient

NCE-1 date: 19 December, 2018

Market Authorisation Date: 19 December, 2014

Treatment: Use of dasabuvir to inhibit viral replication for the treatment of hcv infection.; Treatment of hcv infection using paritaprevir

Dosage: TABLET

VIEKIRA PAK (COPACKAGED) family patents

256. Viekira Xr patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8188104	ABBVIE	Anti-infective agents and uses thereof	May, 2029 (4 years from now)
US8642538	ABBVIE	Macrocyclic hepatitis C serine protease inhibitors	Sep, 2029 (4 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE)	Dec 19, 2019

Drugs and Companies using DASABUVIR SODIUM; OMBITASVIR; PARITAPREVIR; RITONAVIR ingredient

NCE-1 date: 19 December, 2018

Market Authorisation Date: 22 July, 2016

Treatment: Use of dasabuvir to inhibit viral replication for the treatment of hcv infection.; Treatment of hcv infection using paritaprevir

Dosage: TABLET, EXTENDED RELEASE

VIEKIRA XR family patents

257. Vijoice patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8476268	NOVARTIS	Pyrrolidine-1,2-dicarboxamide derivatives	Sep, 2029 (4 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE)	May 24, 2024
Orphan Drug Exclusivity(ODE-396)	Apr 05, 2029

Drugs and Companies using ALPELISIB ingredient

NCE-1 date: 25 May, 2023

Market Authorisation Date: 05 April, 2022

Treatment: NA

Dosage: TABLET; GRANULES

VIJOICE family patents

258. Vimovo patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9393208	HORIZON	Method for delivering a pharmaceutical composition to patient in need thereof	Sep, 2029 (4 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Combination(NC)	Apr 30, 2013
New Patient Population(NPP)	Jul 06, 2020

Drugs and Companies using ESOMEPRAZOLE MAGNESIUM; NAPROXEN ingredient

Market Authorisation Date: 30 April, 2010

Treatment: Risk-reduction of nsaid-associated gastric ulcer in patients requiring nsaid treatment

Dosage: TABLET, DELAYED RELEASE

VIMOVO family patents

259. Viramune Xr patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8460704	BOEHRINGER INGELHEIM	Extended release formulation of nevirapine	Mar, 2029 (4 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Dosage Form(NDF)	Mar 25, 2014
New Patient Population(NPP)	Nov 08, 2015

Drugs and Companies using NEVIRAPINE ingredient

Market Authorisation Date: 08 November, 2012

Treatment: Treatment of hiv-1 by once daily administration

Dosage: TABLET, EXTENDED RELEASE

VIRAMUNE XR family patents

260. Vitrakvi patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9127013	BAYER HEALTHCARE	Method of treatment using substituted pyrazolo[1,5-a] pyrimidine compounds	Oct, 2029 (4 years from now)
US8513263	BAYER HEALTHCARE	Substituted pyrazolo[1,5-a]pyrimidine compounds as Trk kinase inhibitors	Dec, 2029 (5 years from now)
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8865698	BAYER HEALTHCARE	Method of treatment using substituted pyrazolo[1,5-a]pyrimidine compounds	Oct, 2029 (4 years from now)
US9676783	BAYER HEALTHCARE	Method of treatment using substituted pyrazolo[1,5-A] pyrimidine compounds	Oct, 2029 (4 years from now)
US10047097	BAYER HEALTHCARE	Method of treatment using substituted pyrazolo[1,5-a] pyrimidine compounds	Oct, 2029 (4 years from now)
US10005783	BAYER HEALTHCARE	Method of treatment using substituted pyrazolo[1,5-a] pyrimidine compounds	Oct, 2029 (4 years from now)
US10774085	BAYER HEALTHCARE	Method of treatment using substituted pyrazolo[1,5-A] pyrimidine compounds	Oct, 2029 (4 years from now)
US9447104	BAYER HEALTHCARE	Method of treatment using substituted pyrazolo[1,5-a]pyrimidine compounds	Oct, 2029 (4 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE)	Nov 26, 2023
Orphan Drug Exclusivity(ODE-215)	Nov 26, 2025
Orphan Drug Exclusivity(ODE-220)	Nov 26, 2025
Orphan Drug Exclusivity(ODE-221)	Nov 26, 2025

Drugs and Companies using LAROTRECTINIB SULFATE ingredient

NCE-1 date: 26 November, 2022

Market Authorisation Date: 26 November, 2018

Treatment: Method of treating cancerous solid tumors; Method of treating solid tumors that exhibit an ntrk gene fusion after surgical resection; Method of treating neuroblastoma, glioma, thyroid, and breast canc...

Dosage: SOLUTION

VITRAKVI family patents

261. Vitrakvi patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9127013	BAYER HLTHCARE	Method of treatment using substituted pyrazolo[1,5-a] pyrimidine compounds	Oct, 2029 (4 years from now)
US8513263	BAYER HLTHCARE	Substituted pyrazolo[1,5-a]pyrimidine compounds as Trk kinase inhibitors	Dec, 2029 (5 years from now)
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8865698	BAYER HLTHCARE	Method of treatment using substituted pyrazolo[1,5-a]pyrimidine compounds	Oct, 2029 (4 years from now)
US9447104	BAYER HLTHCARE	Method of treatment using substituted pyrazolo[1,5-a]pyrimidine compounds	Oct, 2029 (4 years from now)
US9676783	BAYER HLTHCARE	Method of treatment using substituted pyrazolo[1,5-A] pyrimidine compounds	Oct, 2029 (4 years from now)
US10047097	BAYER HLTHCARE	Method of treatment using substituted pyrazolo[1,5-a] pyrimidine compounds	Oct, 2029 (4 years from now)
US10774085	BAYER HLTHCARE	Method of treatment using substituted pyrazolo[1,5-A] pyrimidine compounds	Oct, 2029 (4 years from now)
US10005783	BAYER HLTHCARE	Method of treatment using substituted pyrazolo[1,5-a] pyrimidine compounds	Oct, 2029 (4 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE)	Nov 26, 2023
Orphan Drug Exclusivity(ODE-215)	Nov 26, 2025
Orphan Drug Exclusivity(ODE-220)	Nov 26, 2025
Orphan Drug Exclusivity(ODE-221)	Nov 26, 2025

Drugs and Companies using LAROTRECTINIB SULFATE ingredient

NCE-1 date: 26 November, 2022

Market Authorisation Date: 26 November, 2018

Treatment: Method of treating cancerous solid tumors; Method of treating solid tumors that exhibit an ntrk gene fusion; Method of treating solid tumors that exhibit an ntrk gene fusion after surgical resection; ...

Dosage: CAPSULE

VITRAKVI family patents

262. Vivitrol patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7919499	ALKERMES	Naltrexone long acting formulations and methods of use	Oct, 2029 (4 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Indication(I-631)	Oct 12, 2013

Drugs and Companies using NALTREXONE ingredient

Market Authorisation Date: 13 April, 2006

Treatment: Treatment of alcohol dependence

Dosage: FOR SUSPENSION, EXTENDED RELEASE

VIVITROL family patents

263. Vonjo patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8153632	CTI BIOPHARMA CORP	Oxygen linked pyrimidine derivatives	Jan, 2029 (4 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE)	Feb 28, 2027
Orphan Drug Exclusivity(ODE-397)	Feb 28, 2029

Drugs and Companies using PACRITINIB CITRATE ingredient

NCE-1 date: 28 February, 2026

Market Authorisation Date: 28 February, 2022

Treatment: Treatment of myelofibrosis with pacritinib

Dosage: CAPSULE

VONJO family patents

264. Vosevi patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7964580	GILEAD SCIENCES INC	NA	Mar, 2029 (4 years from now)
US8633309	GILEAD SCIENCES INC	Nucleoside phosphoramidates	Mar, 2029 (4 years from now)
US8889159	GILEAD SCIENCES INC	Compositions and methods for treating hepatitis C virus	Mar, 2029 (4 years from now)
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7964580 (Pediatric)	GILEAD SCIENCES INC	NA	Sep, 2029 (4 years from now)
US8633309 (Pediatric)	GILEAD SCIENCES INC	Nucleoside phosphoramidates	Sep, 2029 (4 years from now)
US8889159 (Pediatric)	GILEAD SCIENCES INC	Compositions and methods for treating hepatitis C virus	Sep, 2029 (4 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE)	Jul 18, 2022

Drugs and Companies using SOFOSBUVIR; VELPATASVIR; VOXILAPREVIR ingredient

NCE-1 date: 18 July, 2021

Market Authorisation Date: 18 July, 2017

Treatment: Treatment of adult patients with chronic hcv infection who have genotype 1a or 3 infection and have previously been treated with an hcv regimen containing sofosbuvir without an ns5a inhibitor; Treatme...

Dosage: TABLET

VOSEVI family patents

265. Vraylar patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7737142	ABBVIE	(Thio) carbamoyl-cyclohexane derivatives as D3/D2 receptor antagonists	Sep, 2029 (4 years from now)
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
USRE49110	ABBVIE	Pharmaceutical formulations containing dopamine receptor ligands	Jul, 2029 (4 years from now)
USRE49302	ABBVIE	Pharmaceutical formulations containing dopamine receptor ligands	Jul, 2029 (4 years from now)
USRE47350	ABBVIE	Pharmaceutical formulations containing dopamine receptor ligands	Jul, 2029 (4 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE)	Sep 17, 2020
M(M-213)	Nov 09, 2020
New Indication(I-798)	May 24, 2022
New Indication(I-904)	Dec 16, 2025

Drugs and Companies using CARIPRAZINE HYDROCHLORIDE ingredient

NCE-1 date: 18 September, 2019

Market Authorisation Date: 17 September, 2015

Treatment: Treatment of schizophrenia with cariprazine; Treatment of depressive episodes associated with bipolar i disorder (bipolar depression) with cariprazine

Dosage: CAPSULE

VRAYLAR family patents

266. Vyxeos patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8092828	CELATOR PHARMS	Fixed drug ratios for treatment of hematopoietic cancers and proliferative disorders	Apr, 2029 (4 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Product(NP)	Aug 03, 2020
New Patient Population(NPP)	Mar 30, 2024
Orphan Drug Exclusivity(ODE-287)	Aug 03, 2024
Orphan Drug Exclusivity(ODE-350)	Mar 30, 2028

Drugs and Companies using CYTARABINE; DAUNORUBICIN ingredient

Market Authorisation Date: 03 August, 2017

Treatment: For the treatment of newly-diagnosed therapy-related acute myeloid leukemia (t-aml) or aml with myelodysplasia-related changes (aml-mrc) in adults and pediatric patients 1 year and older

Dosage: POWDER

VYXEOS family patents

267. Vyzulta patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8058467	BAUSCH AND LOMB	Prostaglandin derivatives	Feb, 2029 (4 years from now)

Drugs and Companies using LATANOPROSTENE BUNOD ingredient

Market Authorisation Date: 02 November, 2017

Treatment: Reduction of intraocular pressure (iop) in patients with open-angle glaucoma or ocular hypertension

Dosage: SOLUTION/DROPS

VYZULTA family patents

268. Wakix patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8486947	HARMONY	Treatment of Parkinson's disease, obstructive sleep apnea, dementia with Lewy bodies, vascular dementia with non-imidazole alkylamines histamine H3-receptor ligands	Sep, 2029 (4 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Indication(I-846)	Oct 13, 2023
New Chemical Entity Exclusivity(NCE)	Aug 14, 2024
Orphan Drug Exclusivity(ODE-255)	Aug 14, 2026
New Patient Population(NPP)	Jun 21, 2027
Orphan Drug Exclusivity(ODE-331)	Oct 13, 2027
Orphan Drug Exclusivity(ODE-489)	Jun 21, 2031

Drugs and Companies using PITOLISANT HYDROCHLORIDE ingredient

NCE-1 date: 15 August, 2023

Market Authorisation Date: 14 August, 2019

Treatment: Method of treating cataplexy in patients with narcolepsy

Dosage: TABLET

WAKIX family patents

269. Winlevi patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9433628	SUN PHARM	Enzymatic process for obtaining 17α-monoesters of cortexolone and/or its 9,11-dehydroderivatives	Feb, 2029 (4 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE)	Aug 26, 2025

Drugs and Companies using CLASCOTERONE ingredient

NCE-1 date: 26 August, 2024

Market Authorisation Date: 26 August, 2020

Treatment: NA

Dosage: CREAM

WINLEVI family patents

270. Xalkori patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7858643	PF PRISM CV	Enantiomerically pure aminoheteroaryl compounds as protein kinase inhibitors	Oct, 2029 (4 years from now)
US8217057	PF PRISM CV	Polymorphs of a c-MET/HGFR inhibitor	Nov, 2029 (4 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE)	Aug 26, 2016
Orphan Drug Exclusivity(ODE)	Aug 26, 2018
Orphan Drug Exclusivity(ODE-15)	Aug 26, 2018
M(M-163)	Sep 14, 2018
Orphan Drug Exclusivity(ODE-111)	Mar 11, 2023
New Indication(I-852)	Jan 14, 2024
New Indication(I-897)	Jul 14, 2025
Orphan Drug Exclusivity(ODE-328)	Jan 14, 2028
Orphan Drug Exclusivity(ODE-407)	Jul 14, 2029

Drugs and Companies using CRIZOTINIB ingredient

Market Authorisation Date: 07 September, 2023

Treatment: NA

Dosage: CAPSULE, PELLETS; CAPSULE

XALKORI family patents

271. Xaracoll patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
USRE47826	INNOCOLL PHARMS	Drug delivery device for providing local analgesia, local anesthesia or nerve blockage	May, 2029 (4 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Product(NP)	Aug 28, 2023

Drugs and Companies using BUPIVACAINE HYDROCHLORIDE ingredient

Market Authorisation Date: 28 August, 2020

Treatment: A method for inducing a post-surgical analgesia sparing effect by implanting at the surgical site a collagen sponge containing bupivacaine hcl which provides local anesthesia for up to 24 hours follow...

Dosage: IMPLANT

XARACOLL family patents

272. Xartemis Xr patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8372432	MALLINCKRODT INC	Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic	Mar, 2029 (4 years from now)
US8394408	MALLINCKRODT INC	Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic	Mar, 2029 (4 years from now)
US8668929	MALLINCKRODT INC	Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic	Mar, 2029 (4 years from now)
US8377453	MALLINCKRODT INC	Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic	Nov, 2029 (5 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Product(NP)	Mar 11, 2017

Drugs and Companies using ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE ingredient

Market Authorisation Date: 11 March, 2014

Treatment: Management of acute pain in patients requiring opioid analgesia

Dosage: TABLET, EXTENDED RELEASE

XARTEMIS XR family patents

273. Xelpros patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9629852	SUN PHARM	Ophthalmic composition comprising a prostaglandin	Sep, 2029 (4 years from now)

Drugs and Companies using LATANOPROST ingredient

Market Authorisation Date: 12 September, 2018

Treatment: NA

Dosage: EMULSION

XELPROS family patents

274. Xenleta patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8071643	NABRIVA	Pleuromutilin derivatives for the treatment of diseases mediated by microbes	Jan, 2029 (4 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE)	Aug 19, 2024
Generating Antibiotic Incentives Now(GAIN)	Aug 19, 2029

Drugs and Companies using LEFAMULIN ACETATE ingredient

NCE-1 date: 19 August, 2028

Market Authorisation Date: 19 August, 2019

Treatment: NA

Dosage: SOLUTION; TABLET

XENLETA family patents

275. Xepi patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9399014	FERRER INTERNACIONAL	Pharmaceutical topical compositions	Dec, 2029 (5 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE)	Dec 11, 2022

Drugs and Companies using OZENOXACIN ingredient

NCE-1 date: 11 December, 2021

Market Authorisation Date: 11 December, 2017

Treatment: Treatment of impetigo due to staphylococcus aureus or streptococcus pyogenes

Dosage: CREAM

XEPI family patents

276. Xerava patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8796245	TETRAPHASE PHARMS	C7-fluoro substituted tetracycline compounds	Aug, 2029 (4 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE)	Aug 27, 2023
Generating Antibiotic Incentives Now(GAIN)	Aug 27, 2028

Drugs and Companies using ERAVACYCLINE DIHYDROCHLORIDE ingredient

NCE-1 date: 28 August, 2027

Market Authorisation Date: 27 August, 2018

Treatment: Treatment of complicated intra-abdominal infections in patients 18 years of age and older

Dosage: POWDER

XERAVA family patents

277. Xhance patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10076615	OPTINOSE US INC	Nasal delivery	Jul, 2029 (4 years from now)
US8550073	OPTINOSE US INC	Nasal delivery	Oct, 2029 (4 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Product(NP)	Sep 18, 2020
New Indication(I-940)	Mar 15, 2027

Drugs and Companies using FLUTICASONE PROPIONATE ingredient

Market Authorisation Date: 18 September, 2017

Treatment: Method of delivering fluticasone propionate to a nasal airway

Dosage: SPRAY, METERED

XHANCE family patents

278. Xifaxan patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10456384	SALIX PHARMS	Methods for treating irritable bowel syndrome (IBS)	Feb, 2029 (4 years from now)
US11564912	SALIX PHARMS	Methods for treating irritable bowel syndrome (IBS)	Feb, 2029 (4 years from now)
US10765667	SALIX PHARMS	Methods for treating irritable bowel syndrome (IBS)	Feb, 2029 (4 years from now)
US11779571	SALIX PHARMS	Methods for treating irritable bowel syndrome (IBS)	Feb, 2029 (4 years from now)
US8309569	SALIX PHARMS	Methods for treating diarrhea-associated irritable bowel syndrome	Jul, 2029 (4 years from now)
US8946252	SALIX PHARMS	Methods of treating traveler's diarrhea and hepatic encephalopathy	Jul, 2029 (4 years from now)
US10335397	SALIX PHARMS	Methods of treating hepatic encephalopathy	Jul, 2029 (4 years from now)
US10314828	SALIX PHARMS	Methods of treating hepatic encephalopathy	Oct, 2029 (4 years from now)
US7928115	SALIX PHARMS	Methods of treating travelers diarrhea and hepatic encephalopathy	Jul, 2029 (4 years from now)
US10709694	SALIX PHARMS	Methods of treating hepatic encephalopathy	Jul, 2029 (4 years from now)
US9629828	SALIX PHARMS	Methods of treating traveler's diarrhea and hepatic encephalopathy	Jul, 2029 (4 years from now)
US8829017	SALIX PHARMS	Methods of treating traveler's diarrhea and hepatic encephalopathy	Jul, 2029 (4 years from now)
US9421195	SALIX PHARMS	Methods of treating hepatic encephalopathy	Jul, 2029 (4 years from now)
US8642573	SALIX PHARMS	Methods of treating hepatic encephalopathy	Oct, 2029 (4 years from now)
US8969398	SALIX PHARMS	Methods of treating hepatic encephalopathy	Oct, 2029 (4 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Product(NP)	Mar 24, 2013
Orphan Drug Exclusivity(ODE)	Mar 24, 2017
New Indication(I-709)	May 27, 2018

Drugs and Companies using RIFAXIMIN ingredient

Market Authorisation Date: 25 May, 2004

Treatment: Treatment of irritable bowel syndrome with diarrhea (ibs-d) in adults 65 years of age or older; Treatment of irritable bowel syndrome with diarrhea (ibs-d) in adult female subjects; Treatment of irrit...

Dosage: TABLET

XIFAXAN family patents

279. Xigduo Xr patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7919598	ASTRAZENECA AB	Crystal structures of SGLT2 inhibitors and processes for preparing same	Dec, 2029 (5 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE)	Jan 08, 2019
M(M-238)	Feb 22, 2022
New Indication(I-841)	Oct 18, 2022
New Patient Population(NPP)	Jun 12, 2027
Pediatric Exclusivity(PED)	Dec 12, 2027

Drugs and Companies using DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE ingredient

NCE-1 date: 12 December, 2026

Market Authorisation Date: 28 July, 2017

Treatment: NA

Dosage: TABLET, EXTENDED RELEASE

XIGDUO XR family patents

280. Xiidra patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8367701	BAUSCH AND LOMB INC	Crystalline pharmaceutical and methods of preparation and use thereof	Apr, 2029 (4 years from now)
US9447077	BAUSCH AND LOMB INC	Crystalline pharmaceutical and methods of preparation and use thereof	Apr, 2029 (4 years from now)
US8168655	BAUSCH AND LOMB INC	Compositions and methods for treatment of eye disorders	May, 2029 (4 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE)	Jul 11, 2021

Drugs and Companies using LIFITEGRAST ingredient

NCE-1 date: 11 July, 2020

Market Authorisation Date: 11 July, 2016

Treatment: Treatment of signs and symptoms of dry eye disease (ded); Treatment of the signs and symptoms of dry eye disease (ded)

Dosage: SOLUTION/DROPS

XIIDRA family patents

281. Xphozah patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8969377	ARDELYX INC	Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders	Dec, 2029 (5 years from now)
US12016856	ARDELYX INC	Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders	Dec, 2029 (5 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE)	Sep 12, 2024
New Product(NP)	Oct 17, 2026

Drugs and Companies using TENAPANOR HYDROCHLORIDE ingredient

NCE-1 date: 13 September, 2023

Market Authorisation Date: 17 October, 2023

Treatment: NA

Dosage: TABLET

XPHOZAH family patents

282. Xultophy 100/3.6 patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7615532	NOVO	Insulin derivatives	Jun, 2029 (4 years from now)
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8937042	NOVO	Pharmaceutical compositions comprising GLP-1 peptides or extendin-4 and a basal insulin peptide	May, 2029 (4 years from now)
US8937042 (Pediatric)	NOVO	Pharmaceutical compositions comprising GLP-1 peptides or extendin-4 and a basal insulin peptide	Nov, 2029 (4 years from now)
US7615532 (Pediatric)	NOVO	Insulin derivatives	Dec, 2029 (5 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Combination(NC)	Nov 21, 2019
New Chemical Entity Exclusivity(NCE)	Sep 25, 2020
M(M-242)	Aug 08, 2022

Drugs and Companies using INSULIN DEGLUDEC; LIRAGLUTIDE ingredient

NCE-1 date: 26 September, 2019

Market Authorisation Date: 21 November, 2016

Treatment: NA

Dosage: SOLUTION

XULTOPHY 100/3.6 family patents

283. Zecuity patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8366600	TEVA BRANDED PHARM	Polyamine enhanced formulations for triptan compound iontophoresis	Apr, 2029 (4 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Dosage Form(NDF)	Jan 17, 2016

Drugs and Companies using SUMATRIPTAN SUCCINATE ingredient

Market Authorisation Date: 17 January, 2013

Treatment: Method for treating acute migraine in adults, with or without aura, comprising iontophoretic transdermal delivery of sumatriptan or a salt thereof, using a flowable hydrogel formulation

Dosage: SYSTEM

ZECUITY family patents

284. Zejula patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8436185	GLAXOSMITHKLINE	Pharmaceutically acceptable salts of 2-{4-[(3S)-piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide	Apr, 2029 (4 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE)	Mar 27, 2022
New Indication(I-813)	Oct 23, 2022
New Indication(I-814)	Oct 23, 2022
New Indication(I-833)	Apr 29, 2023
Orphan Drug Exclusivity(ODE)	Mar 27, 2024
Orphan Drug Exclusivity(ODE-133)	Mar 27, 2024
Orphan Drug Exclusivity(ODE-277)	Oct 23, 2026
Orphan Drug Exclusivity(ODE-278)	Oct 23, 2026
Orphan Drug Exclusivity(ODE-295)	Apr 29, 2027

Drugs and Companies using NIRAPARIB TOSYLATE ingredient

Market Authorisation Date: 26 April, 2023

Treatment: NA

Dosage: CAPSULE; TABLET

ZEJULA family patents

285. Zelboraf patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7863288	HOFFMANN LA ROCHE	NA	Jun, 2029 (4 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE)	Aug 17, 2016
Orphan Drug Exclusivity(ODE)	Aug 17, 2018
Orphan Drug Exclusivity(ODE-13)	Aug 17, 2018
M(M-184)	Aug 31, 2019
New Indication(I-757)	Nov 06, 2020
Orphan Drug Exclusivity(ODE-158)	Nov 06, 2024

Drugs and Companies using VEMURAFENIB ingredient

NCE-1 date: 18 August, 2015

Market Authorisation Date: 17 August, 2011

Treatment: NA

Dosage: TABLET

ZELBORAF family patents

286. Zepatier patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7973040	MSD SUB MERCK	Macrocyclic quinoxaline compounds as HCV NS3 protease inhibitors	Jul, 2029 (4 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE)	Jan 28, 2021
New Patient Population(NPP)	Dec 09, 2024

Drugs and Companies using ELBASVIR; GRAZOPREVIR ingredient

NCE-1 date: 29 January, 2020

Market Authorisation Date: 28 January, 2016

Treatment: Treatment of patients infected with hepatitis c virus

Dosage: TABLET

ZEPATIER family patents

287. Zeposia patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8796318	BRISTOL	Modulators of sphingosine phosphate receptors	May, 2029 (4 years from now)
US8481573	BRISTOL	Modulators of sphingosine phosphate receptors	May, 2029 (4 years from now)
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9382217	BRISTOL	Modulators of sphingosine phosphate receptors	May, 2029 (4 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Indication(I-860)	May 27, 2024
New Chemical Entity Exclusivity(NCE)	Mar 25, 2025

Drugs and Companies using OZANIMOD HYDROCHLORIDE ingredient

NCE-1 date: 25 March, 2024

Market Authorisation Date: 25 March, 2020

Treatment: Treatment of relapsing forms of multiple sclerosis (ms), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults

Dosage: CAPSULE

ZEPOSIA family patents

288. Zepzelca patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7763615	JAZZ	Ecteinascidin analogs for use as antitumour agents	Dec, 2029 (5 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE)	Jun 15, 2025
Orphan Drug Exclusivity(ODE-304)	Jun 15, 2027

Drugs and Companies using LURBINECTEDIN ingredient

NCE-1 date: 15 June, 2024

Market Authorisation Date: 15 June, 2020

Treatment: Treatment of adult patients with small cell lung cancer (sclc) with disease progression on or after platinum-based chemotherapy.

Dosage: POWDER

ZEPZELCA family patents

289. Zingo patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8540665	POWDER PHARMS	Particle cassettes and processes therefor	Oct, 2029 (4 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Patient Population(NPP)	Jan 08, 2012

Drugs and Companies using LIDOCAINE HYDROCHLORIDE ingredient

Market Authorisation Date: 16 August, 2007

Treatment: Zingo intradermal injection system is a drug delivery system that is capable of delivering fine dry powdered lidocaine hydrochloride monohydrate for local anesthetic action

Dosage: SYSTEM

ZINGO family patents

290. Zioptan patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9999593	THEA PHARMA	Method and composition for treating ocular hypertension and glaucoma	May, 2029 (4 years from now)
US10864159	THEA PHARMA	Method and composition for treating ocular hypertension and glaucoma	May, 2029 (4 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE)	Feb 10, 2017

Drugs and Companies using TAFLUPROST ingredient

NCE-1 date: 11 February, 2016

Market Authorisation Date: 10 February, 2012

Treatment: Reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension

Dosage: SOLUTION/DROPS

ZIOPTAN family patents

291. Zipsor patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7884095	ASSERTIO	Method of treating post-surgical acute pain	Feb, 2029 (4 years from now)
US9561200	ASSERTIO	Method of treating post-surgical acute pain	Feb, 2029 (4 years from now)
US7662858	ASSERTIO	Method of treating post-surgical acute pain	Feb, 2029 (4 years from now)
US7939518	ASSERTIO	Method of treating post-surgical acute pain	Feb, 2029 (4 years from now)
US8623920	ASSERTIO	Method of treating post-surgical acute pain	Feb, 2029 (4 years from now)
US8110606	ASSERTIO	Method of treating post-surgical acute pain	Feb, 2029 (4 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Dosage Form(NDF)	Jun 16, 2012
New Patient Population(NPP)	May 25, 2024

Drugs and Companies using DICLOFENAC POTASSIUM ingredient

Market Authorisation Date: 16 June, 2009

Treatment: Nonsteroidal anti-inflammatory drug indicated for relief of mild to moderate acute pain; Diclofenac potassium for relief of mild to moderate acute pain

Dosage: CAPSULE

ZIPSOR family patents

292. Zulresso patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9750822	SAGE THERAP	Sulfoalkyl ether cyclodextrin compositions	Mar, 2029 (4 years from now)
US10117951	SAGE THERAP	Sulfoalkyl ether cyclodextrin compositions	Mar, 2029 (4 years from now)
US9200088	SAGE THERAP	Sulfoalkyl ether cyclodextrin compositions	Mar, 2029 (4 years from now)
US7635773	SAGE THERAP	Sulfoalkyl ether cyclodextrin compositions	Mar, 2029 (4 years from now)
US8410077	SAGE THERAP	Sulfoalkyl ether cyclodextrin compositions	Mar, 2029 (4 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE)	Jun 17, 2024
New Patient Population(NPP)	Jun 16, 2025

Drugs and Companies using BREXANOLONE ingredient

NCE-1 date: 18 June, 2023

Market Authorisation Date: 17 June, 2019

Treatment: NA

Dosage: SOLUTION

ZULRESSO family patents

293. Zuplenz patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8580830	AQUESTIVE	Non-mucoadhesive film dosage forms	Nov, 2029 (5 years from now)

Drugs and Companies using ONDANSETRON ingredient

Market Authorisation Date: 02 July, 2010

Treatment: NA

Dosage: FILM

ZUPLENZ family patents

294. Zuragard patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8389583	ZUREX PHARMA	Antimicrobial compositions and methods of use	Aug, 2029 (4 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Product(NP)	Apr 26, 2022
M(M-268)	Jun 24, 2024

Drugs and Companies using ISOPROPYL ALCOHOL ingredient

Market Authorisation Date: 26 April, 2019

Treatment: Use as an antiseptic for the preparation of a patient's skin prior to surgery

Dosage: SOLUTION

ZURAGARD family patents

295. Zurampic patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8546437	IRONWOOD PHARMS INC	Compounds and compositions and methods of use	Apr, 2029 (4 years from now)
US8084483	IRONWOOD PHARMS INC	Compounds and compositions and methods of use	Aug, 2029 (4 years from now)
US8357713	IRONWOOD PHARMS INC	Compounds and compositions and methods of use	Dec, 2029 (5 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE)	Dec 22, 2020

Drugs and Companies using LESINURAD ingredient

NCE-1 date: 23 December, 2019

Market Authorisation Date: 22 December, 2015

Treatment: Treatment of hyperuricemia; Reduction of serum uric acid levels; Treatment of gout

Dosage: TABLET

ZURAMPIC family patents

296. Zyclara patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10238645	BAUSCH	Lower dosage strength imiquimod formulations and short dosing regimens for treating genital and perianal warts	Aug, 2029 (4 years from now)
US8598196	BAUSCH	Methods of treating dermatological disorders and inducing interferon biosynthesis with shorter durations of imiquimod therapy	Aug, 2029 (4 years from now)
US11318130	BAUSCH	2x2x2 week dosing regimen for treating actinic keratosis with pharmaceutical compositions formulated with 3.75% imiquimod	Dec, 2029 (5 years from now)
US8222270	BAUSCH	2×2×2 week treatment regimen for treating actinic keratosis with pharmaceutical compositions formulated with 2.5% imiquimod	Dec, 2029 (5 years from now)
US8299109	BAUSCH	Method of treating actinic keratosis with 3.75% imiquimod cream	Dec, 2029 (5 years from now)
US10238644	BAUSCH	2×2×2 week dosing regimen for treating acting keratosis with pharmaceutical compositions formulated with 3.75% imiquimod	Dec, 2029 (5 years from now)
US8236816	BAUSCH	2×2×2 week dosing regimen for treating actinic keratosis with pharmaceutical compositions formulated with 3.75 % imiquimod	Dec, 2029 (5 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Product(NP)	Mar 25, 2013
New Indication(I-636)	Mar 24, 2014
New Strength(NS)	Jul 15, 2014

Drugs and Companies using IMIQUIMOD ingredient

Market Authorisation Date: 15 July, 2011

Treatment: Treatment of perianal warts; Treatment of actinic keratosis

Dosage: CREAM

ZYCLARA family patents

List of large molecules

1. List of Actemra large molecules

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
US11136375	GENENTECH, INC.	Method for production of antibody	Jul, 2029 (4 years from now)
US8568720	GENENTECH, INC.	High concentration antibody-containing liquid formulation	Nov, 2029 (4 years from now)

Ingredients: TOCILIZUMAB

2. List of Avastin large molecules

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
US8460895	GENENTECH, INC.	Method for producing recombinant proteins with a constant content of pCO2 in the medium	Aug, 2029 (4 years from now)

Ingredients: BEVACIZUMAB

Strength	Dosage	Availability
0.1MG/INH;EQ 0.025MG BASE/INH	POWDER	Prescription
0.2MG/INH;EQ 0.025MG BASE/INH	POWDER	Prescription
0.05MG/INH;EQ 0.025MG BASE/INH	POWDER	Prescription

Strength	Dosage	Availability
800MG/8ML (100MG/ML)	SOLUTION	Prescription
800MG/200ML (4MG/ML)	SOLUTION	Prescription
400MG/4ML (100MG/ML)	SOLUTION	Discontinued

Strength	Dosage	Availability
EQ 10.5MG BASE	CAPSULE	Prescription
EQ 21MG BASE	CAPSULE	Prescription
EQ 42MG BASE	CAPSULE	Prescription

Strength	Dosage	Availability
EQ 2.5MG BASE;200MG	TABLET	Discontinued
EQ 10MG BASE;200MG	TABLET	Discontinued
EQ 5MG BASE;200MG	TABLET	Discontinued

Strength	Dosage	Availability
EQ 30MG BASE	TABLET	Discontinued
EQ 60MG BASE	TABLET	Discontinued

Strength	Dosage	Availability
300MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	TABLET	Discontinued
100MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	TABLET	Discontinued
150MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	TABLET	Discontinued
50MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	TABLET	Discontinued

Strength	Dosage	Availability
100MG;4MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	CAPSULE, EXTENDED RELEASE	Discontinued
20MG;0.8MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	CAPSULE, EXTENDED RELEASE	Discontinued
30MG;1.2MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	CAPSULE, EXTENDED RELEASE	Discontinued
50MG;2MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	CAPSULE, EXTENDED RELEASE	Discontinued
80MG;3.2MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	CAPSULE, EXTENDED RELEASE	Discontinued
60MG;2.4MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	CAPSULE, EXTENDED RELEASE	Discontinued

Strength	Dosage	Availability
200MG;50MG/PACKET	PELLETS	Prescription
400MG;100MG	TABLET	Prescription
150MG;37.5MG/PACKET	PELLETS	Prescription
200MG;50MG	TABLET	Prescription

Strength	Dosage	Availability
267MG	CAPSULE	Prescription
801MG	TABLET	Prescription
534MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	TABLET	Discontinued

Strength	Dosage	Availability
500MG/10ML (50MG/ML)	SOLUTION	Prescription
100MG/2ML (50MG/ML)	SOLUTION	Prescription

Strength	Dosage	Availability
EQ 120MG BASE/VIAL	POWDER	Prescription
EQ 80MG BASE/VIAL	POWDER	Prescription

Strength	Dosage	Availability
EQ 2.5MG BASE/ML (EQ 2.5MG BASE/ML)	SOLUTION	Prescription
EQ 5MG BASE/2ML (EQ 2.5MG BASE/ML)	SOLUTION	Discontinued
EQ 0.5MG BASE/ML (EQ 0.5MG BASE/ML)	SOLUTION	Prescription

Strength	Dosage	Availability
45MG;200MG/PACKET	PELLETS	Prescription
90MG;400MG	TABLET	Prescription
33.75MG;150MG/PACKET	PELLETS	Prescription
45MG;200MG	TABLET	Prescription

Strength	Dosage	Availability
300MG	TABLET, EXTENDED RELEASE	Prescription
600MG	TABLET, EXTENDED RELEASE	Prescription

Strength	Dosage	Availability
800PPM	GAS	Prescription
4880PPM	GAS	Prescription
100PPM Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	GAS	Discontinued

Strength	Dosage	Availability
50MG;1GM	TABLET	Prescription
150MG;500MG	TABLET	Prescription
50MG;500MG	TABLET	Prescription
150MG;1GM	TABLET	Prescription

Strength	Dosage	Availability
EQ 400MG BASE	TABLET	Prescription
EQ 100MG BASE	TABLET, CHEWABLE	Prescription
EQ 100MG BASE/PACKET	POWDER	Prescription
EQ 25MG BASE	TABLET, CHEWABLE	Prescription

Strength	Dosage	Availability
EQ 1MG BASE	TABLET	Prescription
EQ 5MG BASE	TABLET	Prescription
EQ 10MG BASE	TABLET	Discontinued

Strength	Dosage	Availability
1GM;EQ 50MG BASE	TABLET	Prescription
500MG;EQ 50MG BASE	TABLET	Prescription

Strength	Dosage	Availability
198MG	CAPSULE	Prescription
158MG	CAPSULE	Prescription
237MG	CAPSULE	Prescription

Pharsight

Pharsight

Drug Patents Expiring in 2029

1. Abilify Mycite Kit patent expiration

ABILIFY MYCITE KIT family patents

2. Acanya patent expiration

ACANYA family patents

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years. Get the exclusive patent insights now. Don't be the last to know. Download Report 3. Actoplus Met patent expiration

ACTOPLUS MET family patents

4. Acuvail patent expiration

ACUVAIL family patents

5. Adlyxin patent expiration

ADLYXIN family patents

6. Afrezza patent expiration

AFREZZA family patents

7. Agamree patent expiration

AGAMREE family patents

8. Akeega patent expiration

AKEEGA family patents

9. Aliqopa patent expiration

ALIQOPA family patents

10. Alunbrig patent expiration

ALUNBRIG family patents

11. Amvuttra patent expiration

AMVUTTRA family patents

12. Angiomax patent expiration

ANGIOMAX family patents

13. Anoro Ellipta patent expiration

ANORO ELLIPTA family patents

14. Arnuity Ellipta patent expiration

ARNUITY ELLIPTA family patents

15. Atripla patent expiration

ATRIPLA family patents

16. Auvi-q patent expiration

AUVI-Q family patents

17. Baxdela patent expiration

BAXDELA family patents

18. Belsomra patent expiration

BELSOMRA family patents

19. Belviq patent expiration

BELVIQ family patents

20. Belviq Xr patent expiration

BELVIQ XR family patents

21. Besivance patent expiration

BESIVANCE family patents

22. Braftovi patent expiration

BRAFTOVI family patents

23. Brenzavvy patent expiration

BRENZAVVY family patents

24. Breo Ellipta patent expiration

BREO ELLIPTA family patents

25. Brisdelle patent expiration

BRISDELLE family patents

26. Bromsite patent expiration

BROMSITE family patents

27. Bydureon patent expiration

BYDUREON family patents

28. Bydureon Pen patent expiration

BYDUREON PEN family patents

29. Cabtreo patent expiration

CABTREO family patents

30. Caldolor patent expiration

CALDOLOR family patents

31. Caplyta patent expiration

CAPLYTA family patents

32. Carnexiv patent expiration

CARNEXIV family patents

33. Colcrys patent expiration

COLCRYS family patents

34. Consensi patent expiration

CONSENSI family patents

35. Contrave patent expiration

CONTRAVE family patents

36. Copiktra patent expiration

COPIKTRA family patents

37. Cotellic patent expiration

COTELLIC family patents

38. Daklinza patent expiration

DAKLINZA family patents

39. Desyrel patent expiration

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

3. Actoplus Met patent expiration

Strength	Dosage	Availability
2.5MG;1GM	TABLET	Prescription
2.5MG;500MG	TABLET	Prescription
2.5MG;850MG	TABLET	Prescription

Strength	Dosage	Availability
13.4MG/PACKET	GRANULE	Prescription
5.8MG/PACKET	GRANULE	Prescription
75MG/PACKET	GRANULE	Prescription
25MG/PACKET	GRANULE	Prescription
50MG/PACKET	GRANULE	Prescription

Strength	Dosage	Availability
EQ 12.5MG BASE;1GM	TABLET	Prescription
EQ 12.5MG BASE;500MG	TABLET	Prescription

Strength	Dosage	Availability
25MG	FILM	Discontinued
20MG	FILM	Discontinued
10MG	FILM	Discontinued
30MG	FILM	Discontinued
15MG	FILM	Discontinued

Strength	Dosage	Availability
25MG	TABLET, ORALLY DISINTEGRATING	Prescription
50MG	TABLET, ORALLY DISINTEGRATING	Prescription
100MG	TABLET, ORALLY DISINTEGRATING	Prescription
200MG	TABLET, ORALLY DISINTEGRATING	Prescription

Strength	Dosage	Availability
EQ 6.14MG BASE;15MG	TABLET	Prescription
EQ 8.19MG BASE;20MG	TABLET	Prescription

Strength	Dosage	Availability
3MG	TABLET, EXTENDED RELEASE	Discontinued
1.5MG	TABLET, EXTENDED RELEASE	Discontinued
4.5MG	TABLET, EXTENDED RELEASE	Discontinued
0.375MG	TABLET, EXTENDED RELEASE	Discontinued
2.25MG	TABLET, EXTENDED RELEASE	Discontinued
0.75MG	TABLET, EXTENDED RELEASE	Discontinued
3.75MG	TABLET, EXTENDED RELEASE	Discontinued

Strength	Dosage	Availability
500MG/5ML (100MG/ML)	SOLUTION	Discontinued
100MG/ML (100MG/ML)	SOLUTION	Discontinued
1GM/10ML (100MG/ML)	SOLUTION	Prescription

Strength	Dosage	Availability
12.5MG;12.5MG;12.5MG;12.5MG	CAPSULE, EXTENDED RELEASE	Prescription
9.375MG;9.375MG;9.375MG;9.375MG	CAPSULE, EXTENDED RELEASE	Prescription
3.125MG;3.125MG;3.125MG;3.125MG	CAPSULE, EXTENDED RELEASE	Prescription
6.25MG;6.25MG;6.25MG;6.25MG	CAPSULE, EXTENDED RELEASE	Prescription

Strength	Dosage	Availability
21MG	CAPSULE, EXTENDED RELEASE	Discontinued
14MG	CAPSULE, EXTENDED RELEASE	Discontinued
28MG	CAPSULE, EXTENDED RELEASE	Discontinued
7MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	CAPSULE, EXTENDED RELEASE	Discontinued